Ocular and systemic markers for vascular function in those at risk of type 2 diabetes mellitus and cardiovascular disease by Patel, Sunni Raman
 
 
1 
 
OCULAR AND SYSTEMIC MARKERS FOR VASCULAR 
FUNCTION IN THOSE AT RISK OF TYPE 2 DIABETES 
MELLITUS AND CARDIOVASCULAR DISEASE 
 
 
 
 
MR SUNNI RAMAN PATEL 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
 
ASTON UNIVERSITY 
May 2011 
 
 
 
This copy of the thesis has been supplied on condition that anyone who consults it is understood to 
recognise that its copyright rests with its author and that no quotation from the thesis and no 
information derived from it may be published without proper acknowledgement. 
Aston University 
 
 
2 
 
Ocular and Systemic Markers for Vascular Function in those at Risk of Type 2 Diabetes Mellitus and Cardiovascular Disease 
Mr Sunni Raman Patel 
Doctor of Philosophy 
May 2011 
 
Thesis Summary 
The devastating impact of Type 2 Diabetes Mellitus (T2DM) -related morbidity and mortality on global 
healthcare is escalating with higher prevalences of obesity, poor diet, and sedentary lifestyles. 
Therefore, the clinical need for early diagnosis and prevention in groups of high-risk individuals is 
necessary. The purpose of this thesis was to investigate the use of surrogate markers, namely retinal 
vascular function, to determine future vascular endothelial dysfunction, atherosclerosis, large vessel 
disease and cardiovascular risk in certain groups. This namely covered normoglycaemic and 
normotensive South Asians (SAs), those with Impaired-Glucose Tolerance (IGT) and individuals with a 
familial history (FH) of T2DM. Additionally the effect of overweight and obesity was studied. 
The techniques and modified protocols adopted for this thesis involved the investigation of endothelial 
function by means of vascular reactivity at the ocular and systemic level. Furthermore, the relationships 
between retinal and systemic function with circulating markers for endothelial cell function and 
cardiovascular risk markers were explored. The principal studies and findings of the research were: 
              Vascular Function in Normoglycaemic Individuals with and without a FH of T2DM 
WE FH individuals exhibited higher levels of total cholesterol levels that correlated well with the 
retinal arterial dilation amplitude to flicker light stimulus. However this did not extend to noticeable 
differences in markers for endothelial cell damage and impaired retinal and systemic function.  
Vascular Function in Normoglycaemic South-Asians vs. White-Europeans without a FH and Vascular 
Disturbances 
Compared to healthy WEs (normo -glycaemic and -tensive), SA participants exhibited levels of 
dyslipidaemia and a state of oxidative stress that extended to impaired vascular function as detected 
by reduced brachial artery flow-mediated dilation, slower retinal arterial vessel dilation reaction times 
(Appendix 3) and steeper constriction profiles. Furthermore, gender sub-group analysis presented in 
a sub-chapter shows that SA males demonstrated 24-hour systemic blood pressure (BP) and heart 
rate variability (HRV) abnormalities and heightened cardiovascular disease (CVD) risk. 
Vascular Function in Individuals Newly Diagnosed with IGT as compared to Normoglycaemic Healthy 
Controls 
Newly-diagnosed WE and SA IGT patients showed a greater risk for CVD and T2DM progression by 
means of 24-hour BP abnormalities, dyslipidaemia, increased carotid artery intimal-media thickness 
(c-IMT), Framingham scores and cholesterol ratios. Additionally, pre-clinical markers for oxidative 
stress and endothelial dysfunction, as evident by significantly lower levels of plasma glutathione and 
increased levels of von-Willebrand factor in IGT individuals, extended to impaired vascular systemic 
and retinal function compared to normal controls. This originally shows retinal, systemic and 
biochemical disturbances in newly-diagnosed IGT not previously reported before.    
Vascular Function in Normal, Overweight and Obese Individuals of SA and WE Ethnicity 
In addition to the intended study chapters, the thesis also investigated the influence of obesity and 
overweight on vascular function. Most importantly, it was found for the first time that compared to 
lean individuals it was overweight and not obese individuals that exhibited signs of vascular systemic 
and ocular dysfunction that was evident alongside markers of atherosclerosis, CVD risk and 
endothelial damage. 
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1. Introduction and Research Rationale 
 
 
1.1. Background 
The incidence of Type 2 Diabetes Mellitus (T2DM) and associated cardiovascular disease (CVD) 
is increasing exponentially worldwide, primarily due to the increase in obesity and a sedentary 
lifestyle. The current worldwide prevalence of DM is estimated to be around 170 million and it is 
thought that this will increase to a number of more than 360 million by 2030.[1] Therefore, the 
rising prevalences of T2DM will undoubtedly confer major burdens on the health care system and 
thus health care and economy costs.  
T2DM is a metabolic condition as a result of the interaction between genetic predisposition and 
environmental as well as behavioural risk factors.[2] The genetic basis behind the aetiology of 
T2DM is yet to be determined, but there is justifiable evidence to suggest that modifiable risk 
factors such as diet, obesity and physical inactivity are some of the main non-genetic 
determinants of T2DM.[3, 4] 
T2DM may largely be preventable, but a comprehensive understanding of its aetiology is still 
needed. The development of atherosclerotic and clinical CVD is the principal complication in 
T2DM, but can also precede development of diabetes, lending support to the hypothesis that both 
vascular disorders share common antecedents.[5-7] 
 
 A syndrome of insulin resistance (IR) may constitute this common antecedent, and is understood 
to be an established factor in the pathogenesis of T2DM. IR is a hallmark of T2DM that precedes 
and predicts the onset for several years, and is related to several cardiovascular risk factors 
including hyperglycaemia, dyslipidaemia and hypertension.[2, 8] Closely interlinked conditions 
such as atherosclerosis, CVD and T2DM have a common pathophysiological basis that is 
underpinned by IR and the Metabolic Syndrome (MetS). Therefore, it is of clinical interest to 
establish whether an IR state contributes to the onset of vascular disease processes such as 
atherosclerosis.[9] 
 
 
Atherosclerosis is a disease of arterial lipid deposition characterised by a complex and dynamic 
number of biological responses central to which is a preliminary oxidative and inflammatory 
reaction. Pathological studies have demonstrated a series of changes in the vessel wall and there 
is further evidence to suggest that before these structural changes, there are important pro-
atherosclerotic changes in vascular endothelial cell phenotyping such as a decline in the 
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bioavailability of the signalling radical nitric oxide (NO).[10] Whether, vascular endothelial cell 
dysfunction; a systemic pathological imbalance between vaso-dilating and –constricting 
substances released (or acting on) the vascular endothelium. This in turn promotes several 
disease processes such as T2DM and atherosclerosis. 
Those with T2DM and known atherosclerosis exhibit a number of risk factors for serious vascular 
complications, and for this reason it is important to also focus on cardio-metabolic risk factors in 
known susceptible individuals. That is, the combined vascular and metabolic components of risk 
that may lead to a CVD or a cardiovascular event. 
 
1.2. Risk Factors 
The clustering of vascular risk factors such as age, familial history, ethnicity, obesity, 
hypertension and dyslipidaemia; risk factors known to contribute towards atherosclerosis and 
ultimately CVD, T2DM and IR have been documented in many urban studies (Table 1.1).[11-13] 
Furthermore, it has been shown that the combinations of these characteristics can occur more 
frequently than expected by chance.[14] 
 
Documented Risk Factors of Vascular Disease 
Age 
Familial History 
Metabolic Syndrome/Obesity 
Circulation Abnormalities (Hypertension and Stroke) 
Ethnicity 
Impaired Glucose Tolerance/Impaired Fasting Glycaemia 
Gestational Diabetes Mellitus 
Mental Health Problems (Schizophrenia) 
Sedentary Lifestyle Factors (Exercise and Diet) 
 
Table 1.1. Known risk factors for vascular disease (T2DM and CVD) 
 
The primary aim of this thesis and its studies will be to investigate the influence of vascular 
endothelial dysfunction on micro- and macro-vascular function alongside biochemical and 
metabolic function on future vascular risk of T2DM and CVD. Furthermore, the use of retinal 
vascular function as a surrogate means of providing a „clinical picture‟ on macrovascular function 
and predictor for future risk of systemic and macrovascular disease will be closely evaluated. 
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Therefore, the studies will focus on ethnicity; namely South Asians (SA) as compared to White 
Europeans (WE), those of WE origin with a family history (FH) of T2DM in one/both parents 
compared to those without, and individuals with impaired glucose tolerance (IGT) vs. 
normoglycaemic individuals. 
 
1.2.1. South Asian Ethnicity (SA) 
The SA diaspora comprises mainly of Indians, Sri Lankans, Pakistanis and Bangladeshis. There 
has been a dramatic increase in the prevalence of T2DM in the SA community in many parts of 
the world. SAs are undeniably at an increased risk of CVD and IR, and much of this excess risk 
may be attributed to the increased risk of T2DM (four to six times that of Europeans) developing 
at about 10 years earlier than in White Europeans (WE).[15] Alarmingly, it has been projected 
that the number of those diagnosed with T2DM in India alone will escalate from 31.7 to 79.4 
million in 2030.[1] More importantly, in the Birmingham area of the UK the Health Survey for 
England reports increasing levels of T2DM, obesity and sedentary lifestyles that contribute 
towards an increased vascular risk. Therefore, the investigation of vascular function in SAs, 
especially of those in the Birmingham area seems valid. 
Although genetic factors play an integral role, the increased incidence of T2DM is strongly 
associated with increasing central obesity and hyperinsulinaemia.[16] For instance, SAs appear 
to be more IR at a much earlier age and as a result of this, the relation between obesity and IR 
may occur at lower levels of obesity in SAs as compared with WEs.[17] 
Furthermore, the prevalence of major established risk factors amongst SAs when compared to 
WEs is also present at a younger age.[18] In comparison to WEs, SAs appear to present with 
higher plasma triglyceride (TG) and lower high-density lipoprotein cholesterol (HDL-C) levels, 
suggesting underlying IR.[19] Additionally, some reports also show higher plasma total and LDL-
C levels in SAs.[20] The higher prevalence of IR, IGT and increased fasting glucose levels in SAs 
have been shown to increase the risk of T2DM and this could be ultimately explained by the close 
link with the higher incidence of the Metabolic Syndrome (MetS) amongst this minority.[21] 
The MetS is intimately linked with IR and is independently associated with a two-fold risk of CVD 
in SAs and therefore could provide a means of identifying high-risk individuals for T2DM and 
CVD.[22-24] It represents an asymptomatic condition that consists of obesity (central intra-
abdominal), IR, impaired glucose metabolism, dyslipidaemia of the high TG and low HDL-C type, 
and elevated blood pressure (BP). 
However, the causes behind the increased prevalence of IR and T2DM in SAs still remain 
unclear. Abdominal obesity contributes to the pathophysiological mechanisms of IR in a number 
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of ways, and despite SAs being more IR than WEs for every level of body fat; it does not fully 
explain the excess risk.[25-27] 
Other emerging environmental and lifestyle confounders must also be taken into account with 
SAs. Physical inactivity and sedentary lifestyles combined with a low protein and high 
carbohydrate, fat, eggs and dairy diet, socioeconomic and cultural factors may also play an 
important role.[21] Furthermore, a number of studies suggest that established risk factors might 
not fully explain the excess risk and that established risk calculators such as the Framingham 
may underestimate vascular risk in SAs.[28] Preliminary studies also show that vascular 
endothelial function might be more impaired in SAs when compared to WEs, suggesting the 
influence of other biological and biochemical processes.[26, 29, 30] For instance, some studies 
have reported higher concentrations of fibrinogen and plasminogen activator inhibitor-1 (PAI-1), 
commonly found with IR and the MetS.[31] Elevated levels of plasma homocysteine and high-
sensitivity C-reactive protein (hs-CRP) in SAs are likely to reflect higher levels of vascular 
inflammation and central obesity in SAs.[32-35] The emergence of genetic studies, ethnicity and 
T2DM also raises the possibility that IR and T2DM are genetically determined to a greater extent 
in SAs than WEs. Nonetheless, these factors help to demonstrate the complicated and multi-
faceted nature behind the risks and pathophysiology of T2DM, IR and IGT in SAs.   
 
1.2.2. Family History (FH) 
Familial history also appears to play an influential independent risk for T2DM as the condition is 
known to be strongly genetically determined.[36] Recent studies have reported a higher 
prevalence of IR and impaired vascular endothelial function in normotensive and normoglycaemic 
offspring of T2DM (FH), suggesting interplay between genetics and atherosclerosis/endothelial 
dysfunction that may be inherited.[36-40]  In contrast, biological studies investigating 
normoglycaemic individuals with a FH of T2DM and those with an identical twin with T2DM have 
found impaired insulin secretion as opposed to IR when correcting for confounding variables 
suggesting a genetic involvement with beta-cell dysfunction.[41] 
Whether FH for T2DM predisposes those at risk to an alteration in vascular endothelial function 
through a genetic „susceptibility‟ or higher prevalence of MetS requires further longitudinal work. 
The limited amount of research into familial history and T2DM restricts understanding behind the 
mechanisms of DM and to understand the role of genetics if any, and whether predisposing 
environmental, lifestyle and cultural factors are causal and effect.  
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1.2.3. Impaired Glucose Tolerance (IGT) 
IGT represents an inter-mediatory between normal glucose tolerance and overt T2DM, and is 
identified by an oral glucose tolerance test (OGTT). Those with IGT have been found to be at an 
increased risk of T2DM and form an important group for investigating primary means of 
intervention.   
IGT is largely the result of reduced insulin-stimulated glucose disposal due to decreased insulin 
secretion and a decreased response of glucose uptake by skeletal muscle to insulin. IGT is 
commonly diagnosed with the threshold criteria established by the World Health Organisation 
(WHO) and the American Diabetes Association (ADA). 
IGT is not uncommon in patients with coronary atherosclerosis and furthermore, is well 
associated with abnormal scores for atherosclerosis surrogate markers (carotid intima-media 
thickness [IMT], flow-mediated brachial artery dilation [FMD] and homeostasis model assessment 
of insulin resistance [HOMA-IR]).[42] Therefore, IGT has been linked with clinical events other 
than sole progression to T2DM, suggesting its clinical significance in cardiovascular mortality.  
Although IGT has been associated with an increased risk behind the development of T2DM and 
adverse clinical outcomes, there is limited amount of research on using microvascular functional 
analysis (especially retinal) for the clinical diagnosis and utility in medical practice. However, 
there is consistent information about differences amongst different ethnic populations and age 
groups.[43] 
 
 
1.3. Anatomy and Physiology 
 
1.3.1. The Vascular Endothelium 
The endothelium is made up of an elaborate network of tight junctions and lacks any 
fenestrations; resembling that of a cobblestone arrangement. Structurally, the endothelium is 
based on an amorphous basal membrane made up of rare internal, dense external and rare 
external layers that contains type IV collagen, glycoproteins, laminin and fibronectin.   
 
Its morphology changes accordingly to the required function and its location. At the capillary 
level the endothelium is a single layer that folds outwards to cover the vessel wall. Additionally 
at this level, pericyte cells form a contractile layer that helps to maintain vessel diameter and 
intimal cell turnover. Pericyte cells are known only to be located at the retinal level and central 
nervous system. In contrast, large vessel endothelium exhibits homogeneity and is 
 
 
19 
 
anatomically made up of a basal membrane covered by the tunica media and adventitia (Figure 
1.1.). 
 
 
Figure 1.1.  An anatomical drawing of the large vessel vascular endothelium, illustrating it as the innermost 
mechanical vessel lining. 
 
The endothelium is classed as an important organ that is involved very heavily in  
cardiovascular haemostasis.[44-47] It is known to have a number of important primary regulatory 
functions; 
 
1.  A  selective  gate  permitting  the  transport  of  glucose,  nutrients,  metabolites  and  
hormones. Importantly, the non-insulin-dependent glucose transporter (GLUT1) transports 
glucose through the endothelial cells. 
2.  The endothelium synthesises collagen I, fibronectin, laminin and growth factors that aid 
tissue synthesis and catabolism. 
3.  It produces intracellular adhesion molecules, vascular cell adhesion molecules, and E-
selectin promoting leukocyte recruitment and activation. 
4.  The presence of lipoprotein lipase in the endothelial layer allows the hydrolysis of low-
density lipoprotein triglycerides to aid lipoprotein metabolism. 
5.  Most importantly, the endothelium produces and releases coagulant and anticoagulant factors 
as well as vasoconstrictor and vasoconstrictor factors to aid haemostasis.  
 
Thus,  under  physiological  conditions  the  endothelium  contributes  to  vascular  haemostasis  
by continuously monitoring blood and local stimuli, and modifying itself in response to these 
stimuli and environmental  changes.[48]  Anatomically,  the  endothelium  is  seen  as  the  
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interface  between circulating  blood  and  the vascular smooth  muscle cells  (VSMC),  but in  
addition  to serving  as  a physical barrier, the endothelium facilitates a complex and intimate 
interaction with the VSMC and a complicated system of chemical mediators. Figure 1.2. 
 
NO, which has been identified as a major endothelial derived relaxing factor is one of the 
most important substances involved in maintaining the normal function of vessels. It is a 
vasodilator, inhibits abnormal growth and inflammation and exerts anti-aggregatory effects on 
platelets. Additionally, NO maintains choroidal vascular tone in humans and plays an important 
role in flicker-induced retinal vasodilation.[49-51] 
 
It is released by the vascular endothelium in response to a variety of chemical and physical 
stimuli (platelet derived factors, shear stress, angiotensin II, acetylcholine, and cytokines) 
which stimulate the production of NO by endothelial nitric oxide synthase (eNOS). eNOS 
synthesizes NO from the terminal guanidine-nitrogen of L-arginine and oxygen. NO, a highly 
reactive free radical, then diffuses into the smooth muscle cells of the blood vessel and interacts 
with soluble guanylate cyclase.  Nitric oxide stimulates the soluble guanylate cyclase to 
generate the second messenger cyclic GMP (3‟,5‟ guanosine monophosphate) from guanosine 
triphosphate (GTP). The soluble cGMP activates cyclic nucleotide dependent protein kinase G 
(PKG or cGKI). PKG is a kinase that phosphorylates a number of proteins that regulate; 
calcium concentrations, calcium sensitization, hyperpolarize cell through potassium channels, 
actin filament and myosin dynamic alterations that result in smooth muscle relaxation.[52] 
 
Impaired endothelial function is synonymous with reduced NO release because of inactivity of 
the endothelial NO enzyme eNOS, as a result of biochemical imbalances, namely 
increased endo- and exo-genous inhibitors and/or low availability of enzyme substrate L-
arginine.[53] 
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VASOCONSTRICTORS - ET-1  
Figure 1.2.  Biochemical processes undergone by the endothelium to maintain adequate blood 
flow. 
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 AGGREGATION AND THROMBOSIS 
1.3.2. The Retina 
The retinal vascular supply is essentially an end-arterial system; whereby the central retinal 
artery emerges at the optic nerve into two major branches. These branches divide further into 
arterioles that supply each retinal quadrant. The venous system is very similar to the arteriolar 
arrangement explained above; the central retinal vein exits through the optic nerve to drain blood 
into the cavernous sinus.[54] 
 
Depending on retinal location, retinal arteries have an unusually developed smooth muscle 
layer and lack internal elastic laminar. The smooth muscle cells that make up this layer lie 
circularly and longitudinally and are surrounded by a basal lamina with progressively increasing 
amounts of collagen towards the acellular adventitia. 
 
Towards the optic nerve, the artery wall comprises of 5-7 layers of smooth muscle cells 
which decreases to 2-3 layers at the equator and furthermore to 1-2 layers at the periphery.[55-
57]  
 
Capillary walls consist of an inner layer of endothelial cells that orientate along the axis of 
the capillary,   which  is  then  surrounded  by  basement  lamina  within  which  pericyte  cells  
form  a discontinuous layer. 
 
Retinal vasculature possesses a l i m i t e d  supply of autonomic innervation, namely from glial 
cell signalling, and unlike the choroid lacks full intrinsic innervation. Therefore, the central retinal 
artery is innervated by sympathetic nerves from the superior cervical ganglion,  whilst  within  
and  throughout  the  retinal  layers;  angiotensin  II,  α-adrenergic  and  β- adrenergic 
receptors are present.[58-61] 
 
Due  to  their  functional  structure,  the  retinal  endothelial  cells  are  considered  to  be  a  
major component of the inner blood-retinal barrier. Retinal  endothelial  cells  release  high  
levels  of  superoxides  and  have  been  found  to  be  more vulnerable  to  the  damaging  
consequences  of  oxidative  stress  associated  with  diabetes.[62]  The endothelium maintains 
retinal blood flow and vessel tone by releasing vasoactive factors (NO, Endothelin-1) to 
stimulate mechanisms.[63] 
 
1.3.2.1. Physiology of Retinal Blood Flow and Autoregulation 
Maintenance of adequate perfusion is a basic requirement for all tissue beds. The local 
vascular mechanism that maintains a relatively constant metabolic environment in the tissue, 
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despite varying conditions that tend to disturb this homeostasis, is called autoregulation.  The 
autoregulation mechanism contributes also to the maintenance of a relatively constant capillary 
pressure, which is important for the tissue fluid balance.[64, 65] 
 
Additionally, blood flow depends on perfusion pressure (the pressure that drives blood), 
vascular resistance and blood viscosity. This is further impacted by other local and 
environmental factors: local haematocrit, shear rate, vessel diameter and length, and 
interactions of systemic factors that affect the tone of pericytes, smooth muscle cells and 
endothelium. For instance, autoregulation is accomplished through the ability of the 
cardiovascular system to adjust the resistance of particular vessels by controlling the diameter 
of their lumen. The lumen diameter is maintained by vascular smooth muscle or other 
contractile elements in the vessel wall.   This vascular tone is adjusted by vasoactive nerves 
and circulating hormones, as well as endothelial factors, myogenic and metabolic factors. 
 
Therefore, autoregulation ensures a constant rate of blood flow in order to preserve the function 
of tissues by a means of different known mechanisms.  This can involve changes in precapillary 
arteriole lumen size, vascular endothelium function, or ocular perfusion pressure above/below 
the critical autoregulatory range. 
 
A number  of  studies  have  shown  that  ocular  and  retinal  circulation  has  been  found  to  
show autoregulatory  capacity  by  a  means  of  inducing  changes in perfusion  pressure  
(increasing Blood Pressure or Intraocular Pressure) or changes in metabolic rate (hypercapnia 
or hyperoxia).[66-70] Thus, blood flow is regulated by the autonomic nervous system (ANS) 
and locally to meet local needs by a number of mechanisms (Table 1.2.). 
 
 
 
 
AUTOREGULATORY MECHANISMS DESCRIPTION 
METABOLIC 
A change in blood supply to satisfy tissue metabolic 
demand by release of vasoactive substances that 
maintains supply of oxygen and removes toxic 
metabolites 
MYOGENIC 
Arterial and arteriolar smooth-muscle cell changes 
proportionate to variations in perfusion pressure 
NEUROGENIC 
Blood circulation maintained by neural sympathetic 
subsystems 
ENDOTHELIUM-MEDIATED 
Vasoactive factors known to interact with the smooth 
muscle cells allow vaso -constriction or -dilation. 
 
Table 1.2. The mechanisms involved in regulating retinal blood flow. 
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1.3.2.2. Metabolic Autoregulation 
The  concept  of  a  metabolic  control  of  the  retinal  blood  flow  is  that  factors  on  which  
retinal metabolism is dependent (retinal-tissue PO2, PCO2, pH, metabolic products) strive to 
optimise retinal blood flow according to the metabolic needs of the retinal tissue. 
 
According to the metabolic hypothesis of blood flow regulation, perfusion and tissue 
metabolism are  tightly  coupled  in  such  a  way  that  any  reduction  in  arterial  inflow  
causes  an  increase  of vasodilator  metabolites  in  the  tissue,  due  to  an  insufficient  
washout  or  to  an  increase  in  the production, or both. Factors involved in determining 
metabolic autoregulat ion include hypoxia, vasoactive substances  (Table 1.3.),  
and, t issue metabolites and ions  (Table 1.4.).  
 
Current evidence suggests that increased production of vasodilator substances due to hypoxia 
is the dominating mechanism for metabolic autoregulation.[71] Hypoxia is caused when there is 
an increased oxygen demand or reduced supply causing a resultant vasodilation in order to 
meet the increased tissue demand. 
 
 
 
 Origin Action 
Nitric Oxide (NO) 
Stimulus-derivative (shear stress, 
growth factors) that activates eNOS 
Vessel protection and vasodilation 
Endothelin (ET-1, ET-2, ET-3) Endothelial cells Vasoconstriction 
Superoxide Anions Endothelial cells 
Inactivates NO to induce indirect 
vasoconstriction 
Angiotensin-converting enzyme 
(ACE) 
Renal 
Inactivates bradykinins to produce 
Angiotensin-II, which then causes 
indirect vasoconstriction 
 
Table 1.3. An example of several vasoactive substances involved in the metabolic autoregulation of retinal 
blood flow. 
 
 Action 
Adenosine A potent vasodilator during hypoxia 
Potassium (K
+
) 
Regulated the NA
+
/K
+
-ATPase pump to regulate muscle 
contraction and thus vasoconstriction 
Carbon Dioxide (CO2) Vasodilator in VSMC 
Hydrogen Ions (H
+
) Vasodilator 
 
Table 1.4. An example of several metabolites and ions involved in the metabolic autoregulation of retinal blood 
flow. 
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1.3.2.3. Myogenic autoregulation 
As blood pressure and flow to a tissue is increased above normal levels, pressure-induced 
vascular myogenic  mechanisms  appear  to  dominate  the  regulation  of  the  vascular  tone.  
By  means  of myogenic   autoregulation,  the  retinal  blood  flow  is  maintained  constantly  
despite moderate variations in perfusion pressure (PP). The stimulus for a myogenic 
mechanism is a variation in the transmural pressure difference during moderate variations in 
PP, and is achieved by changing the vascular resistance. In cases where the pressure 
difference is reduced, as for instance with increased IOP or reduced arterial pressure, the 
activity of the pacemaker cells in the arteriolar wall is reduced, which results in reduced 
arteriolar tone, and consequently, reduced vascular resistance.[72, 73] In addition, a 
contracting endothelium-derived factor released during increases in transmural pressure may 
be another component of myogenic autoregulation.[74, 75] 
 
1.3.2.4. Neurogenic Control of Vascular Tone 
There are a number of vasoactive nerves influencing local blood flow. The eye is a rich supply 
of autonomic nerves within the uvea, the posterior ciliary arteries, and the extraocular portion 
of the central retinal artery.[58, 59] Vessels in the retina and prelaminar portion of the optic 
nerve have no neural innervation.[76] Consequently, a stimulation of the cervical sympathetic 
chain produces a vasoconstriction in the uvea but has no effect on retinal or anterior optic 
nerve blood flow.[77-80] 
 
Neurogenic control is mediated by a multitude of substances such as acetylcholine, 
noradrenaline, calcitonin, gene-related peptide, cholecystokinin, vasoactive intestinal 
polypeptide (VIP), nitric oxide, neuropeptide Y, and adenosine triphosphate (ATP).[81-83] 
 
1.3.2.5. Perfusion Pressure and Autoregulation 
The  driving  force  of  ocular  blood  flow  is PP,  which  is  the difference between the pressure 
in the arteries entering the eye and the pressure in the veins leaving it. The pressure in the 
arteries entering the eye cannot be determined directly, and as a rule the mean arterial 
pressure (MAP) in the brachial artery is used as a substitute.  
 
There is a loss of pressure between the heart, and the pressure in the arteries entering the eye 
is 35-40 mmHg lower than MAP as determined in the brachial arteries when we stand up. 
The pressure in the veins leaving the eye is almost the same as the IOP and for the eye. 
 
Blood flow is reduced if MAP is reduced or IOP increased unless there is a concomitant 
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change in the vascular resistance. In most tissues, such changes in PP are compensated by 
a change in the vascular resistance, and the blood flow is kept at the same level despite 
moderate changes in PP. In the eye, blood flow through the retina is autoregulated, and one 
can estimate that in a healthy eye retinal blood flow is essentially unchanged up to an IOP of 
about 35 mmHg.[84, 85] A reduction in MAP or an increase in venous pressure has the same 
effect on the PP, but the effect on local blood flow may vary. A marked reduction in BP will 
activate the sympathetic nerves. This protective mechanism is aimed to distribute the remaining 
blood to tissues in need. No such mechanism appears to exist in the eye. 
 
1.3.2.6. Retinal changes with diabetic retinopathy 
The damaging effects of chronic hyperglycaemia on the microvasculature and subsequent 
focal ischemia are primary factors in diabetic retinopathy (DR) progression.  Even with no 
clinically detectable retinopathy, haemodynamic and cellular changes are evident. The 
endothelial cell supporting cells, known as pericytes are affected early resulting in endothelial 
damage. Retinal hyper-perfusion caused by dilation of retinal arterioles is an early change 
involved in the pathogenesis of DR.  Under physiological conditions, the retina has the ability 
to regulate blood flow in response to different metabolic demands by autoregulating retinal 
vessel diameter.  This maintains blood flow at a balanced level despite changes in BP. This 
autoregulatory mechanism is impaired in diabetes altering the ocular blood flow and 
promoting retinal perfusion abnormalities; moreover, failure of autoregulation and abnormal 
vascular reactivity is often an early feature of DR.[86-91] Clinically   evident   retinopathy   
begins   to   appear   as   the   systemic   disease and pathophysiological changes progress. 
Thus, the clinical need to investigate haemodynamic processes associated with DR is valid. 
 
There are a number of methods available in clinical practice for the assessment of ocular 
haemodynamics, each possess certain advantages and disadvantages depending on the 
measured variable required (Table 1.5.). For the purpose of this thesis; retinal vessel analysis 
was adopted to determine retinal vessel diameter and reactivity. This technique is explained in 
more detail later on in Section 2.1. 
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Instrument Assessed physiology Measurement output 
Laser Doppler Flowmetry  (LDf) 
Optic nerve head and choroidal 
vessel 
Optic nerve head and choroidal 
capillary blood flow 
Laser Doppler Velocimetry (LDv) Retinal vessels Retinal vessel blood velocity 
Laser interferometry 
Optic nerve head and choroidal 
vessels 
Pulsatile ocular blood flow 
Heidelberg Retina Flowmeter (HRF) Optic nerve head and retinal vessels 
Optic nerve head and retinal velocity 
and flow 
Colour Doppler Imaging (CDI) Retrobulbar blood vessels Retrobulbar vessel blood flow velocity 
Pulsatile Ocular Blood Flow 
system (POBF) 
Choroidal vessels IOP and pulsatile choroidal blood flow 
Fluorescein Angiography (FA) Retinal vessel 
Perfusion mapping and blood flow 
velocity and circulation 
Indocyanine green Angiography 
(IGA) 
Choroidal vessels Choroidal blood flow velocity 
Blue-field stimulation (BFS) Foveal vessels 
Foveal circulation and capillary retinal 
blood flow 
Retinal vessel analyser (RVA) Retinal vessels Continuous and static diameter 
 
Table 1.5. The different instrumentation used in determining retinal haemodynamics in ocular disease. 
 
 
1.4. Endothelial Dysfunction 
 
Normal endothelial function is determined by a harmonious equilibrium of both vaso -active and   
-dilatory substances that allow sufficient permeability, secretion and expression of these 
substances by the endothelial cells according to local and global tissue demand. Therefore, 
endothelial dysfunction indicates a generalised alteration in cell function resulting in abnormal 
vasodilatory responses, impaired endothelial control of inflammation and fibrinolysis and an 
imbalance in the expression of vascular adhesion molecules. 
Endothelial dysfunction is detectable before any angiographic or ultrasound evidence of disease 
in cardiovascular risk factor groups (dyslipidaemia, hypertension, diabetes mellitus and 
smoking), as a result  of  overproduction of reactive oxidative species (ROS) and increased 
oxidative  stress that contribute to reduced bioavailability of vascular NO, promoting cellular 
damage.[92-94] There are a number of associated alterations to the vascular endothelium 
which can contribute towards   endothelial dysfunction.  These  include  impaired  NO  release  
and  response,  increased expression  and   plasma  levels  of  ROS,  vasoconstrictors  (ET-1,  
angiotension  II), adhesion molecules, and enhanced  platelet adhesion to the endothelium.[95, 
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96] Ultimately, the chronic exposure to hyperglycaemia and inflammatory state triggers a set of 
chain reactions causing biochemical changes that finally lead to structural changes. This 
biochemical change  creates an imbalance  of  opposing  physiological  and  molecular  effects  
causing  vascular  inflammation  and coagulation. 
 
The mechanisms of endothelial dysfunction in IR states are not yet fully established. 
Dyslipidaemia, oxidative stress, chronic vascular inflammation and increased low-density 
lipoprotein cholesterol (LDL-C) transport may be considered as important factors.  However, a 
loss of NO bio- activity and -availability has been found to be the central feature of endothelial  
dysfunction  and  is  accepted  to  be  a good  predictor  of  atherosclerosis.  This in turn 
promotes a state of vascular inflammation that causes endothelial cell dysfunction.[97, 98] 
Previous studies have demonstrated impaired insulin-mediated and endothelial-dependent 
vasodilation in IR states, including obesity, T2DM and IGT.[99] Therefore, this suggests that 
endothelial dysfunction may play an integral role into the cause of IR; independent of 
hyperglycaemia. Therefore, it could then be hypothesised that markers of impaired endothelial 
function could be caused by a severe state of IR. 
The vital roles played by the vascular endothelium and NO to reduce vascular tone, platelet 
aggregation and adhesion, thrombosis, leukocyte adhesion and smooth-muscle cell proliferation 
and adhesion, seems to suggest that severely impaired endothelial-dependent vasodilation may 
be partly responsible for the incidence of macrovascular disease observed in T2DM.[100-102] 
 
1.4.1. Markers of Endothelial (Dys)Function 
The assessment of endothelial function refers to the measurement of cell response to 
stimulation, by substances known to be released by, or interact with, the endothelium. 
 
It is hypothesised that T2DM and IGT are associated with impaired endothelial synthesis of NO 
and that this may explain the increased cardiovascular disease risk with these 
conditions.[103-111] Endothelial synthesis of NO can be estimated from vasodilation and/or 
blood flow increase in response to stimuli (Ach, shear stress, bradykinins). These responses 
are collectively referred to as endothelium-dependent vasodilation.[112] 
 
Early r e s e a r c h  h a s  p r o v i d e d  t h e  insight and means of understanding the 
mechanisms (Figure 1.3.) behind thrombosis, vascular inflammation and endothelial 
dysfunction.[113, 114] With the  added knowledge from larger clinical studies, the complex 
interactions that take place between platelet adherence; aggregation and release, clotting 
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factor activation, and vascular endothelial damage with thrombogenesis show that the 
pathogenesis of vascular diseases are multi-factorial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abnormal Blood 
Flow 
 
 
 
 
 
 
 
 
 
 
 
 
Vessel wall 
components 
     Blood    
components 
 
 
 
 
 
 
 
Figure 1.3.  The early proposed mechanisms of vascular thrombosis. 
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1.4.1.3. Circulating Markers 
1.4.1.3.1. Endothelin-1 (ET-1) 
Endothelin-1 (ET-1) is an amino acid peptide produced mainly by vascular endothelial cells and 
is a potent endogenous vasoconstrictor implicated in the pathogenesis of ischaemic heart 
failure, hypertension, vasospasm, stroke and diabetic complications.[115, 116] It has been 
identified in ocular tissues and ET-1 binding sites are located in the retina and choroid. There 
are namely three receptor sites; ETA located on the smooth muscle and therefore plays a key 
role in vasoconstriction, ETB found on endothelial cells and mediates vasodilation by the 
release of NO, and finally ETB2 which mediate direct vasoconstriction.[117, 118] 
 
ET-1 has been implicated in risk for T2DM and its complications. For instance a linear 
relationship between BP, ET-1 and obesity h a s  b e e n  f o u n d  i n  individuals at risk of 
diabetes.[119-122] 
 
Furthermore, animal studies have reported an increase in endogenous ET-1 w i t h  
e x p e r i m e n t a l l y  i n d u c e d  D R  that contributed to the haemodynamic changes found 
with DR, and that with DR there was a profound alteration in density and localisation of retinal 
ET-1 receptors.[91, 123] Additionally it  is also evident that with the administration of ET-1, 
there is an increase in DBP  along  with  an  expected  increase  in  ocular  perfusion  pressure  
(OPP)  but surprisingly there is also a reduction of retinal blood flow by 20%.[118] The retinal 
blood flow, like many other vascular beds, is determined by perfusion pressure and resistance. 
Therefore, for a reduction of this kind, an autoregulatory response would be the cause, (i.e. by a 
change in vascular resistance). However, autoregulation would not allow a decrease in OPP 
beyond baseline, and so it is unknown whether ET-1 causes atherosclerosis, endothelial 
function and autoregulatory disturbances or if it is damage endothelial cells that release 
increased levels of ET-1. 
 
1.4.1.3.2. Von-Willebrand Factor (vWF) 
Von Willebrand factor (vWF)  is  an  important  glycoprotein  (produced  by, released and  
stored  in  the  endothelial  cells and platelets)  involved  in cardiovascular physiology as it is 
associated with platelet aggregation and adhesion. The primary function of vWF is to bind 
other proteins (factor VIII in its inactive form) to be activated by thrombin so that it can 
bind to collagen or platelets when exposed to vessel damage and shear stress. Plasma 
levels of vWF are dependent on factors such as aging via impaired NO production, 
vascular inflammation, ROS and T2DM. Therefore, it has been found that raised levels of 
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vWF are associated with endothelial dysfunction and atherosclerosis and have prognostic 
value in those with heart disease, peripheral vascular disease and inflammatory vascular 
disease.[124-126] However, it  is  also  important  to  note  that  high  levels  of  vWF  can  
sometimes  be attributed to an acute phase reactant as it is a very sensitive marker and is easily 
influenced by many conditions.[127] 
 
There is limited information as to whether increased levels of vWF  worsen disease progression 
and whether therapeutically reducing its levels is beneficial. However, many animal studies 
have confirmed that vWF deficiency (von Willebrand disease and haemophiliacs)   provide   
protection   from   spontaneous   and   diet-induced   atherosclerosis and thrombosis along with 
a lower-than-expected incidence of heart disease.[128-130] 
 
In the case of T2DM, vWF abnormalities have been demonstrated with this disorder with   
increased   urinary   albumin   levels. This confirms   its   involvement   in   the   pathogenesis  of 
vasculopathy, namely nephropathy.[131-133] On the other hand, with IR and MetS, some 
studies have found no correlation with vWF and risk groups. This finding may be attributed to 
smaller patient groups as compared to control groups.[134, 135] 
 
 
 
1.5. Autonomic Nervous System (ANS) 
 
The ANS (or visceral nervous system) is a part of the peripheral nervous system that 
maintains homeostasis in the body. It can be divided into the parasympathetic nervous system 
(PSNS) and sympathetic nervous system (SNS) and also functionally, into its sensory and 
motor systems. 
The ANS and endothelium have closely-linked interactions that help to maintain vascular tone 
by balancing the endothelial release of vasodilating factors and sympathetic nerve terminal 
release of vasoconstricting factors. These opposing factors act on the smooth muscle cells to 
maintain tone.[136] To confirm these findings, a study found that by stimulating the SNS there 
was a resultant reduction in FMD; and this was abolished in those that were given α2-receptor 
blockades.[137] This shows that there may be a possible link between SNS activity and 
reduced endothelial function. Furthermore, there is evidence to show that the endothelium 
possesses both α2-adrenoreceptors and β-adrenoreceptors which could explain ANS influence 
on the endothelium (Figure 1.4.).[138, 139] 
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ANS Nerve Terminals Vascular Endothelium Vessel Lumen Smooth Muscle Cells 
SNS EFFERENTS 
Activation of receptors on SMC : 
 
β-adregenic causes vasodilation 
α1/α2-adregenic causes vasoconstriction  
PSNS EFFERENTS 
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Muscarinic causes vasoconstriction  
Figure 1.4. The influence of SNS and PSNS receptors on the vascular endothelium. 
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Certain conditions (DM, CVD, and Hypertension) have been found to reduce PSNS activation as 
well as enhance SNS activation.  This has been found to impair endothelial function and 
enhance endothelial-mediated atherogenic processes; contributing to endothelial cell 
dysfunction.  However, there are two possibilities for these findings. Firstly, ANS impairment 
may contribute to abnormal endothelial changes or endothelial dysfunction may lead to 
maladaptive alterations in the regulation of the ANS. 
 
1.5.1. Links between ANS and Endothelial Function 
1.5.1.1. Impaired ANS causes Endothelial Dysfunction 
DM, CVD, Hypertension and Coronary Heart Disease (CHD) are associated with ANS regulation 
abnormalities and endothelial dysfunction and there is an increasing amount of indirect evidence 
supporting the linknbetween Heart Rate Variability (HRV) and these states.[140-144] For 
instance, in those with DM, reduced HRV has  been  found  with  increased  levels  of  arterial  
stiffness and vWF, both thought to be indirect  markers  of endothelial function.[145, 146] 
 
1.5.1.2. Endothelial Dysfunction causes ANS Irregularities 
It has been hypothesised that impaired endothelial function may influence the ANS by altering 
neurotransmitter release, reuptake, or receptor sensitivity due to reduced NO release.[147] This, 
in turn, increases the contractile effects of SNS stimulation. Additionally, higher levels of vWF 
found in newly-diagnosed diabetics predict those who developed deficient limb nerve conduction 
velocity, and so the possibility of vWF predicting future autonomic neuropathy should be 
considered.[148] 
 
1.5.1.3. Factors affecting the ANS and the Endothelium 
1. Oxidative Stress has a negative influence on the endothelium and the ANS by br ing ing 
about  free-radical production and lipid peroxidation.[96, 149] It exposes the endothelium to 
oxidants leading to morphological changes that reduces its efficiency in forming a barrier 
between blood and the sub-endothelial matrix by promoting the release of ET-1 and 
leukocyte adhesion.[150] 
Peroxynitrite also mediates neuronal cell death (apoptosis of SNS neurons).[151]  This has 
been confirmed with drug-intervention studies that found improved HRV with Vitamin E 
treatment in diabetics.  This finding reflects the upregulation of the PSNS and 
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downregulation of the SNS with appropriate management, as it attenuates the negative effect 
of oxidative stress on ANS function.[152] 
2. The ANS and endothelium retain a certain degree of plasticity but are prone to age- 
related changes.[153] Reduced FMD[154] and NO release along with increased endothelin-1 
(ET-1) levels with age have a direct effect on the endothelium[155], whereas ANS changes 
with age (enhanced SNS and suppressed PSNS activity)   allow    the   increased   
vasoconstrictive   forces   to   overpower   endothelial-dependent vasodilation.[155, 156] 
3. IR has been associated with impaired HRV and enhanced SNS activity (conversely, SNS  
activity  has  been  found  to  increase  the  state  of  insulin  resistance),  and  poor  
endothelial function.[141, 157] 
4. Suppressed ANS activity increases platelet activation which in turn enhances platelet 
aggregation and adhesion to vessel walls.[158] Additionally enhancing SNS activity 
influences the interplay between the endothelium and circulating platelets allowing platelet 
aggregation at much lower levels of shear stress.[159] 
 
1.5.2. Ambulatory Blood Pressure (ABP) Measurements 
There is an increasing attention of major cardiovascular studies to investigate the 24-hour 
rhythms of the cardiovascular system. Many of these have consistently found a circadian 
pattern in the occurrence of cardiovascular events.[160] Twenty-four hour recordings of 
ambulatory blood pressure (ABP) are widely used in the diagnosis and treatment of hypertension 
as well as in epidemiological studies.  These profiles are better at predicting cardiovascular 
morbidity and mortality than isolated measurements done in clinics and make it possible to 
record BP during habitual daily activities and sleep. 
The main integrating system for BP control is situated in the brain, namely the medullary 
cardiovascular centre. This centre maintains adequate blood flow to the brain and heart via 
sensory inputs from the baroreceptors located in the walls of the aortic arch and carotid artery. 
After integration and analysis of the input, the medullary cardiovascular centre sends appropriate 
efferent outputs via the sympathetic and parasympathetic divisions of the ANS in order to 
regulate the heart function and blood circulation throughout the body. 
The diurnal variation in systemic blood pressure has been extensively studied.[161-163]   
Generally, blood pressure rises rapidly in the morning upon awaking and then continues to do 
so until reaching a plateau during the day (active period). It can often become slightly higher in 
the early evening, until the late evening where blood pressure starts to decline and shows the 
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lowest level during sleep (passive period).  This circadian rhythm may be influenced by 
demographic, neurohormonal, and pathophysiological factors.  For instance, it has been found 
that in night shift workers diurnal blood pressure variation is reversed, becoming higher at night 
and lower during the day.[164-167] Circadian rhythm in BP is defined as active BP minus passive 
BP for both systolic (SBP) and diastolic (DBP), whereby these periods are determined by a 
personal time diary. 
A normal nocturnal dip in blood pressure at night of around 10% or more occurs in 
approximately two thirds of the healthy population. Non-dippers, however exhibit a diminished 
nocturnal BP fall of less  than  10%,  and  are  prone  to  an  increased  frequency  of  
cerebrovascular  damage  including haemorrhages, thrombosis and vascular dementia.[168]  In 
turn, extreme dippers have a nocturnal fall in  BP  of  more  than  20%,  which  may  occur  
naturally  or  due  to  the  use  of  antihypertensive medications.  These patients show a high 
occurrence of ischaemic phenomena, including cardiac ischaemia, silent cerebrovascular 
damage[169] and anterior ischaemic optic neuropathy.[170] 
 
1.5.3. Heart Rate Variability (HRV) 
In normal conditions, the cardiovascular system is stable due to the autonomic control of the 
heart rate, BP, and other factors that react rapidly to a range of internal and external stimuli 
such as ischaemia, metabolic imbalance and changes in physical or mental activity. The 
analysis of sinus heart rate fluctuations, referred to as heart rate variability (HRV) can be used to 
indirectly assess the autonomic control of the heart.[171] 
Both ANS divisions, sympathetic and parasympathetic, densely innervate the sinus node and 
heart rate will reflect their modulating effect on the cardiac pacemaker cells. Parasympathetic 
innervation slows down the heart rate via acetylcholine.[171] Sympathetic activation results in an 
increase in heart rate  and  conduction  system  velocity,  together  with  an  increase  in  
contractility.  This effect is mediated by synaptic release of noradrenaline. The two 
subsystems of ANS tend to operate at different frequencies.[172] In normal individuals cyclic 
changes in heart rate occur in association with respiration[173-175],  and  this  particular   type   
of  high-frequency  cyclical  HRV  is  mediated  by  the parasympathetic nervous system. 
Cyclical variation occurring with changes in baroreceptor activity (due to changes in BP)[176] 
is of low frequency type and is mediated via the sympathetic nervous system. Simultaneous 
measurements of high and low frequency HRV can be used to investigate changes in the 
sympathovagal balance. The analysis of HRV has been extensively applied in the investigation of 
normal physiology as well as in pathological conditions. HRV analysis has provided useful results 
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in clarifying the role of the ANS in regulating the cardiovascular response to change in 
posture, stress and exercise, including: 
  Exploring the physiology of normal ageing and identifying those at risk of premature 
cardiac diseases;[177] 
  Assessing the autonomic function in a variety of non-cardiac diseases such as T2DM[178-
180], renal diseases[181], chronic liver[182], respiratory[183] and neurological diseases; 
  Occupational health, when exploring elevated cardiovascular risk in shift workers;[184-186] 
  Investigating cardiovascular diseases such as myocardial infarction[187], chronic cardiac 
failure[188] and hypertension.[189] 
 
More recently, the investigation of HRV with ocular disease has been proposed.[190] It is 
hypothesised that a change in blood flow regulation at the heart, cerebral or peripheral level 
could have a detrimental effect on the retinal vascular supply. Neurovascular coupling, the 
relationship between local neural activity and subsequent changes in cerebral blood flow, may 
explain this phenomenon. This is furthered by research demonstrating the homogeneity between 
cerebral and retinal microvascular structure and the known endothelial influences on cerebral 
vascular tone. In fact, ocular evidence indicates increased retinal neural activity is mainly 
attributable to increased ganglion activity and additional HRV abnormalities in ocular vascular 
disease.[191]  
 
HRV can be interpreted as either time-domain or frequency-domain specific analysis of 
electrocardiogram (ECG) recordings.[192, 193] For the purpose of this thesis, frequency-domain 
analysis was selected as it provides a simpler and accurate analysis of global ECG variations. 
To allow efficient analysis, ECG recordings must be free of noise and then need to be 
preselected for fourier transform analysis to obtain power spectra of the transform. The power 
spectrum then provides two frequency ranges: low frequency (LF: 0.04-0.15Hz) and high 
frequency (HF: 0.15-0.40Hz) allowing for a measure of sympathetic activity with minor influence 
of the parasympathetic (LF) and sole parasympathetic activity (HF). Furthermore, the calculation 
of LF:HF allows a measure of sympathovagal balance, i.e. an increased value indicates a 
predominance in activity of the sympathetic versus parasympathetic nervous system. 
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1.6. Oxidative Stress 
 
Oxidative  stress  describes  a  state  of  increased  oxidant  production  in  animal  cells  that  
is characterised by an increased release of free radicals that results in cellular degeneration. It 
is seen as  a  major  mechanism  in  the  pathogenesis  of  atherosclerosis  and  endothelial  
dysfunction  (a prerequisite to atherosclerosis) and may serve as the mechanism behind the 
effect of risk factors on the endothelium.[194] Oxidative stress has been implicated in a variety 
of biological and pathological processes, as an excessive production of free radicals can lead 
to different pathological conditions.[195] 
 
A free radical is a species that has one or more unpaired electrons. Normally more than 95% of 
the oxygen consumption by the aerobic organisms is the result of enzymatic reduction to H2O 
in mitochondria by the terminal oxidase of the respiratory chain. When molecular oxygen is 
reduced by one electron, the product is a superoxide radical (O2
-). The addition of a second 
electron to O2
- at physiological pH gives rise to hydrogen peroxide (H2O2), an oxidizing species 
that has no unpaired electrons and thus is not a free radical. The one electron reduction of 
H2O2 yields H2O and an hydroxyl radical (OH), the strongest oxidant produced in biological 
systems. Together, O2
-, H2O2   and OH are known as the reactive oxygen species (ROS) and 
are continuously produced by aerobically growing cells.[195] 
ROS (superoxide anion and hydrogen peroxide) are important signalling molecules of 
endothelial cell damage. To combat the cytotoxic action of the reactive oxygen and nitrogen 
species, cells are equipped with a large variety of antioxidant defences that include: 
 
1.  Enzymes which catalyse the dismutation of O2
- into H2O2 
2. Hydrogen  peroxide  scavenging  enzymes  such  as  catalase  and  glutathione  peroxidase  
which convert H2O2 into H2O 
3.  Hydrophilic radical scavengers such as ascorbate, urate, and glutathione (GSH) 
4.  Lipophilic radical scavengers such as tocopherols, flavonoids, carotenoids, and ubiquinol 
5. Enzymes  involved  in  the  reduction  of  oxidised  forms  of  small  molecular  antioxidants  
(GSH reductase) 
6. Cellular  enzyme  systems  that  maintain  an  NADH,  NADPH,  and  FADH-dependent  
reducing environment (i.e., glucose-6-phosphate dehydrogenase). 
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1.6.1. Markers of Oxidative Stress 
1. The excess production of NO is known to be cytotoxic to tissue and can induce cellular 
damage. The rapid reaction between NO and O2
- yields peroxynitrite (ONOO-), a potent 
oxidizing species.[196] Peroxynitrite is assumed to react preferentially with CO2 in vivo to 
produce nitrogen dioxide (NO2) and trioxocarbonate radicals.  It also nitrates tyrosine residues 
of the proteins, stimulating the production of 3-nitrotyrosine, which disrupts the normal function 
of the proteins. NO is destroyed in a reaction with superoxide anions immediately after it is 
produced. Laboratory  testing  of  NO  and  its  free  radicals  (Nitrates  and  Nitrites)  are  
heavily  influenced  by exercise, diet, intestinal bacteria and contaminants.[197-199] 
 
2. Reduced glutathione (GSH) is a tripeptide, and is primarily a major intracellular antioxidant that 
protects cells from toxins and free-radical damage.  This has been confirmed by many clinical 
studies using N-acetyl-L-cysteine treatments that have found a substantial increase in 
intracellular GSH contributing to reduced levels of plasma vascular adhesion molecules. 
Glutathione is found in high levels w i t h in ocular tissues that are involved in multiple 
functions, to help serve as an antioxidant and as an electron donor for peroxidases.   A 
major study immunohistochemically localising glutathione reductase in the eye of adult rats 
found significant levels to be distributed in the corneal and conjunctival epithelium, corneal 
keratocytes and endothelium, iris and ciliary body, neural retina, and retinal pigment 
epithelium.[200] In addition, glutathione reductase was highly expressed in the retinal 
ganglion cells. This finding goes some way to support its pivotal role in the protection of ocular 
tissues against oxidative stress. 
 
Hyperglycaemia  promotes  the  increased  production  of  free  radicals  (ROS)  and  
impairs  the antioxidant defence system; such as depleting the levels of GSH by glucose 
auto-oxidation and/or non-enzymatic glycation. This promotes the formation of glycation end 
products (AGEs) that induces ROS and vascular inflammation.[180, 201-203] Furthermore, 
oxidative stress may be very important in the pathogenesis of IR as it alters the insulin 
signalling pathways (“phosphoinositide 3-kinase/Akt/protein kinase B” pathway) that emerge 
from the insulin receptors causing a marked reduction in eNOS activation.[197] 
 
3. Oxidatively modified tyrosine: Nitrotyrosine (NT-3) has been proposed as a marker of 
oxidative damage to protein and its levels strongly correlate with the severity of coronary 
artery disease (CAD), peripheral vascular disease and glycaemia.[204-207] 
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Prolonged oxidative stress, inactivity of the endothelial-derived Nitric Oxide synthase enzyme 
(eNOS) and endothelial dysfunction activates the reductase function of the enzyme eNOS. 
This increases the levels of ROS because eNOS has now been shifted from an 
oxygenase that produces NO into a reductase that produces ROS. This in turn further 
exaggerates the levels of oxidative stress and emphasises a cellular proatherogenic role 
as peroxynitrite (cytotoxic oxidant) mediates low-density lipid (LDL) oxidation.[95, 204, 208] 
 
 
1.7. Research Rationale  
 
The pathophysiological mechanism underlying an increased risk of CVD, atherosclerosis and 
T2DM in at risk groups is not yet fully understood. Traditional risk factors such as smoking, 
hypertension and dyslipidaemia only explain a small proportion of the biological processes. 
Therefore, identification of new risk markers will lead to earlier and more effective interventions to 
those at risk of T2DM. 
T2DM accounts for six percent of the total global mortality with fifty percent of diabetes-
associated deaths being attributed to CVD.[1, 209] Therefore, the need for appropriate 
management programmes and prevention strategies targeting high-risk individuals could show 
that much of the morbidity and mortality of T2DM is preventable. 
IR, together with other conventional risk factors has been proposed to be an important 
component for the mechanisms behind the cause of T2DM and cardiovascular disease (CVD). 
Furthermore, it has been reported that IR is associated with other CVD risk factors including age, 
body mass index (BMI), TG, cholesterol and BP. Recently, carotid IMT and vascular endothelial 
function have been frequently used as a surrogate marker of atherosclerosis. Therefore, the 
relationship between IMT and endothelial function in those at risk of T2DM can be determined as 
surrogate markers of independent risk factors for CVD and T2DM.[42]    
Additionally, insulin is well known for its ability to vasodilate skeletal vasculature as a result of 
endothelial nitric oxide (NO) production that stimulates endothelial-dependent vasodilation. Those 
with IR, hypertension and T2DM present with a blunted insulin-mediated endothelial-dependent 
vasodilation as a result of reduced endothelium-derived NO production.  
Subclinical inflammation can also be a precursor to CVD and is associated with IR, therefore, can 
precede the development of T2DM.  Inflammatory mediators may induce systemic endothelial 
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dysfunction; in large arteries this can lead to clinical CVD, whereas in the capillary and arteriolar 
endothelium, with a vast surface area in contact with metabolically active and insulin-sensitive 
tissues, endothelial dysfunction may lead to T2DM.[11, 210, 211]  Therefore, the identification of 
endothelial dysfunction might expand options for diabetes prevention and treatment. 
 
Since endothelial dysfunction is an early phase of atherosclerosis, associated alongside an 
abnormality in the bioavailability of NO, it could be suggested that there is more insulin resistance 
in peripheral tissues as well as vascular endothelial dysfunction in subjects thought to be at risk 
of T2DM.[101] 
 
Traditionally, methods that investigate endothelial function at the macrocirculatory level have 
been used for risk evaluations. Endothelial dysfunction however, is known to occur much earlier 
at the microvascular than at the macrovascular level and, consequently, several vascular 
reactivity tests including retinal vascular function have been developed for the clinical 
assessment of endothelial function in these type of vessels.[212] Indeed, as the eye is vulnerable 
to minor changes in perfusion leading to structural and functional abnormalities it is a suitable site 
to investigate early changes that may predict large vessel disease.[213]. Changes of the retinal 
arteriolar calibre have been shown to be associated with high risk of hypertension and can be 
used as a predictive marker for future vascular complications in already diseased patients. More 
recently, functional retinal vascular impairment using dynamic vessel analysis have been 
reported in patients with diabetes[214, 215], CVD and smoking individuals[216], showing its utility 
as an accurate and clinical means of analysing functional changes in vascular disease.  
Therefore, a key concept in studying groups at risk of T2DM is to recognise that there is a 
clustering of risk factors. For instance, the association of hyperglycaemia, hypertension, 
dyslipidaemia and obesity has been recognised for several years and adopted the clinical 
definition known as the MetS. More recently, the number of associated characteristics has 
evolved to include a spectrum of markers that indicate vascular inflammation, endothelial 
dysfunction, cell adhesion, microalbuminuria, and blood coagulation abnormalities.[43] 
Recent publications investigating vascular function in at-risk individuals have provided a 
foundation in identifying pre-clinical markers for future T2DM and CVD risk.[217-219] However, 
as shown in Table 1.2., there is limited data available to allow for clinical strategies and screening 
programmes to be made available. For the purposes of this thesis, Dynamic Retinal Vessel 
Analysis (DRVA) was used to measure retinal vascular function and is explained later in detail in 
Section 2.1.  
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Therefore, the purpose of this thesis was to investigate vascular function in those at risk of T2DM, 
namely South Asians (SA) and gender differences, those with impaired glucose tolerance (IGT) 
and normoglycaemic offspring of T2DM, i.e. those with a familial history (FH) in an attempt to 
further already existing knowledge. Additional to these main chapters, a subsidiary investigation 
on the effect of overweight and obesity was conducted on vascular function. Furthermore, the 
investigation of surrogate markers and their use in well known at-risk individuals for vascular 
screening will provide clinical information for future applications. 
 
 Family History (FH) South-Asians (SAs) Impaired Glucose 
Tolerance (IGT) 
Retinal 
Haemodynamics 
DR is associated with 
incident T2DM[220] 
↑Arterial MDRT[221] 
 
IGT not related to retinal 
fractal dimension[222] 
 
IGT is associated with 
↑DR[223-226] 
 
↑ Venular calibre 
associated with presence 
of DR[227] 
 
RPE changes and  
lesions with IGT[228, 229] 
 
 
Systemic 
Endothelial 
Function 
 
↓FMD[37-39, 230-236] 
 
No differences in 
FMD[237, 238] 
 
↓FMD[26] 
↓FMD[236, 239-242] 
 
No differences in 
FMD[243] 
Biochemical 
Markers 
 
↑ (vWF, PAI-1) markers of 
endothelial 
dysfunction[244, 245] 
 
State ( ↑ MDA) of 
oxidative stress  [246, 
247] 
 
↑ (vWF, hs-CRP) markers 
of endothelial cell damage 
and dysfunction[26, 248-
251] 
 
IR linked with endothelial 
damage markers[252] 
 
Comparable levels[253, 
254] 
 
↑ (ET-1, CAM-1) markers 
of endothelial 
dysfunction[255] 
 
State (↓ GSH, ↑ MDA) of 
oxidative stress  [246, 
247, 256, 257] 
Autonomic 
Function 
↓HRV[235, 258-260] 
 
↓ANS function in SA 
men[261] 
 
↓HRV[258] 
 
 
↓ANS function[262-269] 
 
No differences in 
ANS[270, 271] 
 
Table 1.2. Recent published vascular function data available on groups known to be at risk of T2DM. DR: 
diabetic retinopathy; ↑: increased; MDRT: maximum diameter reaction time; RPE: retinal pigment 
epithelium; ↓: reduced; FMD: flow mediated dilation; vWF: von Willebrand factor; PAI-1: plasminogen 
activator inhibitor-1; MDA: malondialdehyde; hs-CRP: high sensitivity C-reactive protein; IR: insulin 
resistance; ET-1: endothelin1; CAM-1: cellular adhesion molecule-1; GSH: reduced glutathione; HRV: 
heart rate variability; ANS: autonomic nervous system. 
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2. Methodology  
This chapter explores the methods used for this thesis and its major studies in greater detail, 
discussing the mechanisms and limitations as well as the protocols used for the measurement 
protocols adopted in the Appendix 1. 
 
2.1. Retinal Vessel Analysis 
Dynamic retinal vessel analysis (DRVA) is a technique used to assess retinal artery and venous 
behaviour by means of measuring diameter change. Measurements are obtained with the use of 
a retinal vessel analyser (RVA, IMEDOS GmbH, Germany) that consists of a high resolution 
fundus camera (FF450, Carl Zeiss Meditech, Germany) modified to measure retinal vessel 
diameter continuously. Recordings are stored by video capability that is coupled to the CCD 
camera imaging the retina (Figure 2.1.).  
 
 
 
 
 
 
 
 
 
 
 
                       Figure 2.1. The hardware components of the Dynamic Retinal Vessel Analyser [84]. 
 
In order to obtain a good quality and evenly contrasted and illuminated fundus image, full pupil 
dilation is required using a mydriatic drug (typically Tropicamide 1%, Chauvin Pharmaceuticals, 
UK). The camera is set at an angle to provide 30° field of view with a temporal resolution of 40ms 
to allow a sampling rate of 25Hz (Figure 2.2.). Frame to frame analysis is used to process the 
recordings as described elsewhere.[272] 
 
FUNDUS CAMERA 
FLICKER MODULE 
 
 
CCD SENSOR 
OBSERVER SCREEN 
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Figure 2.2. The DRVA data acquisition software recording retinal vessel diameter of chosen segments in real 
time. 
 
The DRVA measures the width of the red blood cell column within the chosen vessel of interest 
and allows the means of assessing the autoregulatory mechanisms of the retinal vessels.[273] 
This is achieved by using various stimuli (hypercapnia or increased IOP with a suction cup), or, 
measuring vessel dilation to flicker light stimulation.[274-278] 
However, it is important to note that the instrument has limitations that can affect the overall 
measurement outcome. Namely, the image quality is strongly dependent on clear optical media 
and good fixation abilities. Therefore, measurements in subjects with corneal and lenticular 
opacities, central vision loss or poor visual acuity will result in increased variability.  
 
This thesis adopted flickering light provocation to assess retinal vessel reactivity as a means of a 
stimulus of the vessels via metabolic increase (NO-induced endothelial-mediated dilation), neural 
coupling, or a combination of both.  
Flickering light is modulated by the DRVA, and due to the natural reactions of the retina to 
respond to light modulation, flicker provides the most natural stimuli to assess its function.[277-
280]  To achieve flicker light, an optoelectronic shutter is placed in the optical pathway of the 
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camera illumination. The shutter generated flicker by interrupting the illumination to provide a 
bright-to-dark contrast ratio of at least 25:1. As the video frequency is set at 25Hz, the flicker 
frequency provides a sampling rate of 12.5Hz which has been shown to be in the maximal 
exciting flicker frequency range.[277] 
An increase in the metabolic rate (and thus oxygen consumption) of the photoreceptor cells 
triggers the release of NO in retinal vascular endothelial cells to meet the metabolic demands 
causing active vasodilation. Following stimuli cessation, the vessel returns to baseline diameter 
value with the exception of the artery which has been found to constrict beyond its baseline 
diameter. This over-constriction is thought to be a regulatory mechanism of the retinal vascular 
endothelium as a result of an imbalance of vasoactive substances, namely NO and ET-1. 
The measurement procedure used for this thesis has been described and validated 
elsewhere.[281] In short, the whole measurement duration encompasses 350 seconds that 
consists of 50 seconds baseline followed by three 20-second cycles of flicker and 80 seconds of 
recovery.  This protocol has been shown to be of value in a range of clinical and ocular conditions 
including glaucoma[274, 282-285], vein occlusions[286-290] and DM[214, 215, 291-301]. 
(Appendix 2) 
The DRVA then provides a measurement profile for both arteries and veins (Figure 2.3.). The 
algorithm used by the software calculates the maximum diameter response by firstly averaging all 
three flicker cycles and then calculating the flicker response ±3 seconds flicker cessation.[295, 
302]  Therefore, for those that reach maximum retinal dilation before 17 seconds or after 23 
seconds of flicker light commencing, their dilation response will be underestimated. Furthermore, 
the averaging of all three cycles does not take into consideration differences in spatial and 
temporal reaction patterns in each individual cycle. Therefore, taking into account of these 
limitations, an analysis of individual flicker cycles[275-277, 303] has been incorporated with a 
different analysis method known as sequential and diameter response analysis (SDRA). It has 
been tested and validated in volunteers likely to exhibit vascular disturbances and has been 
shown to allow the analysis of dynamic retinal vessel responses and their time course in serial 
stimulation.[216] This has also been further extended in a small sample of otherwise healthy SAs. 
(Appendix 3) 
The absolute diameter (AD) is recorded in arbitrary units (AU) as this best corresponds to μm in 
the ametropic eye; unlike other papers quoting measuring units (MU) as this correspond to μm 
only in the Gullstrand eye.[273, 304] Three single curves, obtained for each flicker cycle, 
alongside averaged values, are used for statistical analyses. Essentially, thirty seconds of 
baseline assessment before twenty seconds of flicker application and thereafter eighty seconds 
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were used for analysis. Due to inter- and intra-individual vessel diameter variation, the baseline 
diameter was defined as 100%.[305]  
 
 
 
 
 
 
 
 
 
 
            
 
Figure 2.3. The patient set-up on the DRVA along with the pre-defined output profiles provided by the DRVA 
software. 
 
The following retinal vessel reactivity and time course parameters were then calculated (Figure 
2.4.); the differences between maximum and minimum baseline vessel diameter termed as 
baseline-diameter fluctuation (BDF), the maximum diameter (MD) was used to describe the 
maximal vessel dilation in response to flicker light stimulation expressed as a percentage from 
baseline, the time taken (seconds) to reach the maximum vessel diameter during twenty second 
flicker exposure was termed as MD reaction time (MDRT), the minimal vessel diameter within 
thirty seconds of the recovery period was calculated as a percentage of  baseline and expressed 
as the maximum constriction (MC) whilst the time taken (seconds) to reach maximal vessel 
constriction was termed maximum constriction reaction time (MCRT), and finally, the difference 
between maximal dilation and constriction responses was termed as the dilation amplitude 
(DA).[117]  
The impact of atherosclerosis and thus vessel stiffness must also be taken into account. For 
instance, depending on a vessel‟s elasticity, the ability to reach MD can be fast or slow. 
Therefore, the calculation of reaction time taken to reach maximum dilation (RT) was performed 
alongside slope analysis for dilation and constriction profiles during and after flicker stimulation 
respectively. The slope analysis has been furthered to involve both MD and MC in order to take 
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into consideration endothelial and autoregulation mechanisms as it is proposed that the initial 
reaction to flicker could be endothelial-mediated until NO reserves are depleted allowing 
autoregulative mechanisms to continue the dilation response. Therefore, MD and MC slopes 
were calculated at 50% and 100% time points (Figure 2.5.) 
 
 
 
 Figure 2.5. Constriction slopes calculated for both 50% and 100% time-points. The green 
dashed lines represent Gaussian distribution and normal distribution as calculated by the 
DRVA software using a limited database of healthy controls. The red line represents an average 
of all three flicker cycles. 
∆D 
 ∆T 
50% MC Slope 
100% MC Slope 
Figure 2.4. The retinal vessel reactivity and time course components used in SDRA. [117] 
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2.2. Flow-mediated Dilation of the Brachial Artery (FMD) 
The capacity of blood vessels to respond to physical and chemical stimuli in the lumen 
confers the ability to self-regulate tone and to adjust blood flow and distribution in response to 
changes in the local environment. Many blood vessels respond to an increase in flow, or more 
precisely shear stress, by dilating. This phenomenon is designated FMD.[112, 117, 306-308] 
 
Therefore, FMD is an endothelium-dependent process that describes the relaxation of a 
conduit artery when it is exposed to increased blood flow (shear stress). Shear stress is 
determined by blood flow and the force that it exerts perpendicular to the long axis of the 
vessel.[309] As the shear stress changes, the endothelium acts as a mechanotransducer and 
subsequently modifies the expression of vasodilators (Figure 2.6.). 
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Shear  stress  is usually  induced  by  increasing  local  blood  flow  (reactive  hyperaemia),  
and this is achieved by inflating a pneumatic cuff 50mmHg above systolic blood pressure 
(SBP). The increase in pressure causes an abrupt decrease in vascular resistance due to an 
occlusion in arterial inflow. This causes ischemia and consequent dilation of downstream 
resistance vessels via autoregulatory mechanisms. Subsequent  cuff  deflation  induces  a  
brief  high-flow  state  through  the  brachial  artery  (reactive hyperaemia) to accommodate 
the dilated  resistance vessels. The resulting increase in shear stress causes the brachial 
artery to dilate.[48, 308] This phenomenon was first described by Schretzenmayer and has 
been demonstrated in a number of conduit arteries (brachial, radial and femoral).[310-315] 
 
The   maximum   post-hyperaemic   diameter   is   determined   and   FMD   is   expressed   
as   the relative change from baseline. An impaired/diminished FMD response reflects 
endothelial dysfunction.[308] 
 
For the purpose of this thesis FMD was detected by means of colour Doppler imaging (CDI), 
a technique that detects the Doppler shift induced by moving red blood cells through the 
use of an ultrasonic signal. CDI combines conventional b-scan (grey-scale imaging of 
anatomical structures) together with the Doppler shift frequency measurement of blood 
flow velocities and the colour representation of blood flow based on these frequency shifts. 
The  Doppler  equation  (Equation 2.1.) explains  the  relationship  (and  thus  the  
mechanism  of  doppler  imaging) between the frequency of the ultrasound beam (f), the 
velocity of the blood (Vblood), the velocity of the ultrasound through the blood (Vsound), and 
the angle of incidence between the direction of the blood flow and the approaching sound 
beam (θ) to give the Doppler shift: 
 
 
Shift =  2(f.Vblood.Cos θ) 
                                                 Vsound 
 
                                            Equation 2.1. The doppler equation. 
 
 
 
The ultrasound system (Acuson Sequoia®,  Siemens Medical Solutions, US) used for  
th is  thes is  consists of a screen unit linked to a keyboard where the data and the 
optimization of the image can be adjusted. In conjunction with the ultrasound system, 
arterial diameters are continuously measured by wall-detection using specialised artificial 
neural networking software (VIA® Software, UK) from the anterior to the posterior 
interface between the media and adventitia on a personal computer (Figure 2.7.). An 8L5 
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liner-array transducer is used to image macrovasculature. A surgical bed is a l s o  used in 
conjunction with this instrument to keep subjects in a supine position. 
 
 
 
 Figure 2.7. The brachial artery image using the Sequoia
®
 system and FMD profile generated by the VIA
®
 
system. 
 
The Sequoia® system allows for the manipulation of certain parameters so that an 
adequate quality of the 2D vessel image representation can be obtained. Additionally, 
certain influences on the image quality can be controlled and taken account of:  
 
1. Aliasing: The Doppler waveform is made up of a series of samples that are in turn 
made of an inherent maximum frequency. When this frequency is exceeded, the 
waveform is no longer constructed accurately, giving an overall lower frequency. 
Therefore, aliasing is the misinterpretation of high frequencies that disobey Shannon‟s 
theorem (above half the sampling rate). 
2. Angle and Blood flow errors: When considering the Doppler shift equation, θ; the angle 
subtended between the ultrasound beam and the longitudinal axis of the vessel, is an 
important factor. Large inaccuracies are found when θ is continually changing 
(influenced by movement, intrinsic spectral broadening). This is because each point 
along the transducer face can become a point source, i.e. with  increased  transducer  
array  width;  there are an  increased  number of  elements  firing  off  a Doppler signal 
if θ is not kept constant. 
3. Mirror Images represent multiple reflections from artefacts; be it resolution artefacts 
(axial, lateral or speckle), or, acoustic shadowing. Mirror images are affected heavily by 
path length errors, finite dimensions of arrays and phase quadrature. 
4. Doppler  Parameters:  The  effect  of  this  variable  is  minimised  if  settings  are  kept  
constant throughout the study procedure. 
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The brachial artery is imaged above the antecubital fossa in the longitudinal plane and a 
segment with clear anterior and posterior intimal interfaces between the lumen and vessel 
wall is selected for continuous 2D greyscale imaging. A baseline rest image is acquired 
for two minutes, and thereafter, arterial occlusion is created by cuff inflation to 
suprasystolic pressure for a standardised five minutes. The longitudinal image of the 
artery is recorded continuously for two minutes (min) after cuff deflation. At least 10 min of 
rest is needed (as according to the protocol adopted) after reactive hyperaemia before 
another image is acquired to reflect the re-established baseline conditions.  An  exogenous  
NO  donor,  such  as  a sublingual  glyceryl  trinitrate  tablet  is  given  to  determine  the  
maximum  obtainable  vasodilator response, and to serve as a  measure of endothelium-
independent vasodilation reflecting vascular smooth muscle function.[308] 
 
In order to achieve optimisation of parameters all known factors that can affect FMD have 
to be limited. For instance, the participant should fast, including taking no caffeine  for 12 
hours before the study, and not have exercised before the test. FMD should be 
measured in the morning in a quiet, temperature-controlled room (22°C). In addition 
participants shouldn‟t smoke and all vasoactive medications should be withheld for 4 half-
lives. Furthermore, the investigator should be cognisant of sleep deprivation, mental 
stress and the phase of the menstrual cycle.[112, 316, 317] 
 
2.3. Endothelin-1 (ET-1) Levels 
ET-1 levels were determined by the author and an experienced lab technician, in fasted 
venous plasma samples collected in EDTA tubes that have been centrifuged at 3000rpm for 
fifteen minutes and then aliqouted and stored in a -80°C freezer. Once all EDTA plasma 
samples have been collected, they are thawed and ET-1 levels are determined using a 
standardised and commercially available ELISA kit which involves: 
 
1. Initially, 100μl of assay buffer, eight standardised solutions and plasma sample are 
pipetted into each microwell. 
2. The plates are sealed and incubated overnight at 4°C. 
3. The microwells are washed seven times using 400μl of wash buffer solution and 100μl of 
labelled antibody is added, sealed and incubated at 37°C for thirty minutes. 
4. Each well is then washed again using 400μl of wash buffer solution for a total of nine 
times before 100μl of substrate solution is added and incubated for thirty minutes at room 
temperature in the dark. 
5. The enzymatic reaction is then stopped using 100μl of composed stop solution and the 
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plates read using a plate reader set at an optical density of 450nm.  
 
2.4. von-Willebrand Factor (vWF) Levels  
In order to evaluate vWF levels, fasted venous blood samples have to be collected in citrate 
tubes. After spinning the blood in a centrifuge at 3000rpm for fifteen minutes, the 
supernatant is aliqouted and stored in a -80°C freezer. The citrated plasma is then thawed 
and analysed for vWF levels using a standardised ELISA kit which was optimised according 
to previously established methods.[318, 319] The procedure carried out by the author and 
an experienced lab technician briefly involves: 
 
1. A microtitre plate is coated with 100μl of dilated primary antiserum solution (30μl in 20.5ml 
coating buffer at pH 9.6) at room temperature and then refrigerated for a minimum of 60 
minutes to overnight. 
2. The microplate is washed four times with 250μl of wash buffer per well before 100μl of 
substrate is added with working strength detection antibody dilutant and incubated for 
sixty minutes at room temperature. 
3. The microplate is then washed three times with wash buffer before 100μl of secondary 
antiserum is added and incubated at room temperature for forty-five minutes. 
4. The microplate is washed again for a final three times and 100μl of substrate is added 
and incubated at room temperature for twenty minutes. 
5. The enzymatic reaction is then stopped by adding 50μl of hydrosulphuric acid. 
6. The absorbance of the solution is then immediately read on a microwell plate reader set 
at 492nm.  
 
2.5. Glutathione Levels  
The ratio of reduced (GSH) and oxidised (GSSG) glutathione within cells is thought to be a 
valid measure of cellular toxicity. For the purpose of this thesis, this marker of oxidative 
stress was determined by centrifuging (15000rpm for five minutes) 30μl of fasted venous 
blood collected in EDTA tubes with 33.3μl of sulfosalicylic acid and 936.7μl of sodium 
phosphate stock buffer solution within ten minutes of blood collection. 150μl of the 
supernatant is aliqouted and cooled at -80°C for later analysis. The adopted protocols have 
been previously optimised in-house according to previously reported and validated methods. 
[320] Glutathione levels were then determined by the author and an experienced lab 
technician using an enzymatic reaction created by: 
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2.1. Firstly, 150μl of daily buffer is added to 50μl of DTNB solution in each microwell. 
2.2. 25μl of the prepared plasma sample is added to each well and incubated at 37°C for   
three minutes. 
2.3. 25μl of GSR solution is added to the previous mixture and read using a microplate 
reader set at 410nm. 
 
2.6. ABPM and HRV  
Both ABP and ECG recordings for HRV analysis can be obtained with a computer-operated 
monitor. The device used in this thesis (Cardiotens-01, PMS Instruments, UK) indirectly 
obtains BP using the oscillometric technique whereby the magnitude of the pressure 
oscillation is compared to the pressure of the cuff. The ECG is measured by using a 
validated electrode and lead set-up. The monitor is programmed via a fibre-optic cable 
connection to a personal computer programmed with the BP monitoring software 
(Cardiovisions 1.7.2., PMS Instruments, UK). This allows for customised protocols set at 
specific measurement intervals alongside graphical and statistical packages for detailed BP 
and ECG analysis. The validated protocol adopted for this device involves 15-minute interval 
BP measurements during the active period and 30-minute interval measurements during the 
passive period (Figure 2.8.).[321]  
 
 
 
Figure 2.8. The 24-hour blood pressure and ECG profiles provided by Cardiotens system and software. 
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Mean arterial pressure (MAP), as a means of describing cardiac output function in relation to 
arteriolar resistance was calculated according to Equation 2.2. 
 
MAP ≈ (⅔ X DBP) + (⅓ X SBP) 
                                                                     Equation 2.2. Mean arterial pressure equation 
 
To allow sufficient BP analysis, a minimum of 80% programmed recordings were required 
and furthermore, any suspected outliers based on pulse pressure (PP) determination (i.e. PP 
<10mmHg with SBP <100mmHg) were rejected on the assumption that the data was non-
physiological.  
HRV analysis was performed for each individual using the Cardiovision software (PMS 
Instruments Ltd., Maidenhead, UK) to obtain twenty-four hour, active and passive period LF, 
HF and LF:HF values. From, this circadian BP and HRV changes were calculated according 
to Equations 2.3. and 2.4. respectively. 
 
Circadian BP = Active Period BP – Passive Period BP 
Equation 2.3. Circadian BP equation 
 
Circadian HRV = Active Period HRV – Passive Period HRV 
Equation 2.4. Circadian HRV equation 
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3. Vascular Function in Normoglycaemic WE Individuals with and 
Without a Family History of T2DM 
 
3.1. Abstract 
3.1.1. Background/Aims: To investigate ocular and systemic vascular reactivity to stress in 
normoglycaemic and normotensive individuals with a parental FH of T2DM. 
3.1.2. Methods: Healthy WE participants aged between 25-55 years with (n=55) and without 
(n=55) a FH of T2DM were recruited. Fasted venous samples were taken to analyse for 
glucose, TG and cholesterol (HDL, LDL and total). Retinal vessel reactivity was assessed by 
using the Dynamic Retinal Vessel Analyser (DRVA, Imedos GmbH, Jena). In addition, 
systemic endothelial function was assessed by using the flow mediated dilation (FMD) 
technique. 
3.1.3. Results: Those with a FH, including gender sub-groups showed higher levels of 
dyslipidaemia (p<0.05) but no differences in retinal artery reactivity or FMD (p>0.05). Those 
with a FH did exhibit negative correlations between cholesterol values (total and LDL) and 
retinal arterial dilation (r=-0.90, p=0.003), maximum dilation (MD; r=-0.90, p=0.03) and 
dilation amplitude (DA; r=-0.94, p=0.019). 
3.1.4. Conclusion: Subjects with a FH of T2DM show similar vascular responses at both 
macro- and microcirculation levels to that of healthy controls. Whether the correlations show 
that, in certain conditions, FH could contribute to a higher risk of developing widespread 
systemic vascular disease before the development of overt diabetes needs further 
investigation. 
 
3.2. Introduction  
In healthy individuals, the vascular endothelium plays an important role in vascular 
homeostasis by regulating vascular tone. In addition, it also acts in preventing inflammation, 
platelet aggregation and leukocytes adhesion. Ageing, smoking, dyslipidemia, hypertension, 
obesity, DM and chronic inflammatory diseases result in the so-called endothelial 
dysfunction, a condition in which NO is reduced and the reactive oxygen species levels are 
increased. Moreover, in addition to vasoconstriction and tissue ischaemia, endothelial 
dysfunction is also characterised by an increase in inflammation and cells adhesion leading 
to atherosclerosis.[48]  
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It has already been documented that endothelial dysfunction contributes to the occurrence 
and progression of both DM and its cardiovascular complications.[322, 323] Moreover, signs 
of endothelial dysfunction have been found in those with a FH of parents suffering from 
T2DM.[38, 39, 234]  Consequently, as endothelial dysfunction contributes to both impaired 
insulin action and occurrence of atherosclerosis, those with a FH of diabetic patients could 
be at an increased risk of early development of a large variety of pathologies, from metabolic 
to cardiovascular disorders.[244] 
As emphasised previously in Section 1.4., it is important to detect changes in vascular 
function that precede cardiovascular events; this is possible through studying endothelial 
function. Indeed, decreased endothelial function is a factor that predicts independently from 
other risk factors the occurrence of cardiovascular disease.[93, 94, 324] Endothelial function 
can be assessed using a large variety of techniques, from laboratory markers, such as 
inflammatory cytokines, adhesion molecules, NO and markers of endothelial damage and 
repair, to vascular reactivity tests such as FMD of the brachial artery by ultrasound (Section 
2.2.), forearm venous pletysmography, digital pulse amplitude tonometry and laser Doppler 
measurements of the peripheral circulation.[212] These methods are successful in 
demonstrating the presence of endothelial dysfunction in both diabetic patients and their 
offspring, however, their complicated nature and reduced reproducibility in medical practice 
have proven to be of limited use in routine clinical screening.[212] Therefore, the need for 
reproducible, non-invasive and less laborious techniques has never been greater. In this 
respect, the measurement of vascular reactivity at both macro- and microvascular levels 
seems to be the best available option.  
Microvascular assessments such as retinal vessel reactivity can be performed quickly using 
relatively affordable techniques and offers reliable information on vascular function in 
patients suffering from various systemic diseases including DM. It is thought that the 
microvascular complications of DM are a direct result of increased vascular permeability and 
impaired autoregulation of blood flow and vascular tone.  Clinical studies using the DRVA in 
patients suffering from DM, hypertension or hypercholesteraemia have shown a reduced 
retinal vessel response to flickering light, demonstrating that endothelial dysfunction may be 
measured at the ocular level in various systemic vascular pathologies.[49] 
Therefore, by using direct visualisation of the vascular function at the retinal vessel level, we 
may be able to diagnose earlier stages of vascular disease in populations at risk. Indeed, 
changes in retinal vessel reactivity in those with T2DM has been extensively studied. Little is 
known about when the first signs of vascular dysfunction occur in both patients with, and 
subjects at risk of this disease.  
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This study aims to investigate the retinal vascular function and its relationship to systemic 
reactivity in normoglycaemic subjects with and without a positive FH of T2DM, and whether 
this helps to further understand and predict the vascular risk. 
 
3.3. Materials and Methods  
The study cohort consisted of healthy WE normotensive participants aged 25-55 years that 
were screened and recruited from the Health Clinics at Aston University, Birmingham, UK. 
FH was confirmed through questionnaire and/or evidence of parental diagnosis. The author 
carried out recruitment, data and blood collection, as well as biochemical and statistical 
analysis on site (Aston University Day Hospital). 
Exclusion criteria were: a positive diagnosis of cardio- or cerebro-vascular disease, (coronary 
artery disease, heart failure, arrhythmia, stroke, transient ischaemic attacks), peripheral 
vascular disease, severe dyslipidaemia (defined as plasma TG>6.00mmol/L or cholesterol 
levels>7.00mmol/L), diabetes, as well as other metabolic disorders or chronic diseases that 
required treatment. 
Furthermore, subjects were also excluded if they had a refractive error of more than ±3DS 
and more than ±1DC equivalent, IOP >24 mmHg, cataract or any other media opacities, as 
well as if they had a history of intraocular surgery or any form of retinal or neuro-ophthalmic 
disease affecting the ocular vascular system. This excluded refractive error and known 
vascular variables and their effects on retinal imaging so that reliable results and retinal 
analysis could be achieved. 
Written informed consent was obtained from all participants and ethical approval was sought 
by the author from local and NHS ethical committees (08/H1202/112). The study was 
designed and conducted in accordance with the tenets of the Declaration of Helsinki. 
An OGTT was performed according to the WHO protocols on all participants a week prior to 
all other measurements and only participants with normal results were asked to come back 
for the subsequent tests.  
The OGTT was carried out by analysing baseline (12-hour fasted) and 2-hour post 
consumption capillary blood samples. The solution was made to a standardised 75g glucose 
drink, whereby 113mL of neutral glucose (Polycal Liquid, Nutricia, Wiltshire, UK) was diluted 
with 87mL of water. The subject was acclimatised to 22°C and was not allowed to undertake 
physical activity, smoke or consume any food or drinks during the test. 
 
 
57 
 
According to an already established procedure when examining endothelial function, female 
participants were asked to fill in a validated menstrual cycle questionnaire and their 
investigations were carried out during the first week of the menstrual cycle (follicular phase) 
thereby controlling for hormonal influences on endothelial function.[112, 317]  
 
3.3.1. Investigations 
3.3.1.1. Blood sampling and analyses 
All participants were asked to fast and refrain from caffeine, alcohol, chocolate and 
carbonated drinks and to not exercise for 12 hours prior to the date of the study. All blood 
samples were obtained by a qualified phlebotomist in the morning, between 9am and 10am. 
Fasting plasma glucose, TG, total and HDL-C were measured using standard routine 
laboratory techniques using the Reflotron Desktop Analyser (Roche Diagnostics, UK).   
The Reflotron Analyser is a microprocessor-controlled reflectance photometer that 
incorporates an Ulbricht‟s sphere to automatically measure reflectance, i.e. the intensity of 
the light directed onto the reagent strip and reflected back according to its depth of colour. 
The depth of colour is determined by the concentration of analyte in the sample undergoing 
investigation. A 30μL measured sample (capillary, fasted venous or plasma) is applied to a 
reagent strip with a laboratory pipette, and then placed in the photometer for testing. The 
analyser provides self-calibrated results for metabolic markers (glucose, TG, total and HDL-
C) using internationally applied reference methods. 
The TG/HDL cholesterol ratio (TG:HDL-C), a measure of endothelial function,[325], and 
Framingham score as a means of cardiovascular risk (including myocardial infarction and 
coronary death) were also determined from the above values. Framingham scores were 
obtained using an automated electronic risk calculator using the Framingham Heart Study  
equation whereby basic medical data was inputted according to the Adult Treatment Panel III 
criteria (National Cholesterol Treatment Panel, USA). The risk factors included in the 
Framingham calculation are age, total cholesterol, HDL-C, SBP, treatment for hypertension, 
and cigarette smoking. Because of a larger database, Framingham estimates are more 
robust for total cholesterol than for LDL-C.  
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3.3.1.2. ABPM and HRV analysis 
Systemic BP was measured using a 24-hour computer-operated ambulatory BP and 
electrocardiography (ECG) monitor (Cardiotens-01, Meditech Ltd., Hungary) for each subject 
(described in detail in Section 2.6.). Measurements were performed in ambulatory conditions 
and programmed to measure BP oscillometrically every 15 minutes during the subject‟s 
active period and every 30 minutes in the passive period.  
 
3.3.1.3. Body Composition Analysis 
Body composition analysis is a physical test that allows for the measurement of various 
components, and thus their proportion to one another, in the human body. It is achieved by 
bioelectrical impedance, whereby the electrical impedance (the opposition to an electrical 
current flow through bodily tissues) is used to calculate an estimate of total body water. This 
in turn can then be used to estimate fat free body mass and, by difference with body weight 
the actual percentage body fat.[326, 327] 
Anthropometric measures including height and weight were measured using standard 
procedures. Body composition was measured using bioelectrical impedance (Biostat 220, 
Biospace, UK) to determine Body Mass Index (BMI), Percentage Body Fat (PBF), Waist-to-
Hip ratio (WHR), total fat and fat free mass. 
 
3.3.1.4. Intima-media thickness 
IMT, is a measurement of the thickness of arterial walls, in this case; the carotid artery, by 
external ultrasound, to detect the presence and track the progression of atherosclerotic 
disease in vivo. Many studies have documented the relationship between carotid artery IMT 
and the presence and severity of atherosclerosis in CVD.[328-330] However, secondary to 
atherosclerosis, local haemodynamics, higher blood pressure and changes in shear stress 
also play an important role as being potential causes of intimal thickening. It is thought that 
these local factors may cause a local delay in lumen transportation of potentially atherogenic 
particles, which in turn favours the penetration of particles into the arterial wall and 
consequent plaque formation. 
For the purpose of this thesis, high-resolution B-mode ultrasound system (Acuson Sequoia, 5 
MHz linear transducer, Siemens, USA) was used to obtain longitudinal images of the right 
and left extracranial far wall of the common carotid artery (CCA). During image acquisition 
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participants were placed in a supine position with the head rotated approximately 45° to the 
opposite side of the body to that being imaged. The jugular vein and carotid artery were first 
imaged transversely and the transducer then rotated 90° around the central line of the 
stacked jugular vein–carotid artery to obtain a longitudinal image. The common carotid artery 
was interrogated from all three angles (anterolateral, lateral or posterolateral). The images 
were evaluated using ultrasonagraphic frames of the CCA as recommended.[331] In each 
carotid segment, far-wall IMT was measured bilaterally for a single CCA view. Each IMT 
measure, also used for statistical analysis, represented an average of three to five 
measurement points.  
 
3.3.1.5. Vascular function studies 
Retinal vessel reactivity was measured using the DRVA (Imedos; GmbH, Jena, Germany). 
All measurements were performed in one unselected eye for each subject, between 8:00 and 
11:00 AM in a quiet, temperature-controlled room (22˚C). Following full pupil dilation with 
Tropicamide 1% (Minims; Chauvin Pharmaceuticals Ltd, UK) a region of interest 
encompassing vessel segments of approximately 500 µm was chosen. Retinal diameters 
were assessed continuously over 350 seconds according to an accepted and widely used 
protocol.[277, 332]  
 
Brachial artery FMD was measured using high-resolution CDI ultrasonography, with a 7 mm 
8MHz linear-array (Siemens; Acuson Sequoia, UK). The arterial diameter of the measured 
brachial artery was determined in real time by edge-detection neural networking software 
(VIA Software®, UK). The technique has already been explained in detail in Section 2.2. 
According to a published protocol,[308], a baseline image was acquired for 2 minutes, and 
thereafter, arterial occlusion was created by inflation of a sphygmomanometer cuff on the 
lower arm to suprasystolic pressure (50 mmHg above systolic pressure) for 5 minutes. 
Following this, the cuff was deflated, and the artery diameter recorded for a subsequent 2 
minutes during the hyperaemic response (endothelial-dependent vasodilation). After 10 
minutes of recovery another image was acquired to reflect the re-established baseline 
conditions. An exogenous NO donor (sublingual 0.3 mg glyceryl trinitrate tablet- GTN) was 
given to determine the maximum obtainable vasodilator response. FMD was expressed as 
the maximal artery dilation during hyperaemia from baseline (%). 
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3.4. Power calculation and statistical analysis 
Based on previous studies, a change of 30% with a SD of 2.5% in retinal vessel reactivity 
was shown to be significant.[214, 304] Additionally FMD studies have shown a 33% 
reduction with a SD of 5.2% in FMD response in those with a FH of diabetes.[39] As the 
study design was multi-factorial in nature it was calculated (using SISA; a web-based sample 
calculator approved by the NHS ethics committee) that n=36 subjects per group was 
sufficient to provide 90% power with an alpha of 0.05. Furthermore, the sensitivity and 
reproducibility of the techniques in healthy subjects has been reported previously.[112, 333] 
All analyses were performed using Statistica® software (StatSoft Inc.; Version 9, USA). Prior 
to any analysis, all data was tested for normal distribution and thus a suitable test was 
adopted. Differences in mean values for each of the measured variables were compared by 
independent samples t-test (or Wilcoxon) for continuous variables. A multivariate analysis 
was performed to test the influence of age, gender, BP, and circulating markers on the 
measured variables. Comparison of retinal vessel reactivity for each flicker period was made 
by repeated measures (or Friedman) analysis of variance (ANOVA) following within-group 
analysis. Differences between groups in retinal and systemic vascular function were 
computed by analysis of covariance (ANCOVA). Univariate linear regression analysis was 
carried out using appropriate correlation analysis. A p value of <0.05 was considered 
statistically significant, unless stricter criteria were adopted for within-group and multiple 
comparisons (p≤0.01 to account for multiple comparisons and thereby minimise bias towards 
Type II errors). 
 
3.5. Results  
A total of 120 subjects were screened for eligibility. Following OGTT, 10 subjects were 
excluded (1 diagnosed with T2DM and 9 with IGT) and the remaining 55 healthy FH subjects 
(30 men and 25 women) and 55 healthy controls (30 men and 25 women) were recruited (in 
excess to the calculated sample calculation) for the final protocol (Appendix 1).  
The baseline characteristics of both groups are presented in Table 3.1. There were no 
statistically significant differences in age, systemic BP, IOP, TG, LDL cholesterol, carotid-IMT 
and Framingham risk scores (p>0.05). Compared to healthy normo -glycaemic and –tensive 
controls, those with a positive FH of T2DM had higher, albeit normal fasting glucose levels, 
lower HDL and only slightly higher total cholesterol values (p=0.035, p=0.013 and p=0.004 
respectively).  
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Furthermore, the body composition variables as outlined in Table 3.2. were comparable 
amongst both groups (p>0.05). This was also the case for plasma markers for oxidative 
stress and endothelial function (p>0.05) in Table 3.3. 
Both groups also exhibited similar twenty-four hour BP and HRV profiles showing non-
statistically significant differences in circadian rhythm or ANS function (p>0.05).  
Additionally, no such differences (anthropometric, biochemical or vascular reactivity) were 
detected when comparing normoglycaemic offspring with one parent or both (n=15) parents 
with T2DM (p>0.05). This is also extended to SA individuals with and without (n=35) a FH of 
T2DM (p>0.05). 
 
 
 Control 
 [n=55] 
   FH 
[n=55] 
T-test     
p-value 
DEMOGRAPHIC DATA    
Age (years) 43.9 ± 12 43.8 ± 11 0.670 
SBP (mmHg) 117 ± 11 120 ± 11 0.178 
DBP (mmHg) 71 ± 8 72  ± 8  0.469 
MAP (mmHg) 86 ± 8 88 ± 9 0.303 
IOP (mmHg) 13 ± 3 14 ± 3 0.077 
    
METABOLIC DATA    
Glucose (mmol/L) 5.37 ± 0.37 5.60 ± 0.55* 0.036 
2 hour GTT (mmol/L) 5.95 ± 1.13 6.16 ± 0.94 0.368 
TG (mmol/L) 1.23 ± 0.50 1.16 ± 0.53 0.483 
HDL Cholesterol (mmol/L) 1.29 ± 0.34 1.11 ± 0.41* 0.013 
LDL Cholesterol (mmol/L) 2.77 ± 0.70 2.76 ± 0.83 0.095 
Total Cholesterol (mmol/L) 4.16 ± 0.84 4.61 ± 0.74* 0.004 
TG:HDL-C (mmol/L) 2.45 ± 1.52 2.76 ± 1.74 0.336 
    
CVD RISK DATA    
R-IMT (mm) 0.060 ± 0.018 0.054 ± 0.013 0.171 
L-IMT (mm) 0.060 ± 0.019 0.057 ± 0.012 0.365 
Framingham Score (%) 2.3 ± 3.3 1.7 ± 2.1 0.067 
 
Table 3.1. Baseline data of both groups. Values quoted in mean ± SD.*Significant differences 
indicated in bold as p<0.05. SBP: systolic blood pressure; DBP: diastolic blood pressure; 
MAP: mean arterial pressure; IOP: intraocular pressure; GTT: glucose tolerance test; TG: 
triglyceride; HDL: high-density lipoprotein; LDL: low density lipoprotein; TG:HDL-C: TG-
to-HDL ratio; R-IMT: right intima media thickness L-IMT: left intima media thickness. 
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 Control 
 [n=55] 
   FH 
[n=55] 
T-test     
p-value 
Weight (kg) 74.6 ± 14.6 78.0 ± 14.7 0.193 
BMI (kg/m2) 25.7 ± 4.9 26.8 ± 3.8 0.143 
WHR (AU) 0.95 ± 0.13 0.92  ± 0.06 0.205 
PBF (%) 30.5 ± 8.8 30.3 ± 7.7 0.845 
Fat Mass (kg) 23.0 ± 8.8 23.7 ± 7.9 0.639 
Fat Free Mass (kg) 51.6 ± 11.2 54.3 ± 11.2 0.169 
 
Table 3.2. Obesity correlates and body composition (by means of bioelectrical impedance) of 
both groups. Values quoted in mean ± SD. BMI: body mass index; WHR: waist-to-hip 
ratio; PBF: percentage body fat. 
 
 
 Control 
 [n=55] 
   FH 
[n=55] 
Wilcoxon     
p-value 
BIOCHEMICAL DATA    
GSH (μM) 878.1 ± 563.5  987.4 ± 755.9 0.366 
GSSG (μM) 105.4 ± 96.5 90.9 ± 86.6 0.379 
GSH:GSSG (μM) 14.3 ± 11.4 16.7 ± 13.2 0.292 
tGSH (μM) 1088.9 ± 576.2 1169.3 ± 783.5 0.519 
vWF (μ/dL) 120.1 ± 56.8 128.7 ± 61.1 0.453 
 
Table 3.3. Plasma markers for oxidative stress and endothelial function in both groups. Values 
quoted in mean ± SD.*Significant differences indicated in bold as p<0.05. GSH: 
reduced Glutathione; GSSG: oxidised glutathione; tGSH: total glutathione; vWF: von 
willebrand factor.  
 
 
The vascular reactivity values for brachial artery and retinal vessels are presented in tables 
3.4. and 3.5. respectively. Both FH individuals and controls showed comparable values in 
response to brachial artery hyperaemia and retinal vessel flicker light (p>0.05).  
 
The characteristics for male and female individuals with a positive FH of T2DM were also 
investigated and shown in Table 3.6. Male subjects showed significant levels of 
dyslipidaemia (higher TG, lower HDL causing higher TG:HDL-C ratio) and poorer glucose 
regulation (greater fasting and 2-hour GTT glucose values) when compared to female 
subjects. Furthermore, the BP profiles were elevated in FH males (p<0.001), contributing to a 
greater overall Framingham score (p<0.001). The obesity correlates in Table 3.7 show that 
female FH subjects had higher fat free mass values that contributed to a greater percentage 
body fat despite weighing significantly less than their male counterparts. No significant 
differences were found in oxidative stress or endothelial function markers between both 
groups (p>0.05). Retinal and brachial vessel responses were also comparable between both 
genders (p>0.05). 
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 Control 
 [n=55] 
   FH 
[n=55] 
Wilcoxon  
p-value 
BRACHIAL ARTERY    
AD (mm) 4.00 (3.37-4.59) 4.14 (3.41-4.66)  0.305 
BDF (mm) 0.39 (0.22-0.45) 0.33 (0.17-0.42) 0.207 
MD (mm) 4.44 (3.84-4.98) 4.50 (3.69-5.09) 0.741 
RT (secs) 23.0 (1-53) 21.6 (3.0-38.0) 0.814 
FMD (%) 7.55 (2.73-11.3) 6.61 (3.7-9.51) 0.400 
    
GTN    
GTN-MD (mm) 5.04 (4.42-5.64) 5.12 (4.37-5.60) 0.723 
RT (secs) 303 (257-395) 315 (267-350) 0.618 
GID (%) 22.66 (16.58-29.43) 23.36 (15.10-30.73) 0.816 
    
FMD/GID (%) 0.16 (0.09-0.52) 0.28 (0.07-0.52) 0.542 
 
Table 3.4. Brachial artery reactivity as means of systemic vascular endothelial function between both 
groups. Values quoted in mean (IQR).  AD: absolute diameter; BDF: baseline diameter 
fluctuation; MD: maximum diameter response; RT: Reaction time; FMD: flow-mediation 
dilation response; GID: GTN-induced dilation; FMD/GID: FMD/GID ratio. 
 
 
 
 
 
 
 
 Control 
 [n=55] 
   FH 
[n=55] 
Friedman 
p-value 
ARTERY    
AD (AU) 123.29 (90.50-161.04) 122.53 (87.70-170.88)  0.789 
BDF (AU) 5.11 (0.97-1.55) 5.56 (1.77-17.49) 0.352 
MD (%) 4.90 (1.01-13.54) 5.38 (0.19-12.92) 0.309 
MDRT (secs) 19.9 (9.0-37.0) 18.1 (6.7-37.5) 0.117 
MC (%) 2.80 (3.53-6.92) 3.55 (0.68-13.33) 0.054 
MCRT (secs) 20.8 (7.7-29.0) 19.5 (7.0-29.3) 0.117 
DA (%) 7.68 (1.67-16.29) 8.93 (2.10-20.58) 0.041 
bFR (%) 2.57 (-3.35-8.36) 3.36 (-5.57-14.15) 0.084 
    
VEIN    
AD (AU) 155.13 (111.74-132.50) 158.19 (112.82-133.77) 0.462 
BDF (AU) 4.15 (3.33-6.79) 4.16 (3.78-7.09) 0.970 
MD (%) 5.43 (3.49-5.94) 6.14 (2.95-7.19) 0.133 
MDRT (secs) 20.3 (14.7-24.5) 20.0 (13.3-22.3) 0.766 
MC (%) 1.80 (4.13-4.43) 1.37 (2.10-4.49) 0.181 
MCRT (secs) 21.7 (18.3-23.7) 21.3 (17.0-23.0) 0.679 
DA (%) 7.23 (6.02-9.19) 7.51 (5.92-11.57) 0.615 
bFR (%) 3.13 (0.83-4.38) 3.35 (1.72-4.75) 0.611 
 
Table 3.5. Retinal arterial and venous measures for both groups. Values quoted in mean (IQR).    
*Significant values in bold (p<0.05). AD: absolute diameter; BDF: baseline diameter 
fluctuation; MD: maximum dilation; MDRT: reaction time to reach maximum diameter to 
flicker stimulation; MC: maximum constriction; MCRT: reaction time to maximum 
constriction post flicker; DA: dilation amplitude; bFR: baseline-corrected flicker 
response. 
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 FH Male 
 [n=30] 
FH Female 
   [n=25] 
T-test     
p-value 
DEMOGRAPHIC DATA    
Age (years) 45.0 ± 10 41.9 ± 13.2 0.309 
SBP (mmHg) 123 ± 11* 114 ± 8 <0.001 
DBP (mmHg) 75 ± 8* 67 ± 6 <0.001 
MAP (mmHg) 91 ± 8* 83 ± 6 <0.001 
IOP (mmHg) 14 ± 3 13 ± 3 0.110 
    
METABOLIC DATA    
Glucose (mmol/L) 5.15 ± 0.61* 4.64 ± 0.78 0.003 
2 hour GTT (mmol/L) 7.07 ± 1.69* 5.95 ± 1.31 0.014 
TG (mmol/L) 1.52 ± 0.79* 1.12 ± 0.40 0.009 
HDL Cholesterol (mmol/L) 1.15 ± 0.40* 1.37 ± 0.30 0.010 
LDL Cholesterol (mmol/L) 2.81 ± 0.68 2.72 ± 0.81 0.644 
Total Cholesterol (mmol/L) 4.64 ± 0.79 4.61 ± 0.83 0.853 
TG:HDL-C (mmol/L) 3.63 ± 3.23* 2.00 ± 1.00 0.006 
    
CVD RISK DATA     
R-IMT (mm) 0.063 ± 0.019 0.054 ± 0.014 0.177 
L-IMT (mm) 0.062 ± 0.020 0.058 ± 0.016 0.570 
Framingham Score (%) 4.6 ± 5.1* 0.8 ± 0.5 <0.001 
 
Table 3.6. Baseline data of positive FH groups of male and female gender. Values quoted in mean ± 
SD.*Significant differences indicated in bold as p<0.05. SBP: systolic blood pressure; 
DBP: diastolic blood pressure; MAP: mean arterial pressure; IOP: intraocular pressure; 
GTT: glucose tolerance test; TG: triglyceride; HDL: high-density lipoprotein; LDL: low 
density lipoprotein; TG:HDL-C: TG-to-HDL ratio; R-IMT: right intima media thickness L-
IMT: left intima media thickness. 
 
 
 
 FH Male 
 [n=30] 
FH Female 
   [n=25] 
T-test     
p-value 
BMI (kg/m2) 26.2 ± 5.2 25.6 ± 5.1 0.634 
WHR (AU) 0.96 ± 0.16 0.93  ± 0.09 0.291 
PBF (%) 25.9 ± 7.0 35.8 ± 8.4* <0.001 
Fat Mass (kg) 21.6 ± 8.8 24.9 ± 9.2 0.137 
Fat Free Mass (kg) 59.8 ± 8.4 43.1 ± 6.3* <0.001 
 
Table 3.7. Obesity correlates and body composition (by means of bioelectrical impedance) of 
positive FH groups of male and female gender. Values quoted in mean ± SD. 
*Significant differences indicated in bold as p<0.05.BMI: body mass index; WHR: 
waist-to-hip ratio; PBF: percentage body fat. 
 
Those with a FH of T2DM showed levels of impaired lipid function by means of raised total 
cholesterol and lower HDL-C values. Furthermore the levels of total cholesterol and LDL-C 
correlated negatively with selected retinal arterial dilation values as shown in Figure 3.1. 
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FH individuals exhibited significantly greater DA values and fasted plasma cholesterol levels 
that both correlated negatively with each other in Figure 3.2. (spearmans r= -0.9374; p= 
0.019). This also extended to negative correlations between DA and LDL-C (r= -0.9718; p= 
0.006) and also bFR with total cholesterol (r= -0.8801; p= 0.049).  
 
 
66 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Cholesterol and Retinal arterial dilation correlations in those with a positive FH. From 
top-left to clockwise. Negative Spearmans correlations for arterial dilation against LDL-C 
(r= -0.9824; p= 0.003), arterial MD against LDL-C (r= -0.9826; p=0.003), arterial dilation 
against total cholesterol (r= -0.9874 ;p= 0.002) and arterial MD against total cholesterol 
(r= -0.9845; p= 0.002). 
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3.6. Discussion 
In this present study, it has been shown that those with a known FH of T2DM have no 
detectable differences in endothelial and vascular function at the micro- and macro-vascular 
level. Therefore, it could be suggested that in young FH individuals there are no clinical signs 
of impaired vascular function or endothelial cell damage at the retinal and systemic level. 
Furthermore, akin to that of the findings reported in this study, several other authors have 
also shown comparable levels in vWF as well as other inflammatory markers (s-ICAM, s-
VCAM and C-reactive protein) in young FH individuals.[334-336] These results are further 
supported by comparable findings between individuals with one or both parents and SAs with 
and without a FH of T2DM. Therefore, this suggests that even within a SA sample; a minority 
with well-documented CVD and T2DM risk, FH may not be an important vascular risk factor 
when considering otherwise healthy individuals. 
 
The importance of detecting when the first signs of vascular dysfunction occur in at-risk 
individuals including FH subjects is well established. Other studies have reported peripheral 
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Figure 3.2. Cholesterol and Retinal arterial dilation amplitude correlation in those with a positive FH  
(r= -0.9374; p= 0.019). 
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microvascular changes, such as reduced skin hyperaemia in subjects with impaired fasting 
glucose (IFG), possibly due to an IR [337],  showing that microvascular abnormalities are 
present and detectable in individuals at risk for diabetes.[338] Furthermore, several vascular 
abnormalities, including increased IR; beta-cell dysfunction, obesity, ET-1, IMT and reduced 
FMD, aortic distensibility and sensitivity to activated protein C, have been reported in 
normoglycaemic FH individuals.[37, 234, 238, 339-344] However, whether this is due to a 
genetic determinant or possibly due to the presence of IR is not fully understood. The results 
of this chapter would suggest that in healthy offspring of diabetics, FH may be a different 
determinant of future vascular risk when compared to genetic and lifestyle factors. 
 
Furthermore, the prevalence, incidence and mortality rates of T2DM are known to increase 
with age; therefore, in this regard FH of T2DM may have an impact on age of diagnosis, 
onset and duration of the disease. Some have reported that those with a FH are diagnosed 
with T2DM at earlier ages, on average around forty-three years of age.[40] Although the 
sample presented in this study are of similar age, the presence of other well-established 
vascular risk factors, namely MetS components, were absent; thus going some way to 
explain the lack of detectable differences in FMD and retinal reactivity. The findings of 
greater prevalences of arterial stiffness with IR also goes some way in showing that in an 
otherwise healthy cohort of FH individuals with metabolic alterations, no such vascular 
disturbances would be expected. Furthermore, there are results supporting positive 
associations between insulin action and endothelial-dependent vasodilation in young FH 
individuals.[335]  
 
However it is important to note that vascular inflammation is not necessarily associated with 
early IR in FH individuals. Despite studies describing T2DM as an inflammatory condition, by 
means of increased C-reactive protein, white blood cell count and fibrinogen levels, there are 
some results showing that the IR state per se is not characterised by inflammation.[36] 
Therefore, if vascular inflammation and endothelial dysfunction are thought to be 
simultaneous events for T2DM pathophysiology and risk, it could be suggested that that the 
FH individuals in this cohort were equally insulin sensitive as their healthy counterparts, 
which led to similar (brachial and retinal) vascular responses.    
 
This can also be said for the current cohort when comparing FMD values. It has been found 
that when comparing FH individuals with controls, FMD has been found to be similar. 
However it is only when sedentary and IR (and reduced insulin sensitivity) individuals with a 
FH are compared to controls and diabetics that endothelial dysfunction, by means of reduced 
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FMD and increased levels of inflammatory markers are reported.[231, 233] This is also true 
of systemic BP, obesity correlates and metabolic plasma markers.[37, 39, 238] 
 
As compared to FMD, retinal vascular function (as a surrogate measure of systemic and 
ocular endothelial function) can be examined quickly and non-invasively and, therefore, can 
become an important investigative tool in everyday clinical practice for early detection of 
vascular risk and complications in subjects at risk.  In addition to macrovascular dysfunction, 
hyperglycaemia can also result in a high level of oxidative stress, inflammation and vascular 
dysfunction that occur at the microvascular level, such as the retinal vascular bed.[345]  For 
example, it has already been demonstrated that in patients suffering from T2DM there is a 
measurable reduction in retinal vascular response to flicker, possibly suggesting local 
endothelial dysfunction that exists in addition or as a consequence to systemic vascular 
changes.[214, 295, 300]   However, it is possible that the retinal vessel analysis performed in 
this study could not identify any changes that would otherwise help to suggest a reduced 
vascular function in those with a FH of T2DM. Nevertheless, the microcirculation still 
represents the first vascular area to be affected by pre-clinical signs of endothelial 
dysfunction.[346, 347] This is supported by findings showing increased carotid-radial pulse-
wave analysis and hence muscular-artery stiffness in FH individuals known to be 
predisposed to IR prior to the development of the MetS.[334] 
 
The presence of a functional correlation between brachial (FMD) and retinal arterial function 
(arterial MD) has also been described previously in healthy participants.[144] However, no 
such associations, (concordant to that also reported in patients with T2DM and 
hypercholesteraemia) were found in the FH group presented in this study (r=0.3302, p>0.05). 
Whether the weak correlation between these two separate vascular beds  provides evidence 
that similar functional vascular changes occur at both a macro- and microvascular circulatory 
level in T2DM and possibly in those with a FH, remains to be seen.[300] Further work to 
investigate correlations between these two distinctly different vascular beds would help to 
see whether a „vascular breakdown‟ corresponds to the high risk reported for developing 
cardiovascular complications before overt diabetes occurs in FH individuals.[38, 244, 348]   
 
The negative correlations with several retinal arterial dilation responses and fasting plasma 
cholesterol in the current FH group, however, is consistent to that previously reported.[112] 
This has been suggested to further the argument that a reduced flicker response is 
endothelial cell-mediated as cholesterol and LDL-C are known to be associated with reduced 
NO bioavailability.[349] Furthermore, statin therapy used to reduce cholesterol levels have 
been shown to improve endothelial function by means of increased FMD.[350] Therefore, 
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understanding the complex relationship between vascular dysfunctions at multiple levels and 
when they occur, as well as their interaction with other various metabolic and genetic factors 
that play a role in the onset of T2DM, could result in early interventions for prevention of 
vascular disease in subjects at risk for this disease. 
 
When compared to other FH studies the sample size adopted for this study appears 
sufficient. Furthermore, the male-to-female ratio adopted is more balanced in order to 
account for gender differences (despite no detectable differences found in reactivity between 
both gender groups).[38] However, post-hoc power calculation analysis suggests that n=94 
would be sufficient to detect a difference between normoglycaemic, normotensive and 
otherwise healthy FH individuals and controls. This could be as a result of using a healthy 
cohort as opposed to individuals with known vascular disturbances or disease. This follows 
that of large-scale prospective studies and would therefore allow a more robust study design 
to be incorporated. 
 
Despite findings inconsistent to the proposed hypothesis and to that of some studies, the 
preliminary results show that in healthy FH individuals without metabolic alterations, obvious 
signs of vascular function impairment are absent. Therefore, the vascular risk noted in those 
with FH of T2DM may need to be revised when considering otherwise healthy individuals. 
However, there is opportunity for further work in IR FH individuals. The concept behind the 
necessity for early screening for diabetes in FH risk groups and more active prevention in 
CVD risk may not be clinically valid or necessary, but can only be validated with larger study 
samples. 
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4. Vascular Function in Normoglycaemic South-Asians vs. 
Normoglycaemic White-Europeans without FH and Vascular 
Disturbances 
 
4.1. Abstract 
4.1.1. Background/Aims: To determine whether differences in retinal and brachial vascular 
function and their relationship to traditional vascular disease risk and endothelial dysfunction 
indicators exist in SAs (Indian, Sri-Lankan, Bangladeshi and Pakistani) when compared to 
WEs. 
4.1.2. Methods: A total of 130 normoglycaemic subjects (65 SA and 65 age- and gender- 
matched WE) were recruited for the present study. Retinal vessel reactivity was assessed 
using the Dynamic Retinal Vessel Analyser (DRVA) according to a modified protocol. 
Brachial artery reactivity, by means of flow-mediated dilation (FMD) was assessed by CDI 
according to an established procedure. Fasting plasma glucose, triglycerides (TG), total, LDL 
and HDL cholesterol were also measured in all individuals. 
4.1.3. Results: SA individuals showed higher fasting triglyceride (p=0.001) and lower HDL 
levels (p=0.007), leading to a higher TG:HDL-C ratio (p=0.001) than age-matched WE 
subjects. Additionally, SAs presented with higher levels of vWF and lower levels of GSH 
(p=0.036) and GSSG (p=0.013) than in WEs. Furthermore, SAs showed reduced FMD 
values (p=0.012), and despite comparable retinal vessel dilation to flicker-light (p>0.05), 
differences in arterial constriction profiles were significant. 
4.1.4. Conclusion: In otherwise healthy SAs there are potential signs of biochemical and 
metabolic imbalances that could result in future endothelial cell damage/dysfunction and a 
permanent state of oxidative stress. Further SDRA analysis in SAs suggests a complex 
interaction with autoregulatory and metabolic mechanisms that cause retinal vascular “over-
compensation”. 
 
4.2. Introduction  
The SA population (Indian, Pakistani, Bangladeshi and Sri-Lankan) represents approximately 
20% of the world‟s populace and is one of the fastest growing populations. There are over 
two million South-Asians in the USA, over one million in Canada and over six million in the 
UK. It is well documented that when compared to WEs, migrant SAs are at an increased risk 
of CVD and vascular disease due to a higher prevalence of established vascular risk factors 
causing higher rates of mortality than in any other minority.[351]  Furthermore, SAs appear to 
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present with CVD at a much younger age when compared to WEs. Despite this, there are 
very few studies that determine vascular risk for CVD and diseases such as T2DM and 
stroke in this minority. 
Findings from studies in urban populations also further extend known CVD risk in SAs, where 
average cholesterol readings have increased from 4.1 to 5.5mmol/L leading to an 
accompanied three-fold increase in the prevalence of CVD. It has therefore been shown that 
SAs present with a specific risk profile that represents that of the MetS ultimately causing a 
state of IR.[352] 
Various factors such as abnormal levels of plasma glucose, fasting insulin, TG, C-reactive 
protein and glycosylated haemoglobin (HbA1c), as well as higher central adiposity have been 
implicated in the increased risk for both IR and T2DM in this population.[27] Although the 
exact mechanism behind a higher risk for vascular disease in SA populations is still unclear, 
IR and its consequences on the vascular health could explain it, at least in part.[17] 
Moreover, signs of possible risk for future vascular disease including T2DM, such as 
subclinical inflammation and endothelial dysfunction are present from early childhood in 
SAs.[353, 354] Consequently, early detection of risk for vascular disease could allow earlier 
primary preventive measures that might reduce the occurrence and/or slow progression of 
disease in populations at risk.  Indeed, it has been proposed that more aggressive preventive 
measure and treatments should be applied to SA populations to prevent CVD.[355]  
The traditional approach to CVD risk assessment is based on identifying and quantifying few 
established cardiovascular risk factors, such as HDL cholesterol, high blood pressure, and 
smoking status. As a result, various scores have been generated. Among those, the 
Framingham Risk Assessment Model is one of the most used and accepted in 
cardiovascular medicine.[356, 357] Nevertheless, this score is based on data collected in a 
White US population and has limited use in other ethnic groups. In addition, the factors 
included in the Framingham score fail to explain up to 50% of cardiovascular morbidity and 
mortality.[358] Therefore, more accurate measures that are tailored to various populations 
should be used. In addition, when looking at risk stratification, pre-clinical modifications in 
vascular function are a better option; they are subtler, precede structural changes and signal 
danger at an earlier stage.[359] This approach would allow more effective, evidence-based 
prevention tailored to apparently healthy individuals and groups but with a higher risk factor. 
The vascular endothelium plays an important role in vascular homeostasis by preserving the 
vascular tone and preventing inflammation, platelet aggregation and leukocytes adhesion. 
Under certain conditions, these functions are affected and the so-called endothelial 
dysfunction occurs. It has been demonstrated that endothelial dysfunction contributes to IR, 
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hypertension, dyslipidaemia, proteinuria and atherosclerosis, most of which are associated 
either with the onset of T2DM or its complications. Moreover, it has been proved that in 
addition to other biochemical or clinical markers, early signs of endothelial dysfunction are 
also present in healthy individuals with various risk factors for T2DM, including SA 
ethnicity.[37, 234, 238, 360] Therefore, the assessment of endothelial function could provide 
a better indicator of individual risk for vascular disease.   
As already mentioned, the SA population is at a higher risk of developing T2DM and 
premature CVD.[361] Moreover, diabetes-related morbidity and mortality, as well as the 
incidence of clinically significant DR are higher amongst this ethnic group than in an age-
matched WE population.[362, 363] Therefore, early identification of pre-clinical markers for 
vascular disease could be very important in this population and, possibly contribute to an 
early implementation of prevention and/or disease-modifying interventions.[364] Retinal 
vessel analysis may provide a means for identifying pre-clinical risk for CVD and vascular 
disease, as shown by increased MDRT in SAs (Appendix 3). 
The purpose of this study was to determine whether healthy (first- and second-generation) 
migrant SAs present with a similar risk profile and evidence of impaired endothelial/vascular 
function that has been shown previously in the older South-Asian generation when compared 
to age- and sex-matched WEs. Furthermore, differences in vascular function with gender 
sub-groups in and between SA and WE samples were also investigated. 
 
4.3. Materials and Methods  
Healthy subjects aged 25-55 years were recruited by advertisement and screened by 
questionnaire to exclude those with a FH of diabetes or existing vascular conditions. SA 
ethnicity (India, Pakistani, Sri Lankan, and Bangladeshi) was defined by a self-reported 
questionnaire.  
Exclusion criteria were: a positive family history for DM, a positive diagnosis of cardio- or 
cerebro-vascular disease, (coronary artery disease, heart failure, arrhythmia, stroke, 
transient ischaemic attacks), peripheral vascular disease, severe dyslipidaemia (defined as 
plasma TG>6.00mmol/L or cholesterol levels>7.00mmol/L), diabetes, as well as other 
metabolic disorders or chronic diseases that required treatment. 
Furthermore, subjects were excluded if they had a refractive error of more than ±3DS and 
more than ±1DC equivalent, IOP >24 mmHg, cataract or any other media opacities, as well 
as if they had a history of intraocular surgery or any form of retinal or neuro-ophthalmic 
disease affecting the ocular vascular system. 
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Written informed consent was obtained from all participants and ethical approval was sought 
by the author from local and NHS ethical committees (08/H1202/112). The study was 
designed and conducted in accordance with the tenets of the Declaration of Helsinki. 
An OGTT was performed according to the WHO protocols on all participants a week prior to 
all other measurements (Section 3.3.) and only participants with normal results were asked 
to come back for the subsequent tests.  
According to an already established procedure when examining endothelial function, female 
participants were asked to fill in a validated menstrual cycle questionnaire and their 
investigations were carried out during the first week of the menstrual cycle (follicular phase), 
thereby controlling for hormonal influences on endothelial function.[112, 317]  
 
4.3.1. Investigations 
4.3.1.1. Blood sampling and analyses 
All participants were asked to fast and refrain from caffeine, alcohol, chocolate and 
carbonated drinks and to not exercise for 12 hours prior to the date of the study. All blood 
samples were obtained by a qualified phlebotomist in the morning, between 9am and 10am. 
Fasting plasma glucose, TG, total and HDL-C were measured using standard routine 
laboratory techniques (outlined in Section 3.3.1.1.) using the Reflotron Desktop Analyser 
(Roche Diagnostics, UK).  The TG/HDL cholesterol ratio,[325], a measure of endothelial 
function and Total/HDL cholesterol ratio alongside Framingham score as a means of 
cardiovascular risk (Section 2.3.1.1.) were also determined from the above values.[365]  
Further analysis extended to laboratory and ELISA-test sampling for fasting plasma vWF and 
blood gluthathione to investigate possible signs for endothelial damage and oxidative stress 
respectively. Validated protocols were used for in-house testing as described in Sections 2.4. 
and 2.5. 
 
4.3.1.2. ABPM and HRV analysis 
Systemic BP was measured using a 24-hour computer-operated ambulatory BP and 
electrocardiography (ECG monitor (Cardiotens-01, Meditech Ltd., Hungary) for each subject. 
Measurements were performed in ambulatory conditions and programmed to measure BP 
oscillometrically every 15 minutes during the subject‟s active period and every 30 minutes in 
the passive period (explained previously in Section 2.6.). Mean arterial pressure (MAP), as a 
means of describing cardiac output function in relation to arteriolar resistance was calculated 
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according to Equation 2.2. The impact of pulse pressure (PP) as a risk factor for CVD was 
also calculated as the below equation:  
 
PP = SBP – DBP 
Equation 4.1. Calculation of Pulse Pressure 
 
HRV analysis was calculated for each individual using the Cardiovision software (PMS 
Instruments Ltd., Maidenhead, UK) to obtain twenty-four hour, active and passive period LF, 
HF and LF:HF values. From, this circadian BP and HRV changes were calculated according 
to Formula 2.3. and 2.4. respectively. 
 
4.3.1.3. Body Composition Analysis 
Anthropometric measures including height and weight were measured using standard 
procedures as explained in section 3.3.1.3. Body composition was measured using 
bioelectrical impedance (Biostat 220, Biospace, UK) to determine BMI, PBF, WHR, total fat 
and fat free mass. 
 
4.3.1.4. Intima-media thickness 
High-resolution B-mode ultrasound system (Acuson Sequoia, 5 MHz linear transducer, 
Siemens, USA) was used to obtain longitudinal images of the right and left extracranial far 
wall of the CCA as described in section 3.3.1.4. Each IMT measure, also used for statistical 
analysis, represented an average of three to five measurement points.  
 
4.3.1.5. Vascular function studies 
Retinal vessel reactivity was measured using the DVRA (Imedos; GmbH, Jena, Germany). 
All measurements were performed in one unselected eye for each subject, between 8:00 and 
11:00 AM in a quiet, temperature-controlled room (22˚C). Following full pupil dilation with 
Tropicamide 1% (Minims; Chauvin Pharmaceuticals Ltd, UK) a region of interest 
encompassing vessel segments of approximately 500 µm was chosen. Retinal diameters 
were assessed continuously over 350 seconds according to an accepted and widely used 
protocol.[277, 332]  
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Retinal vessel reactivity and time course parameters, as explained in Section 2.1., were then 
calculated. Previous work investigating retinal arterial MD and MDRT in SAs has been 
reported previously (Appendix 3). Therefore to further the application of SDRA in this ethnic 
minority, constriction analyses was performed as shown in Section 2.1. 
The effect of atherosclerosis on vessel stiffness is well known, and therefore the clinical 
significance of assessing changes in retinal reactivity is of importance. Depending on a 
vessel‟s “stiffness”, the reaction to flicker can be slow or fast.[118] Thus, the rate at which 
retinal vessel diameter increases to stress seems an ideal approach. This can be 
ascertained by calculating the dilation slope for diameter against time. Furthermore, studies 
have documented the autoregulation response of retinal vessels to stress [65], and so to 
advance the understanding on the mechanisms of retinal flicker response, the slope following 
flicker cessation was also determined. This was named constriction slope.(Section 2.1.)  The 
constriction response is known to occur approximately 10-40 seconds post flicker,[333] but 
the time-course and reasons for the constriction still remain unclear. Therefore, to gain 
further insight, the maximum constriction diameter was calculated within a period of 30 
seconds after flicker and the slope calculated against the maximum dilation to flicker. 
 
Brachial artery FMD was measured using high-resolution CDI ultrasonography, with a 7 mm 
8MHz linear-array (Siemens; Acuson Sequoia, UK). According to a published protocol,[308], 
as described in section 2.2., arterial occlusion was created by inflation of a 
sphygmomanometer cuff on the lower arm to suprasystolic pressure and an exogenous NO 
donor (sublingual 0.3 mg GTN tablet) was given to determine the maximum obtainable 
vasodilator response. FMD was then expressed as the maximal artery dilation during 
hyperaemia from baseline (%). 
 
4.4. Power calculation and statistical analysis 
Based on previous studies, a change of 30% with a SD of 2.5% in retinal vessel reactivity 
was shown to be significant.[214] The reproducibility for repeated measures using the RVA 
has also been investigated and validated for East-Asians.[366] Additionally FMD studies 
have shown typical values of around 6.9% with a SD of 0.3% in FMD response in SAs.[26] 
As the study design was multi-factorial in nature it was calculated (using SISA; a web-based 
sample calculator approved by the NHS ethics committee) that n=30 per group was sufficient 
to provide 90% power with an alpha of 0.05. Furthermore, the sensitivity and reproducibility 
of the techniques in healthy subjects has been reported previously.[112, 333] 
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All analyses were performed using Statistica® software (StatSoft Inc.; Version 9, USA). Prior 
to any analysis, all data was tested for normal distribution and thus a suitable test was 
adopted. Differences in mean values for each of the measured variables were compared by 
independent samples t-test (or Wilcoxon) for continuous variables. A multivariate analysis 
was performed to test the influence of age, gender, BP, and circulating markers on the 
measured variables. Comparison of retinal vessel reactivity for each flicker period was made 
by repeated measures (or Friedman) analysis of variance (ANOVA) following within-group 
analysis. Differences between groups in retinal and systemic vascular function were 
computed by analysis of covariance (ANCOVA). Univariate linear regression analysis was 
carried out using appropriate correlation analysis. A p value of <0.05 was considered 
statistically significant, unless stricter criteria were adopted for within-group and multiple 
comparisons (p≤0.01 to account for multiple comparisons and thereby minimise bias towards 
Type II errors). 
4.5. Results  
A total of 155 subjects were screened for eligibility. Following OGTT, 25 subjects were 
excluded (3 diagnosed with T2DM and 22 with IGT) and the remaining 65 healthy SAs 
subjects (33 men and 32 women) and 65 healthy WE (33 men and 32 women) were 
recruited in excess of the intended sample size for the final protocol (Appendix 1).  
The baseline characteristics of both groups are presented in Table 4.1. There were no 
statistically significant differences in age, SBP, MAP and PP, IOP, fasting plasma glucose, 
LDL and total cholesterol and carotid-IMT. Compared to WE, SAs had raised average DBP 
values (p=0.019), 2-hour glucose tolerance test and TG values (p<0.001), and lower HDL 
levels (p=0.040). This led to the TG:HDL cholesterol ratio (TG:HDL-C) also being significantly 
higher in SAs than in WEs (p<0.001) as well as a higher Total:HDL cholesterol (Total:HDL-C) 
ratio (p=0.001). No such differences were found in HRV components, suggesting similar ANS 
outputs (p>0.05). 
Traditional Framingham risk scores as shown in Table 4.2, were similar between both groups 
(p>0.05), however, when modifying the equations for ethnicity, i.e. adding 10 years to the 
inputted age [296]; SAs presented with a higher CVD percentage risk than WEs (p=0.021). 
This was evident despite any differences in weight, body mass index (BMI), waist-to-hip ratio 
(WHR), percentage body fat (PBF), fat mass and fat free mass indices (p>0.05). Table 4.3. 
When investigating plasma markers of oxidative stress, SAs presented with statistically 
significant levels of reduced GSH, GSSG, tGSH and GSH:GSSG (p=0.019, p=0.016, 
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p=0.013 and p=0.014 respectively). Whilst this minority also showed markedly higher levels 
of von-Willebrand factor (vWF) when compared to WEs, it did fail to reach statistical 
significance. Table 4.4. 
The FMD results for SAs against WEs are presented in Table 4.5./Figure 4.1. and show 
reduced maximal obtainable brachial artery dilation and thus FMD(%). This did not extend to 
any obvious differences in retinal arterial MD (Table 4.6.). There were significant differences 
however; in BDF, arterial constriction post flicker light cessation (MC) and time taken to 
reach maximal constriction; MCRT (p=0.002, p=0.041 and p=0.001 respectively). Further 
slope analysis was performed and presented in tables 4.7. and 4.8. showing increased 
arterial constriction slopes in SAs. This also applied to venous reactions, whereby SAs 
showed increased venous BDF, but also increased venous MD and DA values. Within-group 
repeated measures analysis was performed on these variables and are presented in tables 
4.9. – 4.13 showing no statistically significant differences in SDRA varaibles. MDRT results 
(Table 4.14.) are shown as those reported in a previous publication (Appendix 3). 
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 White European 
        [n=65] 
South Asian 
     [n=65] 
T-test     
p-value 
DEMOGRAPHIC DATA    
Age (years) 39.0 ± 10.6 39.0 ± 10.6     - 
SBP (mmHg) 117 ± 10 120 ± 11 0.129 
DBP (mmHg) 70 ± 8 73  ± 8* 0.010 
MAP (mmHg) 86 ± 8 89 ± 9 0.053 
PP (mmHg) 43 ± 8 44 ± 11 0.680 
IOP (mmHg) 14 ± 3 14 ± 3 0.909 
    
METABOLIC DATA    
Glucose (mmol/L) 4.86 ± 0.75 5.06 ± 0.77 0.121 
2 hour GTT (mmol/L) 6.20 ± 1.44 7.77 ± 2.40* <0.001 
TG (mmol/L) 1.08 ± 0.36 1.49 ± 0.82* <0.001 
HDL Cholesterol (mmol/L) 1.28 ± 1.36 1.07 ± 1.12* 0.001 
LDL Cholesterol (mmol/L) 2.61 ± 0.85 2.68 ± 0.80 0.590 
Total Cholesterol (mmol/L) 4.35 ± 0.88 4.49 ± 0.86 0.345 
TG:HDL-C (mmol/L) 2.12 ± 1.03 3.76 ± 3.15* <0.001 
    
CVD RISK DATA    
Total:HDL-C (mmol/L) 3.65 ± 1.05 4.52 ± 1.78* 0.001 
R-IMT (mm) 0.056 ± 0.016 0.059 ± 0.016 0.435 
L-IMT (mm) 0.055 ± 0.018 0.063 ± 0.017 0.050 
 
Table 4.1. Baseline data of both groups. Values quoted in mean ± SD.*Significant differences 
indicated in bold as p<0.05. SBP: systolic blood pressure; DBP: diastolic blood 
pressure; MAP: mean arterial pressure; PP: pulse pressure; IOP: intraocular pressure; 
GTT: glucose tolerance test; TG: triglyceride; HDL: high-density lipoprotein; LDL: low 
density lipoprotein; TG:HDL-C: TG-to-HDL ratio; Total:HDL-C: Total-to-HDL ratio; R-
IMT: right intima media thickness L-IMT: left intima media thickness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 White European 
        [n=65] 
South Asian 
     [n=65] 
T-test    
p-value 
CVD RISK DATA    
Framingham Score (%) 2.3 ± 2.7 2.5 ± 4.4 0.787 
M1 Framingham (%) 2.4 ± 2.8 3.8 ± 6.6 0.138 
M2 Framingham (%) 2.5 ± 3.1 5.2  ± 8.6* 0.021 
 
Table 4.2. Framingham (and modified) risk scores for both ethnic groups. Values quoted in 
mean ± SD.*Significant differences indicated in bold as p<0.05. M1 Framingham: 
Modified-1 Framingham for ethnicity by adding 50% of original score; M2 
Framingham: Modified-2 Framingham for ethnicity by increasing age by 10 
years.[367] 
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 White European 
        [n=65] 
South Asian 
     [n=65] 
T-test     
p-value 
Weight (kg) 76.9 ± 16.2 76.3 ± 13.7 0.818 
BMI (kg/m2) 26.0 ± 5.0 26.7 ± 4.1 0.365 
WHR (AU) 0.92 ± 0.07 0.95  ± 0.12 0.219 
PBF (%) 29.5 ± 8.4 30.8 ± 8.4 0.356 
Fat Mass (kg) 23.0 ± 9.0 23.6 ± 8.0 0.671 
Fat Free Mass (kg) 53.9 ± 11.7 52.7 ± 10.8 0.541 
 
Table 4.3. Obesity correlates and body composition (by means of bioelectrical impedance) of 
both groups. Values quoted in mean ± SD. BMI: body mass index; WHR: waist-to-rip 
ratio; PBF: percentage body fat. 
 
 
 White European 
         [n=65] 
South Asian 
     [n=65] 
Wilcoxon    
p-value 
BIOCHEMICAL DATA    
GSH (μM) 1015.9 (445.6-
1416.0) 
 710.7 (350.3-
974.9)* 
0.019 
GSSG (μM) 96.7 (32.1-107.6)  76.4 (39.3-96.4)* 0.013 
GSH:GSSG (μM) 17.7 (8.0-22.3)  12.8 (5.1-18.8)* 0.014 
tGSH (μM) 1168.7 (616.1-
1713.2) 
 904.0 (510.3-
1147.5)* 
0.019 
vWF (μ/dL) 121.1 ± 54.0  135.2 ± 58.9 0.154 
 
Table 4.4. Plasma markers for oxidative stress and endothelial function in both groups. Values 
quoted in IQR or mean ± SD.*Significant differences indicated in bold as p<0.05. GSH: 
reduced Glutathione; GSSG: oxidised glutathione; tGSH: total glutathione; vWF: von 
Willebrand factor.  
 
 
 White European 
         [n=65] 
South Asian 
     [n=65] 
Wilcoxon 
p-value 
BRACHIAL ARTERY    
AD (mm) 4.04 (3.44-4.62) 4.10 (3.39-4.64)  0.674 
BDF (mm) 0.38 (0.17-0.44) 0.34 (0.23-0.44) 0.311 
MD (mm) 4.64 (4.01-5.17) 4.25 (3.63-4.85) 0.018 
RT (secs) 19.8 (0.5-50.5) 24.1 (3.0-38.0) 0.465 
FMD (%) 8.23 (3.43-11.13) 5.49 (2.44-8.83) 0.012 
    
GTN    
GTN-MD (mm) 5.24 (4.63-5.78) 4.95 (4.31-5.55) 0.154 
RT (secs) 285 (257-345) 325 (273-401) 0.084 
GID (%) 25.58 (16.21-29.83) 21.50 (13.29-29.43) 0.180 
    
FMD/GID (%) 0.40 (0.13-0.55) 0.07 (0.05-0.46) 0.075 
 
Table 4.5. Brachial artery reactivity as means of systemic vascular endothelial function between both 
groups. Values quoted in mean (IQR).  *Significant differences indicated in bold (p<0.05). 
AD: absolute diameter; BDF: baseline diameter fluctuation; MD: maximum diameter 
response; RT: Reaction time; FMD: flow-mediation dilation response; GID: GTN-induced 
dilation; FMD/GID: FMD/GID ratio. 
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Figure 4.1. Difference in FMD (%) of the brachial artery in response to reactive hyperaemia for 
both ethnic groups. 
SA WE 
Figure 4.2. Correlation between brachial artery FMD and plasma levels of oxidised-form 
glutathione in SAs. Spearmans correlations showing a moderate correlation 
between FMD and GSSG (SAs: r=0.3248, p=0.013; WEs: r=0.287, p=0.048) 
p= 0.012 
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 White European 
         [n=65] 
South Asian 
      [n=65] 
Friedman 
p-value 
ARTERY    
AD (AU) 121.76 (112.72-131.75) 124.71 (87.70-174.28)  0.305 
BDF (AU) 4.56 (3.10-5.46) 6.07 (1.57-17.49) 0.002 
MC (%) 2.73 (1.35-3.40) 3.51 (3.53-10.06) 0.041 
MCRT (secs) 21.5 (19.0-23.7) 18.8 (7.0-29.3) 0.001 
DA (%) 7.65 (5.81-8.91) 8.81 (2.10-20.24) 0.057 
bFR (%) 3.09 (1.68-4.38) 2.74 (-5.57-9.45) 0.462 
    
VEIN    
AD (AU) 153.98 (141.0-164.34) 158.43 (111.74-134.58) 0.271 
BDF (AU) 3.55 (2.32-4.43) 4.65 (3.84-7.64) 0.002 
MC (%) 1.36 (0.32-1.80) 1.70 (2.01-4.82) 0.259 
MCRT (secs) 21.7 (19.5-25.0) 21.5 (15.7-22.3) 0.792 
DA (%) 6.57 (4.62-7.52) 7.84 (6.02-10.96) 0.018 
bFR (%) 3.02 (1.49-4.31) 3.20 (0.85-5.01) 0.692 
 
Table 4.6. Retinal arterial and venous measures for both groups. Values quoted in mean (IQR).  
*Significant differences indicated in bold (p<0.05). AD: absolute diameter; BDF: baseline 
diameter fluctuation; MC: maximum constriction; MCRT: reaction time to maximum 
constriction post flicker; DA: dilation amplitude; bFR: baseline-corrected flicker 
response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 White European 
         [n=65] 
South Asian 
      [n=65] 
Friedman 
p-value 
ARTERY DILATION 
SLOPE  
   
Flicker cycle 1 0.34 (0.15-0.4) 0.37 (0.15-0.43) 0.574 
Flicker cycle 2 0.29 (0.17-0.42) 0.36 (0.18-0.46) 0.124 
Flicker cycle 3 0.31 (0.15-0.46) 0.34 (0.15-0.43) 0.554 
Average 0.31 (0.19-0.40) 0.36 (0.22-0.46) 0.142 
    
VEIN DILATION    
SLOPE 
   
Flicker cycle 1 0.32 (0.14-0.41) 0.34 (0.20-0.39) 0.653 
Flicker cycle 2 0.32 (0.19-0.40) 0.37 (0.21-0.50) 0.475 
Flicker cycle 3 0.29 (0.18-0.32) 0.34 (0.18-0.46) 0.160 
Average 0.31 (0.21-0.38) 0.37 (0.24-0.47) 0.029 
 
Table 4.7. Retinal arterial and venous dilation slope values for each individual flicker cycle. Values 
quoted in mean (IQR).   
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 White European 
        [n=65] 
South Asian 
      [n=65] 
Friedman 
p-value 
ARTERY CONSTRICTION 
SLOPE  
   
Flicker cycle 1 -0.38 (-0.19/-0.45) -0.47 (-0.25/-0.64) 0.089 
Flicker cycle 2 -0.46 (-0.23/-0.48) -0.55 (-0.28/-0.60) 0.280 
Flicker cycle 3 -0.33 (-0.19/-0.39) -0.55 (-0.22/-0.59) 0.026 
Average -0.39 (-0.26/-0.45) -0.52 (-0.28/-0.64) 0.015 
    
VEIN CONSTRICTION   
SLOPE 
   
Flicker cycle 1 -0.34 (-0.18/-0.44) -0.55 (-0.20/-0.56) 0.080 
Flicker cycle 2 -0.37 (-0.16/-0.56) -0.50 (-0.23/-0.55) 0.134 
Flicker cycle 3 -0.36 (-0.18/-0.41) -0.43 (-0.22/-0.55) 0.255 
Average -0.36 (-0.21/-0.48) -0.50 (-0.26/-0.55) 0.022 
 
Table 4.8. Retinal arterial and venous constriction slope values for each individual flicker cycle.  
Values quoted in mean (IQR).  *Significant differences indicated in bold (p<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 White European 
        [n=65] 
South Asian 
      [n=65] 
Post-hoc 
p-value 
ARTERY BDF (AU)    
Flicker cycle 1 4.48 (2.97-5.26) 6.06 (3.41-8.20) 0.002 
Flicker cycle 2 4.73 (2.53-5.25) 6.23 (3.36-8.08) 0.017 
Flicker cycle 3 4.35 (2.77-5.52) 5.79 (3.61-7.33) 0.006 
    
Within-group ANOVA 0.194 0.454  
    
VEIN BDF (AU)    
Flicker cycle 1 3.55 (2.09-4.50) 4.34 (2.61-4.59) 0.083 
Flicker cycle 2 3.84 (2.32-4.70) 4.51 (2.42-5.96) 0.173 
Flicker cycle 3 3.56 (2.24-4.38) 4.72 (2.97-5.43) 0.007 
    
Within-group ANOVA 0.986 0.596  
 
Table 4.9. Retinal arterial and venous BDF for each individual flicker cycle. Values quoted in mean 
(IQR).  *Significant differences indicated in bold (p<0.05). BDF: baseline diameter 
fluctuation. 
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 White European 
         [n=65] 
South Asian 
      [n=65] 
Post-hoc 
p-value 
ARTERY MC (%)    
Flicker cycle 1 2.77 (1.13-3.87) 3.53 (1.26-4.90) 0.111 
Flicker cycle 2 2.81 (1.80-4.21) 3.73 (2.01-5.16) 0.063 
Flicker cycle 3 2.67 (0.65-3.64) 3.27 (1.57-4.17) 0.215 
    
Within-group ANOVA 0.909 0.261  
 
Table 4.10. Retinal arterial MC for each individual flicker cycle. Values quoted in mean (IQR).  
*Significant differences indicated in bold (p<0.05). MC: maximum constriction as a 
percentage from initial baseline diameter.  
 
 
 
 
 
SA WE 
Figure 4.3. Repeated-measure values for retinal arterial baseline-diameter fluctuations in each 
flicker cycle for both ethnic groups 
p= 0.002 
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 White European 
         [n=65] 
South Asian 
      [n=65] 
Post-hoc 
p-value 
ARTERY MCRT (secs)    
Flicker cycle 1 22.8 (19.0-28.0) 19.0 (13.5-24.0) 0.002 
Flicker cycle 2 20.6 (14.0-27.0) 17.5  (11.0-24.0) 0.003 
Flicker cycle 3 21.2 (17.0-26.0) 19.7 (13.0-27.0) 0.242 
    
Within-group ANOVA 0.237 0.297  
 
Table 4.11. Retinal arterial MCRT for each individual flicker cycle. Values quoted in mean ± SD.  
*Significant differences indicated in bold (p<0.05). MCRT: maximum constriction 
reaction time post-flicker. 
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 White European 
         [n=65] 
South Asian 
      [n=65] 
Post-hoc 
p-value 
VEIN MD (%)    
Flicker cycle 1 5.18 (2.86-6.36) 5.66 (4.18-7.57) 0.385 
Flicker cycle 2 5.30 (3.55-6.34) 7.03 (4.28-8.34) 0.008 
Flicker cycle 3 5.22 (3.40-6.11) 5.79 (3.83-7.59) 0.312 
    
Within-group ANOVA 0.928 0.055  
 
Table 4.12. Retinal venous MD for each individual flicker cycle. Values quoted in mean ± SD.  
*Significant differences indicated in bold (p<0.05). MD: maximum dilation. 
 
Figure 4.4. Differences in arterial RT to reach maximal constriction diameter post-flicker for both 
ethnic groups 
SA WE 
p= 0.002 
p= 0.003 
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 White European 
         [n=65] 
South Asian 
      [n=65] 
Post-hoc 
p-value 
VEIN DA (%)    
Flicker cycle 1 18.1 (4.28-7.68) 22.8 (5.15-9.72) 0.011 
Flicker cycle 2 19.5 (4.60-9.03) 19.4 (5.50-10.17) 0.947 
Flicker cycle 3 16.9 (4.42-7.51)) 21.6 (4.89-9.36) 0.022 
    
Within-group ANOVA 0.166 0.067  
 
Table 4.13. Retinal venous DA for each individual flicker cycle. Values quoted in mean and IQR.  
*Significant differences indicated in bold (p<0.05). DA: dilation amplitude. 
 
 
 
 White European South Asian Post-hoc 
p-value 
ARTERY MDRT (secs)    
Flicker cycle 1 18.7 ± 10.6 19.5 ± 10.7 0.694 
Flicker cycle 2 21.3  ± 11.7  19.8 ± 11.8 0.527 
Flicker cycle 3 16.2 ± 6.9 20.0 ± 10.9* 0.039 
    
VEIN MDRT (secs)    
Flicker cycle 1 20.4 ± 9.3 19.7 ± 7.7 0.705 
Flicker cycle 2 20.6 ± 12.1 19.8 ± 7.6 0.689 
Flicker cycle 3 21.7 ± 12.7 21.7 ± 9.6 0.989 
    
Table 4.14. Retinal arterial MDRT for each individual flicker cycle. Values quoted in mean and IQR. 
*Significant differences indicated in bold (p<0.05). MDRT: maximum dilation reaction 
time. 
 
 
Correlation analysis between distinct biomarkers and vascular tests yielded weak-to-
moderate correlations between oxidative stress markers, namely GSSG and FMD (Figure 
4.2.) but not with any retinal vessel components. The time taken for SAs (but not WEs) to 
reach maximal retinal arterial constriction, termed MCRT, did correlate modestly with GSH 
(r=0.372, p=0.009); tGSH (r=0.376, p=0.009); TG (r=-0.330, p=0.012) and TG:HDL-C ratio 
(r=-0.361, p=0.006). (Figure 4.5). Finally, arterial baseline-diameter fluctuations (BDF) 
correlated, but again somewhat moderately, to TG:HDL-C (r=0.277, p=0.004) and Total:HDL-
C (r=0.322, p=0.014) in SAs.  
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4.5.1. Influence of Gender on ANS and Vascular Function Differences in SAs 
Further analysis involved comparisons between male (n=33) and female (n=32) groups in 
both cohorts. The demographic data for SA males is presented in Table 4.15, and showed 
similar distributions for age, systemic BP, MAP, IOP, fasting levels of glucose; HDL, LDL and 
total cholesterol, and carotid-IMT. When compared to their WE counterparts, SA males did 
however show abnormally higher (borderline IGT values) 2-hour post consumption glucose 
values (p=0.007), and raised TG (p=0.022) and cholesterol ratios; evident by higher TG:HDL-
C (p=0.011) and Total:HDL-C (p=0.013) levels. 
Figure 4.5. Biochemical and MCRT correlations in SAs. From top-left to clockwise. Positive 
Spearmans correlations for MCRT against GSH (r= 0.372; p= 0.013) and tGSH (r= 0.376; 
p=0.009), and negative correlations between MCRT and TG (r= -0.330 ;p= 0.012) and 
TG:HDL (r= -0.361; p= 0.006). 
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The demographic values for the female subgroups in Table 4.16 showed comparable profiles 
with only significant differences in 2-hour GTT levels, plasma TGs and left-side common 
carotid artery intima media thickness (p=0.018, p=0.036, and p=0.030 respectively). 
When comparing Framingham scores for CVD risk (Table 4.17), however, there were no 
differences between both genders in either group (p>0.05). This was also true for plasma 
markers for oxidative stress and endothelial function. Nor were there any significant 
differences in micro- and macro-vascular function (ANOVA p>0.05).  
 
 
 
 
 
 
 
 
 WE Male 
  [n=33] 
SA Male 
  [n=33] 
T-test     
p-value 
DEMOGRAPHIC DATA    
Age (years) 40.0 ± 9.4 39.3 ± 10.3 0.739 
SBP (mmHg) 122 ± 10 124 ± 11 0.435 
DBP (mmHg) 74 ± 7 75  ± 8  0.764 
MAP (mmHg) 93 ± 8 94 ± 12 0.672 
IOP (mmHg) 14 ± 3 14 ± 3 0.659 
    
METABOLIC DATA    
Glucose (mmol/L) 5.14 ± 8.67 5.10 ± 14.63 0.800 
2 hour GTT (mmol/L) 6.53 ± 1.30 7.60 ± 2.63* 0.007 
TG (mmol/L) 1.18 ± 1.01 1.57 ± 0.83* 0.010 
HDL Cholesterol (mmol/L) 1.16 ± 0.29 1.01 ± 0.39 0.084 
LDL Cholesterol (mmol/L) 2.64 ± 0.78 2.65 ± 0.81 0.951 
Total Cholesterol (mmol/L) 4.32 ± 0.87 4.37 ± 0.81 0.782 
TG:HDL-C (mmol/L) 2.51 ± 1.32 4.28 ± 3.40* 0.011 
    
CVD RISK DATA    
Total:HDL-C (mmol/L) 3.91 ± 1.02 4.91 ± 1.91* 0.013 
R-IMT (mm) 0.063 ± 0.018 0.060 ± 0.016 0.567 
L-IMT (mm) 0.061 ± 0.021 0.063 ± 0.016 0.722 
 
Table 4.15. Baseline data for male subgroups. Values quoted in mean ± SD.*Significant differences 
indicated in bold as p<0.05. SBP: systolic blood pressure; DBP: diastolic blood 
pressure; MAP: mean arterial pressure; IOP: intraocular pressure; GTT: glucose 
tolerance test; TG: triglyceride; HDL: high-density lipoprotein; LDL: low density 
lipoprotein; TG:HDL-C: TG-to-HDL ratio; Total:HDL-C: Total-to-HDL ratio; R-IMT: right 
intima media thickness L-IMT: left intima media thickness. 
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 WE Female 
    [n=32] 
SA Female 
    [n=32] 
T-test     
p-value 
DEMOGRAPHIC DATA    
Age (years) 39.5 ± 10.0 38.2 ± 11.5 0.521 
SBP (mmHg) 114 ± 8 111 ± 5 0.209 
DBP (mmHg) 66 ± 6 69  ± 5 0.123 
MAP (mmHg) 82 ± 6 82 ± 4 0.968 
IOP (mmHg) 14 ± 2 13 ± 3 0.375 
    
METABOLIC DATA    
Glucose (mmol/L) 4.61 ± 0.86 4.97 ± 0.67 0.090 
2 hour GTT (mmol/L) 5.88 ± 1.53 7.07 ± 1.67* 0.018 
TG (mmol/L) 1.00 ± 0.25 1.31 ± 0.77* 0.036 
HDL Cholesterol (mmol/L) 1.34 ± 0.31 1.40 ± 0.39 0.540 
LDL Cholesterol (mmol/L) 2.58 ± 0.85 2.78 ± 0.80 0.426 
Total Cholesterol (mmol/L) 4.37 ± 0.91 4.76 ± 0.91 0.120 
TG:HDL-C (mmol/L) 1.78 ± 0.55 2.44 ± 1.89 0.070 
    
CVD RISK DATA    
Total:HDL-C (mmol/L) 3.43 ± 1.05 3.56 ± 0.86 0.621 
R-IMT (mm) 0.049 ± 0.012 0.056 ± 0.015 0.227 
L-IMT (mm) 0.050 ± 0.013 0.064 ± 0.018* 0.030 
 
Table 4.16. Baseline data for female subgroups. Values quoted in mean ± SD.*Significant 
differences indicated in bold as p<0.05. SBP: systolic blood pressure; DBP: diastolic 
blood pressure; MAP: mean arterial pressure; IOP: intraocular pressure; GTT: 
glucose tolerance test; TG: triglyceride; HDL: high-density lipoprotein; LDL: low 
density lipoprotein; TG:HDL-C: TG-to-HDL ratio; Total:HDL-C: Total-to-HDL ratio; R-
IMT: right intima media thickness L-IMT: left intima media thickness. 
 
 
 
 
 
 
 
 
 
 
CVD RISK 
DATA 
Framingham 
Score (%) 
M1 Framingham 
(%) 
M2 Framingham 
(%) 
WE Male 3.9 ± 3.2 4.1 ± 3.4 4.3 ± 3.7 
SA Male 3.2 ± 5.1 4.9 ± 7.6 6.9 ± 7.6 
T-test p-value 0.500 0.604 0.185 
    
    
WE Female 0.9 ± 0.7 0.9 ± 0.7 0.9 ± 0.7 
SA Female 0.7 ± 0.2 1.0 ± 0.4 1.1 ± 0.8 
T-test p-value 0.140 0.632 0.384 
 
Table 4.17. Framingham (and modified) risk scores for gender subgroups. Values quoted in 
mean ± SD. M1 Framingham: Modified-1 Framingham for ethnicity by adding 50% of 
original score; M2 Framingham: Modified-2 Framingham for ethnicity by increasing 
age by 10 years.[367] 
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Additional analysis extended to comparing gender groups within the SA cohort as presented 
in Table 4.18. This yielded comparative differences in systemic BP profiles, with SA men 
showing higher SBP, DBP, MAP and PP values (p<0.001, p=0.006, p<0.001 and p<0.001 
respectively) than SA women. Despite higher fasting glucose values (p=0.002), SA males 
gave similar 2-hour GTT results as SA women (p>0.05). Both groups showed similar levels in 
plasma markers of metabolic function, with only statistically significant differences in HDL 
cholesterol (p<0.001) and TG:HDL-C (p=0.019) and Total:HDL-C (p=0.002). However, it is 
important to note that SA males presented with lower total cholesterol values that was close 
to, but didn‟t reach, statistical significance. This impacted CVD risk scores, with SA men 
showing significantly higher percentages for eventual CVD in 10 years (p=0.020, p=0.020 
and p=0.007). (Table 4.19/Figure 4.6.) 
ANS functional analysis by means of twenty-four hour BP and HRV measurements are 
presented in Table 4.20 and 4.21 respectively. Unlike the similar findings found between SA 
and WE groups, when compared to SA women, SA men exhibited statistically significant 
signs of possible ANS dysfunction by means of increased systemic BP profiles and 
sympathetic innervation (raised LF readings p=<0.05) and reduced parasympathetic 
stimulation (lower HF readings p=<0.05). Despite these consistent findings in SA men, there 
were no significant differences found in circadian parameters (p>0.05). Correlations between 
glucose levels and sympathovagal imbalances (LF:HF values) were evident in SA men in 
both active (r=0.376, p=0.017) and passive phases (p=0.421, p=0.007). (Figure 4.7.) 
Although SA men weighed more than their female counterparts (p<0.001), both groups had 
similar BMI and WHR values. Despite this, SA females had greater levels of body fat as 
evident by a higher PBF value, and lower fat free mass, total body water, protein, mineral 
and skeletal muscle mass scores (p<0.001) when compared to SA males. Table 4.22 
Despite apparent differences in obesity indices, there were no significant disparities in 
plasma markers for oxidative stress and endothelial function (p>0.05). 
Additionally, SA men and women presented with similar retinal vessel reactivity and SRDA 
components showing no differences in retinal vascular function. However, as shown in Table 
4.23, SA men did exhibited reduced, albeit the lower side of normal, brachial artery MD as 
induced by reactive hyperaemia (p=0.002) and GTN (p=0.035). 
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 SA Male 
  [n=33] 
SA Female 
    [n=32] 
Unpaired 
T-test     
p-value 
DEMOGRAPHIC DATA    
Age (years) 39.3 ± 10.3 38.2 ± 11.5 0.670 
SBP (mmHg) 124 ± 11* 110 ± 5 <0.001 
DBP (mmHg) 75 ± 8* 69  ± 5 0.006 
MAP (mmHg) 91 ± 9* 82 ± 4 <0.001 
PP (mmHg) 47 ± 9* 38 ± 13 <0.001 
IOP (mmHg) 14 ± 3 13 ± 3 0.367 
    
METABOLIC DATA    
Glucose (mmol/L) 5.69 ± 0.61* 5.16 ± 0.42 0.002 
2 hour GTT (mmol/L) 7.60 ± 2.63 7.07 ± 1.66 0.135 
TG (mmol/L) 1.57 ± 0.83 1.30 ± 0.77 0.191 
HDL Cholesterol (mmol/L) 1.01 ± 0.39* 1.40 ± 0.39 <0.001 
LDL Cholesterol (mmol/L) 2.65 ± 0.81 2.78 ± 0.80 0.523 
Total Cholesterol (mmol/L) 4.37 ± 0.81 4.76 ± 0.91 0.065 
TG:HDL-C (mmol/L) 4.28 ± 3.40* 2.44 ± 1.89 0.019 
    
CVD RISK DATA    
Total:HDL-C (mmol/L) 4.91 ± 1.91* 3.56 ± 0.86 0.002 
R-IMT (mm) 0.060 ± 0.016 0.056 ± 0.015 0.429 
L-IMT (mm) 0.063 ± 0.016 0.064 ± 0.018 0.911 
 
Table 4.18. Baseline data for SA gender subgroups. Values quoted in mean ± 
SD.*Significant differences indicated in bold as p<0.05. SBP: systolic blood 
pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; PP: 
pulse pressure; IOP: intraocular pressure; GTT: glucose tolerance test; TG: 
triglyceride; HDL: high-density lipoprotein; LDL: low density lipoprotein; 
TG:HDL-C: TG-to-HDL ratio; Total:HDL-C: Total-to-HDL ratio; R-IMT: right 
intima media thickness L-IMT: left intima media thickness. 
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 Framingham 
Score (%) 
M1 Framingham 
(%) 
M2 Framingham 
(%) 
SA Male 3.2 ± 5.1* 4.9 ± 7.6* 6.9 ± 7.6* 
SA Female 0.7 ± 0.2 1.0 ± 0.4 1.1 ± 0.8 
Unpaired T-test  0.020 0.020 0.007 
 
Table 4.19. Framingham (and modified) risk scores for SA gender subgroups. Values quoted in 
mean ± SD.*Significant differences indicated in bold as p<0.05. M1 Framingham: 
Modified-1 Framingham for ethnicity by adding 50% of original score; M2 
Framingham: Modified-2 Framingham for ethnicity by increasing age by 10 
years.[367] 
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Figure 4.6. Framingham risk score differences for different gender sub-groups in WE and SA 
categories. Risk Score: traditional Framingham %, Risk Score-M1: modified risk score 
to account for ethnicity by increasing traditional score by 50%, Risk Score-M2: modified 
risk score to account for ethnicity by increasing the inputted age by 10 years. 
WE Male WE Female SA Female SA Male 
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BP PROFILE DATA SA Male 
  [n=33] 
SA Female 
    [n=32] 
Unpaired 
T-test      
p-value 
24 hr-SBP (mmHg) 124 ± 11* 110 ± 5 <0.001 
24 hr-DBP (mmHg) 75 ± 8* 69  ± 5 0.006 
24 hr-MAP (mmHg) 91 ± 9* 82 ± 4 <0.001 
    
Active-SBP (mmHg) 129 ± 11* 114 ± 5 <0.001 
Active-DBP (mmHg) 80 ± 8* 72  ± 4 <0.001 
Active-MAP (mmHg) 95 ± 11* 85 ± 4 <0.001 
    
Passive-SBP (mmHg) 115 ± 12* 103 ± 4 <0.001 
Passive-DBP (mmHg) 66 ± 9* 61  ± 8 0.033 
Passive-MAP (mmHg) 66 ± 11 65 ± 10 0.684 
    
Circadian-SBP (mmHg) 14 ± 11 13 ± 5 0.759 
Circadian-DBP (mmHg) 15 ± 12 12 ± 8 0.117 
Circadian-MAP (mmHg) 29 ± 12 20 ± 10 0.883 
 
Table 4.20. Systemic BP data for SA gender subgroups. Values quoted in mean ± SD.*Significant 
differences indicated in bold as p<0.05. SBP: systolic blood pressure; DBP: diastolic 
blood pressure; MAP: mean arterial pressure. 
 
 
 
 
 
 
 
 
 
 
 
ANS PROFILE DATA SA Male 
  [n=33] 
SA Female 
    [n=32] 
Unpaired 
T-test     
p-value 
24 hr-LF (NU) 68 ± 10* 62 ± 11 0.043 
24 hr-HF(NU) 30 ± 10 34  ± 10 0.077 
24 hr-LF/HF (NU) 2.7 ± 1.3 2.2 ± 1.2 0.155 
    
Active-LF (NU) 72 ± 9* 63 ± 11 <0.001 
Active-HF (NU) 26 ± 9* 34  ± 10 <0.001 
Active-LF/HF (NU) 3.1 ± 1.4* 2.1 ± 1.2 0.006 
    
Passive-LF (NU) 66 ± 12* 58 ± 10 0.008 
Passive-HF (NU) 32 ± 12* 39 ± 10 0.020 
Passive-LF/HF (NU) 2.6 ± 1.7* 1.6 ± 0.7 0.015 
    
Circadian-LF (NU) 6.7 ± 21.5 7.4 ± 13.7 0.892 
Circadian-HF (NU) -6.0 ± 12.7 -4.8 ± 9.3 0.717 
Circadian-LF/HF (NU) 0.5 ± 1.6 0.4 ± 0.9 0.768 
 
Table 4.21. HRV data for SA gender subgroups. Values quoted in NU (normalised units) mean ± 
SD.*Significant differences indicated in bold as p<0.05. LF: low frequency component 
of the HRV, HF: high frequency component of the HRV. 
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 SA Male 
  [n=33] 
SA Female 
    [n=32] 
Unpaired 
T-test    
p-value 
Weight (kg) 81.3 ± 12.2* 65.4 ± 9.9 <0.001 
BMI (kg/m2) 26.8 ± 3.8 26.3 ± 4.5 0.603 
WHR (AU) 0.95 ± 0.13 0.94  ± 0.08 0.649 
PBF (%) 27.2 ± 6.4 38.8 ± 6.9* <0.001 
Fat Mass (kg) 22.6 ± 8.1 25.6 ± 7.7 0.107 
Fat Free Mass (kg) 58.7 ± 6.8 39.6 ± 4.6* <0.001 
SMM (kg) 33.1 ± 4.2 21.5 ± 2.8* <0.001 
TBW (l) 43.1 ± 5.0 29.0 ± 3.4* <0.001 
Protein (kg) 11.6 ± 1.4 7.8 ± 0.9* <0.001 
Mineral (kg) 4.0 ± 0.5 2.8 ± 0.3* <0.001 
 
Table 4.22. Obesity correlates and body composition (by means of bioelectrical impedance) of 
SA gender subgroups. Values quoted in mean ± SD. *Significant differences 
indicated in bold as p<0.05. BMI: body mass index; WHR: waist-to-hip ratio; PBF: 
percentage body fat; SMM: skeletal muscle mass; TBW: total body water. 
 
 
 
 
 
Figure 4.7. Correlation between glucose levels and sympathovagal imbalances in SA men. 
Spearmans correlations showing a moderate correlation between hyperglycaemia and 
passive LF:HF (r=0.421, p=0.007) and a weaker correlation on the right side for active 
LF:HF (r=0.376, p=0.017) 
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 SA Male 
  [n=33] 
SA Female 
    [n=32] 
Mann-
Whitney 
p-value 
BRACHIAL ARTERY    
AD (mm) 4.42 (4.09-4.91) 3.32 (3.06-3.48)  <0.001 
BDF (mm) 0.33 (0.17-0.44) 0.34 (0.17-0.44) 0.919 
MD (mm) 4.89 (4.32-5.37) 4.03 (3.37-4.10) 0.002 
RT (secs) 24.3 (1.0-55.0) 23.6 (6.0-37.0) 0.941 
FMD (%) 8.30 (3.18-11.33) 8.08 (5.47-10.86) 0.886 
    
GTN    
GTN-MD (mm) 5.35 (4.63-5.88) 4.12 (3.27-5.03) 0.035 
RT (secs) 281 (255-346) 328 (321-333) 0.529 
GID (%) 24.97 (16.21-29.69) 31.89 (8.45-36.48) 0.431 
    
FMD/GID (%) 0.40 (0.13-0.55) 0.39 (0.04-0.91) 0.980 
 
Table 4.23. Brachial artery reactivity as means of systemic vascular endothelial function between 
both groups. Values quoted in mean (IQR).  *Significant differences indicated in bold 
(p<0.05). AD: absolute diameter; BDF: baseline diameter fluctuation; MD: maximum 
diameter response; RT: Reaction time; FMD: flow-mediation dilation response; GID: GTN-
induced dilation; FMD/GID: FMD/GID ratio. 
 
 
 
 
 
 
4.6. Discussion 
The findings, in this chapter, suggest that an otherwise healthy second-generation SA 
immigrant population present with an early risk for vascular disease, as shown by increased 
Framingham scores, reduced brachial artery FMD and retinal arterial over-constriction.  
Additionally, when compared to WEs, SAs presented with a pattern of dyslipidaemia 
(increased TG, lower HDL concentrations and higher cholesterol ratios) characteristically 
present in their parents and older generations that is also found with T2DM and is an 
important feature found in the MetS.[368] Furthermore, gender influences in SAs showed 
differences in lipid and systemic BP profiles and ANS function in SA men. 
 
Dyslipidaemia and CVD risk  
Even though the total cholesterol values were comparable amongst SAs and WEs, this is not 
an uncommon finding.[369, 370] Interestingly, albeit normal, some studies have reported 
cholesterol values higher than their SA counterparts in the Indian subcontinent.[361] 
However, total cholesterol as a means of predicting vascular risk, tends to underestimate the 
risk in SAs when using CVD risk predictors. The Total:HDL Cholesterol ratio (Total:HDL-C) 
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has instead been proven to be a better predictor for CVD in this ethnic minority.[365] This is 
supported by the findings of this thesis with significantly higher ratios in the SA cohort despite 
similar total cholesterol findings.  
Very similar to other vascular risk studies, the current results show that with migration, lipid 
profiles are becoming more adverse; illustrated by falling HDL and rising TG and cholesterol 
ratio values.[371, 372] Furthermore, a majority of studies have reported classic lipid profile 
anomalies in the form of lower HDL concentrations and increased prevalence of atherogenic 
small particle-sized LDL cholesterol levels.[373] These findings alongside those reported in 
this thesis strongly suggest that abnormal lipid profiles are a contributing factor to excess 
vascular risk in SAs.[374, 375] 
Interestingly, when accounting for vascular risk, the widely used Framingham risk calculator 
shows little differences when comparing SAs with WEs. This is despite definite differences in 
systemic BP, HDL-C and TG. It is only when the traditional risk calculator is modified for 
ethnicity, i.e. by adding 10 years to the Framingham equation, that SAs show a definite 
increased risk for CVD. This suggests, and has indeed been proposed on a number of 
occasions, that thresholds should be significantly lowered for SAs when accounting for CVD 
risk.[28, 367] This is true too, for SA men who showed a greater sensitivity and considerable 
difference in risk percentages when modified for ethnicity as compared to SA women. 
Whether this could allow for reduced thresholds in vascular function studies; i.e. reduced 
FMD and RVA values to account for ethnicity, opens up avenues for further work and a 
clinical need for normative databases in different ethnic groups. 
The relevance of obesity and central adiposity within the SA community has also been 
highlighted by many large population-based studies.[376] Abdominal obesity significantly 
contributes to the pathogenesis of IR through a number of mechanisms.[377-380] Unlike that 
of the results reported in this chapter, these studies have shown increased WHR values in 
SAs than in WEs.[381-384] Although obesity can contribute, only in part, towards the excess 
vascular risk, it has been suggested that for every level of body fat SAs appear more IR than 
WEs.[25, 26, 384, 385] This could possibly be the case for SA women as shown by their 
significantly different obesity components when compared to SA men. This is supported by 
data suggesting that skeletal muscle mass and distribution is important in many physiological 
and disease processes, including ageing.[386, 387] However, to investigate this fully, further 
body composition studies would need to be conducted. 
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SAs are also known to present with BP profiles indicative of future hypertensive and CVD 
risk, by means of higher SBP, DBP and PP recordings, which was only evident with 
increased DBP values in this cohort.[388, 389] The influence of dyslipidaemia and 
hyperglycaemia in SAs on increased heart rate and abnormal cardiac sympathovagal 
balance is also well recorded. However, consistent with other studies, further 24-hour 
systemic BP and ECG analysis yielded no differences in ANS and HRV function between 
SAs and WEs.[390]  
 
Gender Differences 
It is only when considering SA men alone that increased BP profiles are consistently seen 
and early signs of HRV and ANS dysfunction (increased LF and reduced HF components) 
are registered. These results show that cardiac burden and future risk, by means of 
autonomic dysfunction is evident in otherwise healthy SA men, but was not found to be a 
relevant factor in SA females (independent of height ANCOVA p>0.05). Although this is 
consistent to previously reported data, only moderate influences were found between 
hyperglycaemia and ANS dysfunction.[261] Unlike previous findings, SA men in this cohort 
presented with higher FMD results (8.30% versus 6.9%) and furthermore this was 
comparable to the WE sample. This would suggest endothelial dysfunction may occur 
independently to ANS dysfunction in SA men.[26, 383] To validate these findings though, 
extensive longitudinal data are required. This would also establish whether the impact of 
CVD risk in men is mediated through metabolic and/or autonomic processes. 
Interestingly, SA women showed reduced FMD and GID percentages when compared to 
their male counterparts, suggesting a slightly blunted response in both endothelial and 
smooth-muscle cell response when compared to SA men. However, this cannot be explained 
by smaller initial brachial artery diameters (p<0.001) as multiple regressional analysis yielded 
no influence (ANCOVA p>0.05) and no such correlations existed between obesity 
parameters and brachial artery dilation (p>0.05). Therefore, further work would need to be 
conducted to understand the influence on gender and ethnicity on endothelial function. 
The findings of the present study can be applied to healthy males, and future studies would 
need to examine whether ethnic differences are demonstrable in those with overt vascular 
risk factors.  
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Systemic Endothelial Function 
FMD allows for the assessment of the shear-stress mediated NO production mechanism and 
brachial artery FMD is closely related with coronary vasomotor response.[391] Therefore, a 
reduction in FMD is thought to represent an early functional disturbance in the development 
of CVD. The SA sample in this thesis demonstrated significantly lower FMD than WEs, 
indicating reduced NO bioavailability. Furthermore, the average FMD of 5.49% in SAs falls 
short of healthy FMD values of 7-10% of the baseline diameter and instead follows that of 
impaired FMD values found in CVD.[392-397] Whether this relates to endothelial-cell 
dysfunction remains to be seen. The increased but not significant levels of vWF in the SA 
sample though, could help to suggest so (no correlations were found between these two 
variables). However, contradictory reports showing comparable indices in angiogenesis and 
endothelial-cell dysfunction in SAs suggest that their pathophysiological role in CVD is 
minimal.[253] The results of this thesis would suggest otherwise but could only be 
substantiated with further research. 
The findings in SA diabetics that oxidative stress pathway genes are important predictors for 
the development of diabetic complications also help to show the importance of determining 
oxidative stress levels in SAs.[398] The findings of lower levels in GSH and GSSG and its 
correlations with reactivity/SDRA components in SAs but not the WE group support this 
thinking (Figure 4.2. and  4.5.). 
 
Retinal Vascular Function 
Despite evidence for endothelial cell damage/dysfunction (reduced FMD, lower GSH/GSSG 
levels and increased vWF) in SAs, this did not relate to impaired retinal vessel reactivity. 
Previous reports have shown that SDRA may be more sensitive in detecting retinal vascular 
function, and this may be the case with SAs (Appendix 3) Although there were no differences 
detected in the rate of retinal vessel diameter increase with flicker stimulation, i.e. the dilatory 
slopes, SAs exhibited interesting constriction profiles post-flicker cessation. The increased 
retinal arterial constriction percentages (MC), which suggest a possible over-constriction 
when compared to WEs, follow that found in chronic smokers.[399] Furthermore, the 
increased arterial (Figure 4.3.) and venous baseline fluctuations (BDF) as well as higher 
dilation and dilation amplitude responses are not surprising results when considering other 
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vascular haemodynamics findings. Several studies have shown a shifted vasomotion in 
chronic smokers that leans towards greater vaso-constriction as a result of interacting 
mechanisms. Additionally, these subjects have also shown to suffer from a “chronic 
vasodilation” due to an alteration in vaso-active substances. [216, 399] This is somewhat 
supported by the correlation analysis of this chapter, albeit moderate, between arterial 
constriction components and GSH, tGSH, TG and TG:HDL-C as well as BDF and TG:HDL-C 
and Total:HDL-C ratios (Figure 4.5.). This could, therefore, suggest a biochemical 
involvement, not just autoregulative, in quicker MCRT (Figure 4.4.) and possible steeper 
constriction slopes in the SA group. 
 
Conclusions 
Compared to previous studies, this thesis is presenting newly-found systemic and retinal 
vascular function data in SAs. The data as a whole suggests quantitatively for the first time 
that the increased risk of future vascular disease presents at a much earlier age than in WEs. 
The interplay between systemic, retinal and biochemical markers for endothelial 
function/damage, metabolic control and oxidative stress also illustrates the complex nature of 
vascular risk in SAs. Furthermore, SA men, compared with corresponding SA women of 
similar age and glycaemic status, present with greater levels of dyslipidaemia, Framingham 
scores and abnormal BP and HRV independent of height (ANCOVA p>0.05), which may 
contribute to increased CVD risk in SA men. 
It is not clear whether the observed metabolic and vascular abnormalities in SA migrants are 
genetic in origin or whether environmental factors might contribute to expression of the 
abnormalities. One obvious limitation to these results is indeed the small sample size. 
However, as the data presented in this chapter is preliminary, further work would need to be 
performed in order to validate the use of SDRA in ethnic vascular screening and whether 
these functional tests would also be beneficial in diagnostic and therapeutic approaches to 
those with established vascular disease; namely SAs with T2DM, stroke or CVD.  
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5. Vascular Function in Individuals Newly Diagnosed with IGT as 
compared to Normoglycaemic Healthy Controls 
 
5.1. Abstract 
5.1.1. Background/Aims: To investigate and demonstrate whether endothelial 
dysfunction/damage at an ocular and systemic level exists in newly-diagnosed IGT patients 
when compared to age-matched healthy controls. 
5.1.2. Methods: A total of 80 normotensive (SA and WE) subjects (40 IGT and 40 age- and 
gender- matched controls) were recruited for the present study. Baseline measurements 
including body composition, c-IMT, 24-hour systemic BP and HRV, fasting plasma glucose, 
TG, total, LDL-C, HDL-C were measured in all individuals. Retinal vessel reactivity to 
flickering light was assessed by means of the Dynamic Retinal Vessel Analyser (DRVA) and 
brachial artery reactivity to reactive hyperaemia (FMD) by means of ultrasound according to 
a modified protocol. Blood glutathione and plasma vWF were also measured in all 
individuals. 
5.1.3. Results: IGT individuals showed signs of dyslipidaemia as indicated by higher fasting 
triglyceride (p<0.001) and TG:HDL-C ratio (p<0.001) than age-matched normoglycaemic 
subjects. Additionally, in IGT subjects, an increase in carotid artery wall thickening as 
determined by means of ultrasound IMT measurement, was evident (p=0.010 and p=0.005). 
Impaired systemic vasomotor function as shown by blunted FMD (p=0.026) and retinal 
vessel reactivity as represented by greater fluctuations in arterial diameter (p=0.026), longer 
retinal arterial reaction time in response to flicker stimulation (p=0.032) and a reduced flicker 
response (p=0.045) was present only in subjects with IGT. Furthermore, regression analysis 
demonstrated correlations between arterial-BDF and several lipid markers as well as arterial-
RT and FMD (r=-0.4546, p=0.017). 
5.1.4. Conclusion: In newly-diagnosed IGT subjects free of other systemic vascular 
pathologies, there are potential signs of retinal and systemic vascular function impairment 
that highlights the importance for early vascular screening in pre-diabetes. 
 
5.2. Introduction  
Isolated IGT refers to an intermediate metabolic state between normal and diabetic glucose 
homeostasis and is characterised by IR and impairments in insulin secretion, involving more 
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severe muscle IR than hepatic IR. The prevalences of IGT have been likened to that of a 
pandemic, with expected numbers to rise from 200 to 400 million people worldwide.[400]  
Very little is known about the effect of IGT on vascular function. The recognition however, of 
IGT and its associated heightened risk of CVD, along with its role as a risk factor for T2DM 
and the emergence of new treatment options have resulted in IGT being recognised clinically 
as a disease state.[401] 
With IGT being linked with clinical events other than progression to T2DM, establishing it as 
a condition with clinical significance, illustrates the impact of the condition on healthcare. Its 
relationship with an increased risk of CVD and increased mortality risk when compared to 
those with normal glucose tolerance also suggest that the threshold of risk may vary 
amongst different populations. 
A proportion (5-12%) of those diagnosed with IGT develop T2DM each year, and alarmingly, 
associated microvascular complications during this pre-diabetic phase are encountered 
more commonly.[402]          
Identifying populations at risk of T2DM and developing atherosclerosis and then determining 
their glucose metabolism and vascular function could allow for an improved understanding 
behind the pathophysiology of IR and help further the characterisation of IGT and its 
associations with other disease processes.  
Recent evidence showing that endothelial dysfunction can be detected early on in IR, even 
before the detection of distinct carbohydrate intolerance or clinical manifestations of MetS, 
suggest that the investigation of endothelial function in IGT groups could be of clinical 
relevance in the primary management of vascular risk.[403] 
Therefore, the aim of this study was to investigate vascular risk for CVD and T2DM 
progression by means of systemic and ocular vascular function in newly-diagnosed (within 
six months of official diagnosis made by OGTT by a Diabetologist) individuals with IGT. 
 
5.3. Materials and Methods  
IGT subjects (SA and WE; with and without a FH) aged 25-55 years were recruited and 
screened through a nurse- led community OGTT clinic in the Birmingham vicinity. The OGTT 
was carried out under standardised protocols and diagnosis made under WHO criteria 
(Section 3.3.). 
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Exclusion criteria were: a positive diagnosis of cardio- or cerebro-vascular disease, (coronary 
artery disease, heart failure, arrhythmia, stroke, transient ischaemic attacks), peripheral 
vascular disease, severe dyslipidaemia (defined as plasma TG>6.00mmol/L or cholesterol 
levels>7.00mmol/L), diabetes, as well as other metabolic disorders or chronic diseases that 
required treatment. 
Furthermore, subjects were excluded if they had a refractive error of more than ±3DS and 
more than ±1DC equivalent, IOP >24 mmHg, cataract or any other media opacities, as well 
as if they had a history of intraocular surgery or any form of retinal or neuro-ophthalmic 
disease affecting the ocular vascular system. 
Written informed consent was obtained from all participants and ethical approval was sought 
by the author from local and NHS ethical committees (08/H1202/112). The study was 
designed and conducted in accordance with the tenets of the Declaration of Helsinki. 
According to an already established procedure when examining endothelial function, female 
participants were asked to fill in a validated menstrual cycle questionnaire and their 
investigations were carried out during the first week of the menstrual cycle (follicular phase) 
thereby controlling for hormonal influences on endothelial function.[112, 317] 
  
5.3.1. Investigations 
5.3.1.1. Blood sampling and analyses 
All participants were asked to fast and refrain from caffeine, alcohol, chocolate and 
carbonated drinks and to not exercise for 12 hours prior to the date of the study. All blood 
samples were obtained by a qualified phlebotomist in the morning, between 9am and 10am. 
Fasting plasma glucose, TG, total and HDL-C were measured using standard routine 
laboratory techniques using the Reflotron Desktop Analyser (Roche Diagnostics, UK) as 
described in Section 3.3.1.1.  The TG/HDL cholesterol ratio, a measure of endothelial 
function, [244], and Framingham score as a means of cardiovascular risk (Section 3.3.1.1.) 
was also determined from the above values. 
Further analysis extended to laboratory and ELISA-test sampling for blood glutathione and 
plasma vWF to investigate possible signs for endothelial damage. Validated protocols were 
used for in-house testing as described in Sections 2.4. and 2.5. 
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5.3.1.2. ABPM and HRV analysis 
Systemic BP was measured using a 24-hour computer-operated ambulatory BP and 
electrocardiography (ECG) monitor (Cardiotens-01, Meditech Ltd., Hungary) for each 
subject. Measurements were performed in ambulatory conditions and programmed to 
measure BP oscillometrically every 15 minutes during the subject‟s active period and every 
30 minutes in the passive period (as explained in Sections 2.6.). Mean arterial pressure 
(MAP), as a means of describing cardiac output function in relation to arteriolar resistance 
was calculated according to Equation 2.2. The impact of pulse pressure (PP), as a risk factor 
for CVD was also calculated by using Equation 4.1. 
HRV analysis was calculated for each individual using the Cardiovision software (PMS 
Instruments Ltd., Maidenhead, UK) to obtain twenty-four hour, active and passive period LF, 
HF and LF:HF values. From, this circadian BP and HRV changes were calculated according 
to Equations 2.3. and 2.4. respectively. 
 
5.3.1.3. Body Composition Analysis 
Anthropometric measures including height and weight were measured using standard 
procedures as outlined in Section 3.3.1.3. Body composition was measured using 
bioelectrical impedance (Biostat 220, Biospace, UK) to determine BMI, PBF, WHR, total fat 
and fat free mass. 
 
5.3.1.4. Intima-media thickness 
High-resolution B-mode ultrasound system (Acuson Sequoia, 5 MHz linear transducer, 
Siemens, USA) was used to obtain longitudinal images (described in Section 3.3.1.4.)  of the 
right and left extracranial far wall of the CCA. Each IMT measure, also used for statistical 
analysis, represented an average of three to five measurement points.  
 
5.3.1.5. Vascular function studies 
Retinal vessel reactivity was measured using the DRVA (Imedos; GmbH, Jena, Germany). 
All measurements were performed in one unselected eye for each subject, between 8:00 and 
11:00 AM in a quiet, temperature-controlled room (22˚C). Following full pupil dilation with 
Tropicamide 1% (Minims; Chauvin Pharmaceuticals Ltd, UK) a region of interest 
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encompassing vessel segments of approximately 500 µm was chosen. Retinal diameters 
were assessed continuously over 350 seconds according to an accepted and widely used 
protocol.[277, 332]  
 
Brachial artery FMD was measured using high-resolution CDI ultrasonography, with a 7 mm 
8MHz linear-array (Siemens; Acuson Sequoia, UK). According to a published protocol,[308], 
as described in Section 2.2., arterial occlusion was created by inflation of a 
sphygmomanometer cuff on the lower arm to suprasystolic pressure and an exogenous NO 
donor (sublingual 0.3 mg GTN tablet) was given to determine the maximum obtainable 
vasodilator response. FMD was then expressed as the maximal artery dilation during 
hyperaemia from baseline (%). 
 
5.4. Power calculation and statistical analysis 
Based on previous studies, a change of 30% with a SD of 2.5% in retinal vessel reactivity 
was shown to be significant.[214, 301] Additionally FMD studies have shown a 20% 
reduction with a SD of 1.85% in FMD response in those with IGT.[242] As the study design 
was multi-factorial in nature it was calculated (using SISA; a web-based sample calculator 
approved by the NHS ethics committee) that n=25 per group was sufficient to provide 90% 
power with an alpha of 0.05. Furthermore, the sensitivity and reproducibility of the techniques 
in healthy subjects has been reported previously.[112, 333]  
All analyses were performed using Statistica® software (StatSoft Inc.; Version 9, USA). Prior 
to any analysis, all data was tested for normal distribution and thus a suitable test was 
adopted. Differences in mean values for each of the measured variables were compared by 
independent samples t-test (or Wilcoxon) for continuous variables. A multivariate analysis 
was performed to test the influence of age, gender, BP, and circulating markers on the 
measured variables. Comparison of retinal vessel reactivity for each flicker period was made 
by repeated measures (or Friedman) analysis of variance (ANOVA) following within-group 
analysis. Differences between groups in retinal and systemic vascular function were 
computed by analysis of covariance (ANCOVA). Univariate linear regression analysis was 
carried out using appropriate correlation analysis. A p value of <0.05 was considered 
statistically significant, unless stricter criteria were adopted for within-group and multivariate 
(p≤0.01 to account for multiple comparisons and thereby minimise bias towards Type II 
errors). 
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5.5. Results 
Following OGTT diagnosis and recruitment, 40 IGT subjects (20 men and 20 women) and 40 
healthy controls (20 men and 20 women) were recruited in excess to the calculated sample 
size for the final protocol. Following close examination of the data acquired, a total of 10 
patients were excluded (due to poor fixation, poor image quality and missing data sets) and 
therefore only 30 individuals were included for the SDRA element of the study. 
The baseline characteristics showing several demographic differences of both groups are 
presented in Table 5.1. There were no significant dissimilarities in age, IOP, and cholesterol 
levels (HDL, LDL and Total). Compared to healthy age- and sex- matched controls, the IGT 
group had significantly higher SBP, DBP, MAP and PP values (p=0.001, p=0.017, p=0.004 
p=0.023 respectively), alongside raised fasting levels of glucose, TG and 2-hour post-
consumption glucose (p<0.001). Although cholesterol values were alike amongst both 
groups, the cholesterol ratios and Framingham score were still significantly higher in those 
with IGT (p<0.001). Furthermore, those with IGT showed greater right (p=0.017) and left-side 
(p=0.005) carotid artery IMT. 
When comparing obesity components between both groups, those with IGT showed similar 
weight, BMI, WHR, PBF, and fat mass values to their healthy equivalent (p>0.05). (Table 
5.2.) 
Markers for oxidative stress, as outlined in Table 5.3., showed reduced levels of plasma GSH 
(p<0.001), GSSG (p=0.039) and t-GSH (p<0.001), with obvious differences also in vWF 
plasma levels (p=0.014). 
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 Control 
 [n=40] 
  IGT 
[n=40] 
T-test     
p-value 
DEMOGRAPHIC DATA    
Age (years) 47.7 ± 10 47.7 ± 10.2     - 
SBP (mmHg) 118 ± 12 127 ± 18* 0.001 
DBP (mmHg) 75 ± 8 80  ± 11* 0.010 
MAP (mmHg) 89 ± 10 96 ± 13* 0.004 
PP (mmHg) 43 ± 10 47 ± 10* 0.010 
IOP (mmHg) 14 ± 3 15 ± 2 0.090 
    
METABOLIC DATA    
Glucose (mmol/L) 4.84 ± 0.69 5.46 ± 0.84* <0.001 
2 hour GTT (mmol/L) 6.06 ± 1.03 9.81 ± 2.09* <0.001 
TG (mmol/L) 1.20 ± 0.51 1.76 ± 1.02* <0.001 
HDL Cholesterol (mmol/L) 1.21 ± 0.38 1.08 ± 0.40 0.120 
LDL Cholesterol (mmol/L) 2.65 ± 0.77 2.67 ± 1.03 0.883 
Total Cholesterol (mmol/L) 4.39 ± 0.82 4.56 ± 1.06 0.372 
TG:HDL-C (mmol/L) 2.59 ± 1.62 4.81 ± 4.36* <0.001 
    
CVD RISK DATA    
Total:HDL-C (mmol/L) 3.98 ± 1.33 4.78 ± 2.17* 0.010 
R-IMT (mm) 0.055 ± 0.015 0.065 ± 0.015* 0.010 
L-IMT (mm) 0.057 ± 0.017 0.069 ± 0.016* 0.005 
Framingham Score (%) 1.9 ± 2.8 4.5 ± 5.8* <0.001 
 
Table 5.1. Baseline data of both groups. Values quoted in mean ± SD.*Significant 
differences indicated in bold as p<0.05. SBP: systolic blood pressure; DBP: 
diastolic blood pressure; MAP: mean arterial pressure; PP: pulse pressure; 
IOP: intraocular pressure; GTT: glucose tolerance test; TG: triglyceride; HDL: 
high-density lipoprotein; LDL: low density lipoprotein; TG:HDL-C: TG-to-HDL 
ratio; Total:HDL-C: Total-to-HDL ratio; R-IMT: right intima media thickness L-
IMT: left intima media thickness. 
 
 
 
 
 
 Control 
 [n=40] 
  IGT 
[n=40] 
T-test    
p-value 
Weight (kg) 75.6 ± 14.7 80.2 ± 14.6 0.127 
BMI (kg/m2) 26.0 ± 4.22 27.6 ± 5.33 0.092 
WHR (AU) 0.93 ± 0.11 0.97  ± 0.05 0.075 
PBF (%) 30.0 ± 8.2 31.1 ± 9.2 0.564 
Fat Mass (kg) 22.9 ± 8.4 25.0 ± 8.5 0.238 
Fat Free Mass (kg) 52.7 ± 10.9 55.3 ± 12.2 0.250 
 
Table 5.2. Obesity correlates and body composition (by means of bioelectrical 
impedance) of both groups. Values quoted in mean ± SD. BMI: body mass 
index; WHR: waist-to-hip ratio; PBF: percentage body fat. 
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 Control 
 [n=40] 
  IGT 
[n=40] 
Wilcoxon     
p-value 
GSH (μM) 934.3 (407.2-
1293.8) 
536.1 (300.2-688.5) <0.001 
GSSG (μM) 98.1 (40.9-
117.3) 
64.5 (26.8-68.4) 0.039 
GSH:GSSG (μM) 15.3 (5.4-21.9) 13.1 (6.1-18.8) 0.311 
tGSH (μM) 1130.5 (592.7-
1634.9) 
665.2 (399.5-761.2) <0.001 
vWF (μ/dL) 122.3 ± 54.9 149.8 ± 59.2* 0.014 
 
Table 5.3. Plasma markers for oxidative stress and endothelial function in both 
groups. Values quoted in IQR/mean ± SD.*Significant differences 
indicated in bold as p<0.05. GSH: reduced glutathione; GSSG: oxidised 
glutathione; tGSH: total glutathione; vWF: von willebrand factor.  
 
 
 
 
 
Table 5.4. represents the FMD values for the IGT versus control samples showing an 
increased brachial artery diameter (p=0.015) and reduced FMD (%) (p=0.026). Furthermore, 
the glyceryl-trinitrate induced dilation, known to represent endothelial-independent brachial 
artery dilation, was also reduced in the IGT group (p=0.012) resulting in a greater FMD:GID 
ratio (p=0.034). (Figure 5.1.) 
 
This extended to differences in retinal vessel reactivity as represented in Table 5.5. which 
shows greater fluctuations in arterial diameter; termed BDF (p=0.026), longer arterial dilation 
time to flicker light; known as MDRT (p=0.032) and also a reduced flicker response, i.e. an 
attenuated bFR (p=0.045). Additionally, those with IGT showed increased venous MDRT that 
was close to reaching statistical significance (p-0.053). Although there were no obvious 
correlations between retinal and brachial parameters with known biomarkers, arterial-BDF 
[positive spearmans correlations with Total:HDL (r= 0.924; p= 0.008), TG (r= 0.985; 
p=<0.001), TG:HDL (r= 0.979 ;p= 0.001) and a negative correlation with HDL-C (r= -0.962; 
p= 0.002)] and arterial-RT (spearmans r=   -0.4546, p=0.017) did show correlations with lipid 
markers and FMD respectively (Figure 5.2. and 5.4. respectively). 
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 Control 
 [n=40] 
  IGT 
[n=40] 
Wilcoxon 
p-value 
BRACHIAL ARTERY    
AD (mm) 4.04 (3.34-4.61) 4.53 (3.94-4.91)  0.015 
BDF (mm) 0.35 (0.19-0.43) 0.37 (0.20-0.44) 0.690 
MD (mm) 4.40 (3.63-5.000) 4.72 (4.26-5.26) 0.119 
RT (secs) 21.7 (0-40.0) 23.9 (0-54.0) 0.763 
FMD (%) 8.61 (2.98-10.65) 5.50 (2.16-8.51) 0.026 
    
GTN    
GTN-MD (mm) 5.02 (4.31-5.56) 5.27 (4.67-5.94) 0.307 
RT (secs) 314.5 (263-373) 288.5 (267-401) 0.346 
GID (%) 25.20 (17.35-31.69) 16.28 (14.16-19.27) 0.012 
    
FMD/GID (%) 0.11 (0.08-0.40) 0.57 (0.32-0.60) 0.034 
 
Table 5.4. Brachial artery reactivity as means of systemic vascular endothelial function 
between both groups. Values quoted in mean (IQR).  *Significant differences 
indicated in bold (p<0.05). AD: absolute diameter; BDF: baseline diameter 
fluctuation; MD: maximum diameter response; RT: Reaction time; FMD: flow-
mediation dilation response; GID: GTN-induced dilation; FMD/GID: FMD/GID 
ratio. 
 
 
 
 
 Control 
 [n=30] 
  IGT 
[n=30] 
Friedman 
p-value 
ARTERY    
AD (AU) 123.94 (112.85-133.77) 121.61 (96.91-174.28)  0.501 
BDF (AU) 5.14 (3.47-6.44) 6.42 (1.57-13.16) 0.026 
MD (%) 5.05 (3.18-6.37) 5.48 (1.17-10.3) 0.433 
MDRT (secs) 18.4 (13.3-22.7) 21.4 (10.7-37.0) 0.032 
MC (%) 3.24 (1.84-4.29) 2.96 (0.45-6.48) 0.546 
MCRT (secs) 20.1 (17.3-23.3) 19.7 (8.3-29.0) 0.691 
DA (%) 8.27 (5.99-9.73) 8.44 (2.19-16.47) 0.820 
bFR (%) 3.13 (1.48-4.75) 2.01 (-5.57-7.17) 0.045 
    
VEIN    
AD (AU) 155.75 (142.16-170.29) 159.29 (124.70-202.27) 0.468 
BDF (AU) 4.03 (2.54-4.96) 4.66 (2.04-9.89) 0.150 
MD (%) 5.71 (4.09-6.54) 5.92 (1.61-12.08) 0.704 
MDRT (secs) 19.5 (17.0-22.0) 21.7 (12.0-31.7) 0.053 
MC (%) 1.43 (0.40-1.84) 2.01 (0.95-10.15) 0.114 
MCRT (secs) 21.9 (19.3-25.3) 20.3 (7.0-29.3) 0.149 
DA (%) 7.14 (4.90-8.54) 7.83 (3.12-13.09) 0.290 
bFR (%) 3.12 (1.57-4.30) 3.14 (-1.92-10.76) 0.975 
 
Table 5.5. Retinal arterial and venous measures for both groups Values quoted in mean 
(IQR).  *Significant differences indicated in bold (p<0.05). AD: absolute diameter; 
BDF: baseline diameter fluctuation; MD: maximum dilation; MDRT: reaction time 
to reach maximum diameter to flicker stimulation; MC: maximum constriction; 
MCRT: reaction time to maximum constriction post flicker; DA: dilation 
amplitude; bFR: baseline-corrected flicker response. 
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Figure 5.1. FMD and NND percentage differences in control and IGT groups. 
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p= 0.012 
 
 
110 
 
 Control 
 [n=30] 
  IGT 
[n=30] 
Post-hoc 
p-value 
ARTERY BDF (AU)    
Flicker cycle 1 5.19 (1.16-16.33) 6.12 (1.22-16.00) 0.141 
Flicker cycle 2 5.14 (0.59-19.40) 7.25 (1.81-18.74) 0.005 
Flicker cycle 3 5.00 (1.15-23.62) 5.85 (1.54-13.39) 0.188 
    
Within-group ANOVA 0.673 0.097  
    
VEIN BDF (AU)    
Flicker cycle 1 3.79 (0.96-15.44) 4.78 (1.79-12.10) 0.070 
Flicker cycle 2 3.97 (1.20-19.61) 5.14 (1.53-18.03) 0.045 
Flicker cycle 3 4.17 (0.99-15.75) 4.42 (1.78-14.65) 0.637 
    
Within-group ANOVA 0.397 0.748  
 
Table 5.6. Retinal arterial and venous BDF for each individual flicker cycle. Values quoted 
in mean (IQR).  *Significant differences indicated in bold (p<0.05). BDF: baseline 
diameter fluctuation. 
 
 
 
 
 
 
 
 
 
Figure 5.2. Lipid level and arterial baseline-diameter fluctuation correlations in IGTs. From top-left to 
clockwise. Positive Spearmans correlations for BDF against Total:HDL (r= 0.924; p= 
0.008), arterial BDF against TG (r= 0.985; p=<0.001), and BDF against TG:HDL (r= 0.979 ;p= 
0.001) and a negative correlation with arterial BDF against HDL-C (r= -0.962; p= 0.002). 
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 Control 
 [n=30] 
  IGT 
[n=30] 
Post-hoc 
p-value 
ARTERY MDRT (secs)    
Flicker cycle 1 18.1 (2.0-39.0) 22.8 (2.0-50.0) 0.011 
Flicker cycle 2 19.5 (1.0-51.0) 19.4 (4.0-50.0) 0.947 
Flicker cycle 3 16.9 (3.0-50.0) 21.6 (4.0-50.0) 0.022 
    
Within-group ANOVA 0.157 0.511  
    
VEIN MDRT (secs)    
Flicker cycle 1 20.2 (1.0-50.0) 22.1 (12.0-48.0) 0.287 
Flicker cycle 2 19.4 (3.0-48.0) 21.1 (3.0-50.0) 0.313 
Flicker cycle 3 19.9 (5.0-47.0) 22.0 (9.0-49.0) 0.233 
 
Table 5.7. Retinal arterial and venous RT for each individual flicker cycle. Values quoted in 
mean (IQR).  *Significant differences indicated in bold (p<0.05). MDRT: maximum 
dilation reaction time. 
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Figure 5.3. Arterial MDRT for each individual flicker cycle for the IGT group as compared to 
controls. 
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 Control 
 [n=30] 
  IGT 
[n=30] 
Post-hoc 
p-value 
ARTERY bFR (%)    
Flicker cycle 1 3.17 (-9.11-13.70) 2.08 (-5.11-12.22) 0.173 
Flicker cycle 2 3.38 (-5.13-13.42) 1.55 (-7.89-8.18) 0.014 
Flicker cycle 3 2.94 (-10.12-16.64) 2.31 (-4.90-8.13) 0.415 
    
Within-group ANOVA 0.417 0.820  
    
VEIN bFR (%)    
Flicker cycle 1 3.09 (-7.11-14.19) 3.05 (-3.98-12.27) 0.957 
Flicker cycle 2 3.74 (-6.37-15.66) 3.19 (-6.88-14.53) 0.472 
Flicker cycle 3 2.73 (-2.61-9.36) 2.95 (-4.21-11.28) 0.716 
 
Table 5.8. Retinal arterial and venous bFR for each individual flicker cycle. Values quoted 
in mean (IQR).  *Significant differences indicated in bold (p<0.05). bFR: baseline-
corrected flicker response. 
Figure 5.4. Negative average arterial MDRT correlation with brachial artery FMD in the IGT 
group (Spearmans r= -0.4546, p=0.017). 
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5.6. Discussion 
It is thought that atherosclerotic processes already develop in a „pre-diabetic‟ stage, i.e. 
during stages of IGT or when abnormal glucose haemostasis begins.[404] The results of this 
chapter furthers this suggestion, by illustrating that newly-diagnosed IGT patients present 
with levels of dyslipidaemia and higher, albeit within the normal range; systemic BP values 
that may contribute to future vascular risk for T2DM and CVD progression. These 
characteristic levels of higher TG and cholesterol ratios are indicative of the traits found with 
the MetS. Furthermore, the presence of impaired endothelial function detected by FMD and 
DVA shows that newly-diagnosed IGT individuals have blunted ocular and endothelial 
reactivity alongside reduced blood glutathione, increased vWF plasma levels and greater c-
IMT than healthy controls. 
The IGT individuals in this study exhibited associations with features of IR and MetS, 
including endothelial dysfunction (reduced FMD), markers of vascular inflammation 
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Figure 5.5. Arterial baseline-corrected retinal vessel response for each individual flicker 
cycle for the IGT group as compared to controls. 
p= 0.014 
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(increased vWF), hypertension, and dyslipidaemia (higher TG levels and cholesterol 
ratios).[405-408] Secondary analyses from large, international, randomised clinical trials 
have provided further supporting evidence, consistent with this study, that there is a 
clustering of traits of the MetS in those with IGT prior to progression into T2DM.[409-411] 
Although IGT is associated with IR and increased insulin secretion, it has been suggested 
that the IGT condition alone is not equivalent in predicting the development of T2DM or 
CVD.[412] 
Therefore, the importance of assessing known markers of vascular and endothelial 
dysfunction by means of functional tests is well established and clinically necessary. The 
current IGT cohort showed evidence of impaired systemic endothelial function by means of 
blunted FMD responses. Abnormal vasomotion by means of FMD has also been found in 
first-degree relatives of those with T2DM; however, this observation is true mainly in those 
with IR. Therefore, IR itself appears to be associated with endothelial dysfunction, thus 
implicating the links between vascular insulin signalling alterations, endothelial dysfunction 
and insulin itself contributing to vascular damage and the cause of IR.[413]  
Furthermore, the impaired vascular smooth muscle cell function, as indicated by a lower GID, 
alongside reduced FMD is also important to note in the current IGT group. Especially so as 
hyperglycaemia is known to elicit an activation of protein kinase-C, elevation in advanced 
glycation end (AGE) products and oxidative stress. These changes can then activate 
proliferation and migration of vascular smooth muscle cell inducing atherogenesis. 
Furthermore, impaired endothelial-independent brachial artery dilation in DM has been 
reported as a possible implication of increased oxidative stress.[414]  
The findings of FMD abnormalities in IGT individuals also extends further to biochemical 
imbalances in the blood redox system as shown by differences in glutathione levels, and the 
endothelial-cell system by increased levels of vWF. Although this is supported by previous 
publications showing differences in biochemical markers (Table 5.6.), the current data is the 
first to our knowledge to report findings of imbalances in newly-diagnosed IGT 
individuals.[256] However as there were no correlations found, whether this indicates early 
oxidative stress and endothelial damage with future implications on vascular function and 
T2DM/CVD risk still requires further exploration. 
In addition to systemic differences, the IGT sample also exhibited signs of impaired retinal 
vessel reactivity as assessed by the DRVA. It has been shown that the DRVA allows for 
quick and non-invasive assessment in a number of systemic conditions with ocular 
consequences. However, the data presented in this chapter shows that for the first time, 
DRVA and the newly-adopted SDRA can detect retinal vasomotion abnormalities in pre-
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diabetes. This was evident in the current IGT individuals by means of greater fluctuations in 
arterial BDF that also extended to increased MDRT and a reduced bFR. 
As suggested previously (Appendix 3), the increased arterial reaction time; MDRT, could be 
a useful measure in asymptomatic individuals and represent atherosclerotic vessel wall 
changes or increased arterial stiffness.[227, 415-419] Furthermore, the possibility of reduced 
NO bio-availability to peripheral tissues in IGT could also have an influence. Indeed, an 
increased MDRT could also characterise a combination of one or both factors.[216] This 
would be supported by the data of the current chapter showing increased c-IMT thickness 
and reduced FMD values in the normotensive IGT sample when compared to their age- and 
sex-matched counterparts. Whether a greater fluctuation in arterial diameter (BDF) has a 
similar aetiology remains to be seen. However, as shown previously in smokers, the greater 
BDF in those with IGT could suggest a greater propensity to impaired retinal 
vasomotion.[399]  
The lack of association between these two retinal components, i.e. MDRT and BDF (r=0.341, 
p=0.065), could also suggest subtle differences in autoregulation within the retinal vascular 
architecture and the influence of these measures on retinal vascular function. The link with 
arterial BDF and dyslipidaemia furthers the argument that abnormal lipid metabolism is 
implicated in the causation of IR which, in turn, is linked to both endothelial dysfunction and 
vascular disease.[420] Furthermore, the correlation between FMD and SDRA components, 
namely brachial artery percentage dilation (FMD%) and retinal arterial dilation time (MDRT), 
suggests that pre-diabetes and possibly certain other vascular disorders, such as T2DM, can 
affect different vascular beds with diverse functions similarly. Therefore, the results of this 
chapter as shown by increased MDRT and reduced flicker response by means of bFR help 
to support the hypothesis that alterations in retinal vasculature are present in those with IGT. 
Furthermore, the correlations with SDRA and systemic markers help to support the theory of 
flicker-induced vasodilation as NO-mediated and thus reflecting endothelial function.[49] 
Whether this finding would extend to larger samples and support the use of SDRA as a 
surrogate marker to future vascular risk needs further work. 
This increase in c-IMT also conforms to that generally observed with IGT subjects as a third 
of that usually seen in T2DM.[421] Therefore, the data in this chapter suggests that 
endothelial cell dysfunction can indeed be detected very early in the onset of IR in IGT 
subjects and that early structural change, indicated by a thickening of the c-IMT layer, and 
increased brachial diameter and larger fluctuations in retinal arterial diameter are found. 
Thus, IGT subjects show high risk for accelerated atherosclerosis and vascular disease as 
indicated by FMD, c-IMT and lipid results. However, as it has not been reported previously, 
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the study also suggests that for the first time, there are obvious changes at the retinal level in 
newly-diagnosed IGT individuals. Whether this would apply to larger samples, as the current 
sample was quite small, remains to be seen. 
The signs of endothelial dysfunction with IGT also suggest that vascular damage, potentially 
associated with oxidative stress, vascular inflammation and thrombosis may also be present. 
Therefore, early recognition and treatment of IR are critical in the prevention of 
atherosclerosis and T2DM. Whether therapeutic or lifestyle interventions improve endothelial 
function in IR and also decrease CVD risk remain to be researched. Therefore, to justify 
pharmacological treatments for IGT, identification of high-risk individuals is necessary. 
Alongside this, a greater understanding of the underlying mechanisms and differences, if 
any, in vascular and endothelial function in IGT patients may help to improve the prediction 
of T2DM and enhance targeted therapeutics. 
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6. Vascular Function in Normal, Overweight and Obese Individuals 
of SA and WE ethnicity 
 
6.1. Abstract 
6.1.1. Background/Aims: To investigate ocular and systemic vascular reactivity to stress in 
otherwise healthy overweight and obese individuals and whether this would extend to 
differences in known markers of atherosclerosis and cardiovascular risk. 
6.1.2. Methods: In this cross-sectional study, healthy participants (SA and WE) aged between 
25-45 years classed as overweight (n=50) or obese (n=50) and lean age- and sex-matched 
controls (n=50) were recruited. Baseline measurements including body composition, carotid 
intimal-media thickness (c-IMT), 24-hour systemic blood pressure (BP), fasting plasma 
glucose, triglycerides (TG) and cholesterol were measured in all individuals. Retinal vessel 
reactivity to flickering light was assessed by means of the Dynamic Retinal Vessel Analyser 
(DRVA, Imedos GmbH, Jena) to a modified protocol. Additionally brachial artery reactivity to 
reactive hyperaemia by means of ultrasound was measured alongside fasting plasma von 
Willebrand factor (vWF) levels. 
6.1.3. Results: Overweight and Obese individuals presented with levels of dyslipidaemia and 
CVD risk by means of increased c-IMT and Framingham scores. Moreover, it is only 
overweight individuals that showed levels of endothelial damage (increased vWF levels 
p=0.004), impaired coronary vasomotion (blunted brachial MD p=0.002), and reduced retinal 
artery reactivity to flicker (lower arterial MD p=0.039 and bFR p=0.022 alongside prolonged 
MDRT p=0.047). 
6.1.4. Conclusion: Overweight individuals may have an increased risk for vascular disease 
when compared to lean individuals. Furthermore, the retinal functional abnormalities 
alongside classic cardiovascular and endothelial damage markers warrants further 
investigation into vascular disease risk in this group. 
 
6.2. Introduction  
Obesity is defined as a preventable condition characterised by abnormal or excessive fat 
accumulation and with prevalences of obesity doubling over the past three decades, it has 
also been identified as a major risk factor for non-communicable diseases such as T2DM 
and CVD.[422]  Furthermore, obesity is now ranked as the fifth leading cause for global 
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deaths, and in addition, a high proportion of co-morbidity and mortality related burdens 
(economical, social and healthcare) are attributable to obesity. 
Obesity is a major risk factor for CVD and can induce several other major risk factors that are 
evident by increased arterial stiffness, carotid intimal media thickness and microvascular 
dysfunction.[423-425] Therefore, it is important to detect changes in vascular function that 
precede cardiovascular events; possible through studying endothelial function. Indeed, 
decreased endothelial function is a factor that predicts, independently from other risk factors, 
the occurrence of CVD.[324] Endothelial function can be assessed using a large variety of 
techniques, from laboratory markers, such as inflammatory cytokines, adhesion molecules, 
NO and markers of endothelial damage and repair, to vascular reactivity tests such as FMD 
of the brachial artery by ultrasound, forearm venous pletysmography, digital pulse amplitude 
tonometry and laser Doppler measurements of the peripheral circulation.[212]  Microvascular 
assessments such as retinal vessel reactivity, however, can be performed quickly using 
relatively affordable techniques and offers reliable information on vascular function in 
patients suffering from various systemic diseases including DM, hypertension and 
hypercholesterolaemia.[214, 300] More recently DRVA and its proposed analysis methods 
have been proven useful in asymptomatic individuals and in those with established coronary 
disease.[221, 426] 
 
As reported recently, retinal microvascular data on obese individuals has been distributed as 
a control group with BMI of normal-moderate weight (BMI 19-27.5 kg/m2) and an obese group 
(BMI >27.5-29.9 kg/m2).[304] Further to this, grouping overweight and obese individuals 
together (BMI >25 kg/m2) also seems a plausible approach to investigate the effect of obesity 
on vascular function. 
Therefore the aims of this study was to further microvascular data on the groups suggested 
previously (normal-moderate and obese), by incorporating sub-analysis of an overweight-
obese group and the three groups (normal, overweight and obese) as recommended 
definitions by the WHO. Furthermore, the study aimed to investigate whether signs of 
impaired systemic (FMD) and biochemical (vWF) endothelial function was evident alongside 
previously reported retinal abnormalities in obese and overweight individuals. 
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6.3. Materials and Methods  
The study cohort consisted of healthy normotensive participants aged 30-45 years (SA and 
WE with and without a FH) that were screened and recruited from the Health Clinics at Aston 
University, Birmingham, UK. Obesity classifications were determined according to WHO 
definitions, whereby normal weight was classed as a BMI of 18.5–24.9 kg/m2; overweight 
individuals as a BMI of 25–29.9 kg/m2; and obese subjects with a BMI of 30 kg/m2 or greater.  
Exclusion criteria were: a positive diagnosis of cardio- or cerebro-vascular disease, (coronary 
artery disease, heart failure, arrhythmia, stroke, transient ischaemic attacks), peripheral 
vascular disease, severe dyslipidaemia (defined as plasma TG>6.00mmol/L or cholesterol 
levels>7.00mmol/L), diabetes, as well as other metabolic disorders or chronic diseases that 
required treatment. 
Furthermore, subjects were excluded if they had a refractive error of more than ±3DS and 
more than ±1DC equivalent, IOP >24 mmHg, cataract or any other media opacities, as well 
as if they had a history of intraocular surgery or any form of retinal or neuro-ophthalmic 
disease affecting the ocular vascular system. 
Written informed consent was obtained from all participants and ethical approval was sought 
by the author from local and NHS ethical committees (08/H1202/112). The study was 
designed and conducted in accordance with the tenets of the Declaration of Helsinki. 
According to an already established procedure when examining endothelial function, female 
participants were asked to fill in a validated menstrual cycle questionnaire and their 
investigations were carried out during the first week of the menstrual cycle (follicular phase) 
thereby controlling for hormonal influences on endothelial function.[112, 317] 
  
6.3.1. Investigations 
6.3.1.1. Blood sampling and analyses 
All participants were asked to fast and refrain from caffeine, alcohol, chocolate and 
carbonated drinks and to not exercise for 12 hours prior to the date of the study. All blood 
samples were obtained by a qualified phlebotomist in the morning, between 9am and 10am. 
Fasting plasma glucose, TG, total and HDL-C were measured using standard routine 
laboratory techniques using the Reflotron Desktop Analyser (Roche Diagnostics, UK) as 
described in Section 3.3.1.1.  The TG/HDL cholesterol ratio, a measure of endothelial 
function, [244], and Framingham score as a means of cardiovascular risk (Section 3.3.1.1.) 
was also determined from the above values. 
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Further analysis extended to laboratory and ELISA-test plasma sampling for vWF to 
investigate possible signs for endothelial damage. Validated protocols were used for in-
house testing as described in Section 2.4. 
 
6.3.1.2. ABPM and HRV analysis 
Systemic BP was measured using a 24-hour computer-operated ambulatory BP and 
electrocardiography (ECG) monitor (Cardiotens-01, Meditech Ltd., Hungary) for each 
subject. Measurements were performed in ambulatory conditions and programmed to 
measure BP oscillometrically every 15 minutes during the subject‟s active period and every 
30 minutes in the passive period (as explained in Sections 2.6.). Mean arterial pressure 
(MAP), as a means of describing cardiac output function in relation to arteriolar resistance 
was calculated according to Equation 2.2. The impact of pulse pressure (PP), as a risk factor 
for CVD was also calculated by using Equation 4.1. 
HRV analysis was calculated for each individual using the Cardiovision software (PMS 
Instruments Ltd., Maidenhead, UK) to obtain twenty-four hour, active and passive period LF, 
HF and LF:HF values. From, this circadian BP and HRV changes were calculated according 
to Formula 2.3. and 2.4. respectively. 
 
6.3.1.3. Body Composition Analysis 
Anthropometric measures including height and weight were measured using standard 
procedures as outlined in Section 3.3.1.3. Body composition was measured using 
bioelectrical impedance (Biostat 220, Biospace, UK) to determine BMI, PBF, WHR, total fat 
and fat free mass. 
 
6.3.1.4. Intima-media thickness 
High-resolution B-mode ultrasound system (Acuson Sequoia, 5 MHz linear transducer, 
Siemens, USA) was used to obtain longitudinal images (described in Section 3.3.1.4.)  of the 
right and left extracranial far wall of the CCA. Each IMT measure, also used for statistical 
analysis, represented an average of three to five measurement points.  
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6.3.1.5. Vascular function studies 
Retinal vessel reactivity was measured using the DRVA (Imedos; GmbH, Jena, Germany). 
All measurements were performed in one unselected eye for each subject, between 8:00 and 
11:00 AM in a quiet, temperature-controlled room (22˚C). Following full pupil dilation with 
Tropicamide 1% (Minims; Chauvin Pharmaceuticals Ltd, UK) a region of interest 
encompassing vessel segments of approximately 500 µm was chosen. Retinal diameters 
were assessed continuously over 350 seconds according to an accepted and widely used 
protocol.[277, 332]  
 
Brachial artery FMD was measured using high-resolution CDI ultrasonography, with a 7 mm 
8MHz linear-array (Siemens; Acuson Sequoia, UK). According to a published protocol,[308], 
as described in Section 2.2., arterial occlusion was created by inflation of a 
sphygmomanometer cuff on the lower arm to suprasystolic pressure and an exogenous NO 
donor (sublingual 0.3 mg GTN tablet) was given to determine the maximum obtainable 
vasodilator response. FMD was then expressed as the maximal artery dilation during 
hyperaemia from baseline (%). 
 
6.4. Power calculation and statistical analysis 
Based on previous studies, a change of 28% with a SD of 1.8% in retinal vessel reactivity 
was shown to be significant.[304] Additionally FMD studies have shown a 15-45% reduction 
with a SD of 2.7-4.0% in FMD response in young obese individuals.[233, 427] As the study 
design was multi-factorial in nature it was calculated (using SISA; a web-based sample 
calculator approved by the NHS ethics committee) that n=40 per group was sufficient to 
provide 90% power with an alpha of 0.05.  Furthermore, the sensitivity and reproducibility of 
the techniques in healthy subjects has been reported previously.[112, 333]  
All analyses were performed using Statistica® software (StatSoft Inc.; Version 9, USA). Prior 
to any analysis, all data was tested for normal distribution and thus a suitable test was 
adopted. Differences in mean values for each of the measured variables were compared by 
independent samples t-test (or Wilcoxon) for continuous variables. A multivariate analysis 
was performed to test the influence of age, gender, BP, and circulating markers on the 
measured variables. Comparison of retinal vessel reactivity for each flicker period was made 
by repeated measures (or Friedman) analysis of variance (ANOVA) following within-group 
analysis. Differences between groups in retinal and systemic vascular function were 
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computed by analysis of covariance (ANCOVA). Univariate linear regression analysis was 
carried out using appropriate correlation analysis. A p value of <0.05 was considered 
statistically significant, unless stricter criteria were adopted for within-group and multivariate 
(p≤0.01 to account for multiple comparisons and thereby minimise bias towards Type II 
errors). 
 
6.5. Results 
A total of 160 subjects were screened for eligibility. Following OGTT, 10 subjects were 
excluded (1 diagnosed with T2DM and 9 with IGT) and the remaining 150 healthy were 
recruited and allocated to normal (n=50), overweight (n=50) or obese (n=50) groups for the 
final protocol (Appendix 1).  
The baseline characteristics of normal-moderate and obese groups are presented in Table 
6.1. There were no significant differences in age, IOP, Total Cholesterol, HDL cholesterol 
(albeit close with p=0.05), LDL cholesterol, and cholesterol ratios (p>0.05). Compared to 
healthy normo -glycaemic and –tensive normal-moderate subjects, obese individuals had 
higher, albeit normal fasting glucose levels and greater TG levels (p=0.048 and p=0.047 
respectively). Furthermore, obese individuals presented with greater systemic BP values 
(p<0.001), c-IMT measurements (p=0.005 and p=0.006) as well as greater CVD risk as 
indicated by higher Framingham scores (p=0.007). 
There were no evident signs of endothelial damage or dysfunction as found by comparable 
vWF levels amongst both groups (p=0.452). Unlike that reported previously the obese group 
also showed no significant differences in retinal vessel reactivity or SDRA components when 
compared to normal-moderates (p>0.05). This also did not extend to apparent differences in 
FMD between both groups (p>0.05). 
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 Normal-Moderate 
 [n=100] 
Obese 
[n=50] 
p-value 
DEMOGRAPHIC DATA    
Age (years) 41.9 ± 10.8 43.2 ± 10.2 0.075 
SBP (mmHg) 117 ± 10 125 ± 12 <0.001 
DBP (mmHg) 75 ± 10 80  ± 9 <0.001 
MAP (mmHg) 89 ± 11 94 ± 11 0.010 
IOP (mmHg) 13 ± 2 14 ± 4 0.077 
    
BODY COMPOSITION DATA    
Weight (kg) 71.9 ± 11.2 95.8 ± 15.5 <0.001 
BMI (kg/m2) 24.6 ± 3.2 33.2 ± 3.5 <0.001 
WHR (AU) 0.92 ± 0.10 1.01 ± 0.05 <0.001 
PBF (%) 28.8 ± 7.7 33.2 ± 7.4 <0.001 
Fat Mass (kg) 20.6 ± 5.9 36.1 ± 8.5 <0.001 
Fat Free Mass (kg) 51.3 ± 10.3 59.6 ± 12.8 <0.001 
    
METABOLIC DATA    
Glucose (mmol/L) 5.49 ± 0.58 5.76 ± 0.47 0.048* 
2 hour GTT (mmol/L) 7.04 ± 2.22 7.54 ± 1.54 0.368 
TG (mmol/L) 1.25 ± 0.63 1.52 ± 0.79 0.047* 
HDL Cholesterol (mmol/L) 1.21 ± 0.40 1.05 ± 0.28 0.050 
LDL Cholesterol (mmol/L) 2.63 ± 0.84 2.56 ± 0.81 0.672 
Total Cholesterol (mmol/L) 4.40 ± 0.91 4.30 ± 0.79 0.571 
TG:HDL-C (mmol/L) 2.86 ± 2.59 3.68 ± 2.30 0.115 
    
CVD RISK DATA    
R-IMT (mm) 0.055 ± 0.014 0.067 ± 0.016 0.005 
L-IMT (mm) 0.059 ± 0.016 0.072 ± 0.020 0.006 
Framingham Score (%) 1.9 ± 2.9 4.0 ± 5.4 0.007 
Total:HDL (mmol/L) 4.01 ± 1.48 4.42 ± 1.77 0.204 
    
BIOCHEMICAL DATA    
v-WF (μ/dL) 127.3 ± 50.6 136.7 ± 50.4 0.452 
 
Table 6.1. Baseline data of both groups. Values quoted in mean ± SD. Significant differences 
indicated in bold as p<0.01. *Significant differences if p<0.05. SBP: systolic blood 
pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; IOP: intraocular 
pressure; BMI: body mass index; WHR: waist-to-hip ratio; PBF: percentage body fat; 
GTT: glucose tolerance test; TG: triglyceride; HDL: high-density lipoprotein; LDL: low 
density lipoprotein; TG:HDL-C: TG-to-HDL ratio; R-IMT: right intima media thickness L-
IMT: left intima media thickness; vWF: von-willebrand factor. 
 
 
The data presented in Table 6.2. shows the demographic result of groups when organised 
into a normal weight and an overweight-obese sample. When compared to healthy lean 
individuals, the overweight-obese group showed greater systemic BP values as indicated by 
higher SBP, DBP and MAP (p<0.001). Furthermore, there were significant differences in 
glucose (p=0.010), TG (<0.001), HDL (p=0.010) and cholesterol ratios (p=0.008 and 
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p=0.009). This ultimately led to greater c-IMT measurements (p=0.010 and p<0.001) but not 
higher Framingham scores (p=0.093). 
Alongside obvious differences in body composition and obesity indices, the overweight-
obese group also showed greater levels of blood vWF (p=0.004) that also extended to 
differences in FMD as shown in Table 6.3. and a reduced retinal arterial dilatory response 
(as well as near statistical differences in arterial DA) in Table 6.4. 
 
 Normal 
 [n=50] 
Overweight-Obese 
[n=100] 
p-value 
DEMOGRAPHIC DATA    
Age (years) 41.7 ± 11.1  42.6 ± 10.3 0.832 
SBP (mmHg) 114 ± 14 124 ± 13 <0.001 
DBP (mmHg) 72 ± 10 79 ± 9 <0.001 
MAP (mmHg) 86 ± 10 93 ± 10 <0.001 
IOP (mmHg) 13 ± 3 14 ± 3 0.166 
    
BODY COMPOSITION DATA    
Weight (kg) 65.4 ± 9.4 84.2 ± 14.3 <0.001 
BMI (kg/m2) 22.4 ± 3.1 29.2 ± 3.5 <0.001 
WHR (AU) 0.90 ± 0.14 0.97 ± 0.05 <0.001 
PBF (%) 25.8 ± 7.1 33.9 ± 7.9 <0.001 
Fat Mass (kg) 16.8 ± 5.3 28.4 ± 8.0 <0.001 
Fat Free Mass (kg) 48.7 ± 9.2 55.8 ± 11.7 <0.001 
    
METABOLIC DATA    
Glucose (mmol/L) 4.78 ± 0.75 5.09 ± 0.77 0.010 
2 hour GTT (mmol/L) 6.67 ± 2.29 7.39 ± 2.00 0.077 
TG (mmol/L) 1.08 ± 0.41 1.46 ± 0.77 <0.001 
HDL Cholesterol (mmol/L) 1.27 ± 0.41 1.11 ± 0.35 0.010 
LDL Cholesterol (mmol/L) 2.53 ± 0.79 2.67 ± 0.86 0.343 
Total Cholesterol (mmol/L) 4.30 ± 0.83 4.44 ± 0.91 0.341 
TG:HDL-C (mmol/L) 2.36 ± 2.06 3.49 ± 2.75 0.008 
    
CVD RISK DATA    
R-IMT (mm) 0.052 ± 0.015 0.061 ± 0.015 0.010 
L-IMT (mm) 0.053 ± 0.016 0.067 ± 0.017 <0.001 
Framingham Score (%) 1.7 ± 2.4 2.8 ± 4.3 0.093 
Total:HDL (mmol/L) 3.70 ± 1.32 4.38 ± 1.64 0.009 
    
BIOCHEMICAL DATA    
v-WF (μ/dL) 112.4 ± 58.7 140.7 ± 53.3 0.004 
 
Table 6.2. Baseline data of both groups. Values quoted in mean ± SD. Significant differences 
indicated in bold as p<0.01. SBP: systolic blood pressure; DBP: diastolic blood 
pressure; MAP: mean arterial pressure; IOP: intraocular pressure; BMI: body mass 
index; WHR: waist-to-hip ratio; PBF: percentage body fat; GTT: glucose tolerance test; 
TG: triglyceride; HDL: high-density lipoprotein; LDL: low density lipoprotein; TG:HDL-
C: TG-to-HDL ratio; R-IMT: right intima media thickness L-IMT: left intima media 
thickness; vWF: von-willebrand factor. 
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 Normal 
 [n=50] 
Overweight-Obese 
[n=100] 
p-value 
BRACHIAL ARTERY    
AD (mm) 4.28 (3.75-4.77) 3.76 (3.20-4.31)* <0.001 
BDF (mm) 0.35 (0.18-0.44) 0.36 (0.21-1.42) 0.808 
MD (mm) 4.67 (4.04-5.18) 4.11 (3.53-4.69)* <0.001 
RT (secs) 22.0 (3.0-46.0) 23.0 (2.0-42.0) 0.811 
FMD (%) 7.83 (2.67-9.48) 5.98 (3.66-11.94) 0.083 
    
GTN    
GTN-MD (mm) 5.27 (4.75-5.61) 4.75 (4.13-5.64)* 0.012 
RT (secs) 313 (265-400) 327 (277-383) 0.546 
GID (%) 21.32 (14.16-27.25) 26.27 (18.59-31.00) 0.109 
    
FMD/GID (%) 0.27 (0.12-0.55) 0.13 (0.05-0.44) 0.430 
 
Table 6.3. Brachial artery reactivity as means of systemic vascular endothelial function between both 
groups. *Significant values in bold (p<0.05). Values quoted in mean (IQR).  AD: absolute 
diameter; BDF: baseline diameter fluctuation; MD: maximum diameter response; RT: Reaction 
time; FMD: flow-mediation dilation response; GID: GTN-induced dilation; FMD/GID: FMD/GID 
ratio. 
 
 
 
 Normal 
 [n=50] 
Overweight-Obese 
[n=100] 
p-value 
ARTERY    
AD (AU) 121.59 (112.40-132.60) 126.09 (112.87-133.84)  0.120 
BDF (AU) 5.71 (3.75-7.09) 5.00 (2.67-6.44) 0.146 
MD (%) 5.55 (3.66-7.12) 4.55 (2.82-5.74)* 0.029 
MDRT (secs) 17.2 (12.3-20.7) 19.1 (14.3-24.3) 0.803 
MC (%) 3.24 (1.66-4.57) 3.09 (1.49-3.96) 0.686 
MCRT (secs) 19.7 (17.3-23.3) 20.4 (17.3-23.3) 0.444 
DA (%) 8.78 (6.78-10.18) 7.63 (5.09-8.93) 0.061 
bFR (%) 3.07 (1.02-4.83) 2.63 (0.89-3.95) 0.357 
    
VEIN    
AD (AU) 156.73 (139.18-173.78) 156.20 (142.48-167.16) 0.896 
BDF (AU) 4.13 (2.56-5.12) 4.23 (2.67-5.27) 0.770 
MD (%) 5.59 (4.44-6.54) 5.87 (3.84-6.70) 0.540 
MDRT (secs) 20.1 (17.3-22.7) 29.9 (17.0-23.0) 0.870 
MC (%) 1.44 (0.33-4.84) 1.72 (0.62-2.10) 0.375 
MCRT (secs) 21.8 (19.7-25.3) 21.2 (18.7-23.7) 0.517 
DA (%) 7.27 (5.33-9.00) 7.31 (4.76-9.27) 0.942 
bFR (%) 3.12 (1.74-4.40) 3.13 (1.19-4.72) 0.990 
 
Table 6.4. Retinal arterial and venous measures for both groups. Values quoted in mean (IQR).    
*Significant values in bold (p<0.05). AD: absolute diameter; BDF: baseline diameter 
fluctuation; MD: maximum dilation; MDRT: reaction time to reach maximum diameter to 
flicker stimulation; MC: maximum constriction; MCRT: reaction time to maximum 
constriction post flicker; DA: dilation amplitude; bFR: baseline-corrected flicker 
response. 
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The characteristics for normal, overweight and obese individuals were also investigated and 
shown in Table 6.5. Obese subjects showed significant levels of dyslipidaemia (higher TG, 
lower HDL causing higher TG:HDL-C and Total:HDL ratios) and greater fasting glucose 
values when compared to normal weight subjects. Furthermore, the BP profiles were 
elevated with obesity (p<0.001), contributing to a greater overall Framingham score 
(p<0.001) and c-IMT. 
The overweight group presented with similar results showing greater TG and glucose levels 
alongside higher cholesterol ratios and systemic BP values. This also extended to significant 
differences in left-side c-IMT, weight indices and vWF levels (p<0.01). 
Tables 6.6. and 6.7. shows the systemic (brachial artery) and the ocular (retinal artery and 
vein) reactivity to shear stress and flickering light respectively. Obese individuals showed no 
apparent differences in reactivity at a systemic or ocular level presenting with similar values. 
It is only when investigating the overweight group that significant disparities are found. This is 
shown by reduced brachial artery diameter and maximal obtainable diameter (Figure 6.1.) 
following reactive hyperaemia (MD), increased retinal artery MDRT and reduced arterial MD 
(Figure 6.2.) and bFR. However this did not extend into venous reactions (p>0.05). 
Correlational analysis in obese individuals showed no significant associations between 
retinal and brachial reactivity and anthropometric measures. 
Overweight individuals showed strong correlations between macrovascular function (brachial 
MD) and obesity correlates (fat free mass and PBF) as shown in Figure 6.3 (MD and fat free 
mass (r= 0.620, p<0.001), MD and PBF (r=-0.589, p<0.001). However this did not extend to 
known correlations between SDRA components and obesity correlates (p>0.05) 
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 Normal 
 [n=50] 
Overweight 
[n=50] 
Obese 
[n=50] 
DEMOGRAPHIC DATA    
Age (years)  41.7 ± 11.1  42.2 ± 10.6 43.2 ± 10.2 
SBP (mmHg) 114 ± 14 123 ± 12* 125 ± 12* 
DBP (mmHg) 72 ± 10 11  ± 9* 80  ± 9* 
MAP (mmHg) 86 ± 10 92 ± 9* 94 ± 11* 
IOP (mmHg) 13 ± 3 14 ± 2 14 ± 4 
    
BODY COMPOSITION DATA    
Weight (kg) 65.4 ± 9.4 78.5 ± 9.3* 95.8 ± 15.5*† 
BMI (kg/m2) 22.4 ± 3.1 27.4 ± 1.3* 33.2 ± 3.5*† 
WHR (AU) 0.90 ± 0.14 0.95 ± 0.03* 1.01 ± 0.05*† 
PBF (%) 25.8 ± 7.1 32.1 ± 7.6* 33.2 ± 7.4*† 
Fat Mass (kg) 16.8 ± 5.3 24.8 ± 4.7* 36.1 ± 8.5*† 
Fat Free Mass (kg) 48.7 ± 9.2 53.7 ± 10.7* 59.6 ± 12.8*† 
    
METABOLIC DATA    
Glucose (mmol/L) 4.78 ± 0.75 5.12 ± 0.64* 5.76 ± 0.47 
2 hour GTT (mmol/L) 6.67 ± 2.29 7.33 ± 2.14 7.54 ± 1.54 
TG (mmol/L) 1.08 ± 0.41 1.42 ± 0.79* 1.52 ± 0.79* 
HDL Cholesterol (mmol/L) 1.27 ± 0.41 1.14 ± 0.38 1.05 ± 0.28* 
LDL Cholesterol (mmol/L) 2.53 ± 0.79 2.74 ± 0.88 2.56 ± 0.81 
Total Cholesterol (mmol/L) 4.30 ± 0.83 4.53 ± 0.97 4.30 ± 0.79 
TG:HDL-C (mmol/L) 2.36 ± 2.06 3.37 ± 2.95* 3.68 ± 2.30* 
    
CVD RISK DATA    
R-IMT (mm) 0.052 ± 0.015 0.058 ± 0.014 0.067 ± 0.016*† 
L-IMT (mm) 0.053 ± 0.016 0.064 ± 0.015* 0.072 ± 0.020* 
Framingham Score (%) 1.7 ± 2.4 2.1 ± 3.4 4.0 ± 5.4* 
Total:HDL (mmol/L) 3.70 ± 1.32 4.36 ± 1.57* 4.42 ± 1.77* 
    
BIOCHEMICAL DATA    
v-WF (μ/dL) 112.37 ± 58.67 141.24 ± 55.36* 136.73 ± 50.38 
 
Table 6.5. Baseline data of all groups. Values quoted in mean ± SD. *Significant differences when 
compared to normal weight controls (p<0.01). †Significant differences when overweight and 
obese groups compared (p<0.01). SBP: systolic blood pressure; DBP: diastolic blood 
pressure; MAP: mean arterial pressure; IOP: intraocular pressure; BMI: body mass index; 
WHR: waist-to-hip ratio; PBF: percentage body fat; GTT: glucose tolerance test; TG: 
triglyceride; HDL: high-density lipoprotein; LDL: low density lipoprotein; TG:HDL-C: TG-to-
HDL ratio; R-IMT: right intima media thickness L-IMT: left intima media thickness; vWF: von-
willebrand factor. 
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 Normal 
 [n=50] 
Overweight 
[n=50] 
Obese 
[n=50] 
BRACHIAL ARTERY    
AD (mm) 4.28 (3.75-4.77) 3.77 (3.20-4.32)* 4.39 (3.94-4.93) 
BDF (mm) 0.35 (0.18-0.44) 0.36 (0.20-0.43) 0.34 (0.21-0.44) 
MD (mm) 4.67 (4.04-5.18) 4.11 (3.53-4.72)* 4.68 (3.98-5.17) 
RT (secs) 22.0 (3.0-46.0) 21.9 (3.0-43.0) 25.0 (9.0-32.0) 
FMD (%) 7.83 (2.67-9.48) 7.78 (3.59-12.07) 5.15 (2.98-9.64) 
    
GTN    
GTN-MD (mm) 5.27 (4.75-5.61) 4.77 (4.13-5.64) 5.52 (5.41-5.94) 
RT (secs) 313 (265-400) 330 (285-383) 341 (316-400) 
GID (%) 21.32 (14.16-27.25) 26.45 (18.59-31.00) 23.96 (17.76-29.43) 
    
FMD/GID (%) 0.27 (0.12-0.55) 0.11 (0.05-0.44) 0.17 (0.10-0.51) 
 
Table 6.6. FMD data between all groups. Values quoted in mean (IQR).  *Significant values in bold (p<0.05). AD: 
absolute diameter; BDF: baseline diameter fluctuation; MD: maximum diameter response; RT: Reaction 
time; FMD: flow-mediation dilation response; GID: GTN-induced dilation; FMD/GID: FMD/GID ratio. 
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                                                        Figure 6.1. Brachial artery MD for all groups 
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 Normal 
 [n=50] 
Overweight 
[n=50] 
Obese 
[n=50] 
ARTERY    
AD (AU) 121.59 (112.40-132.60) 120.96 (109.19-131.22)  122.30 (113.20-133.84) 
BDF (AU) 5.71 (3.75-7.09) 5.04 (2.77-6.67) 5.24 (3.32-6.90) 
MD (%) 5.55 (3.66-7.12) 4.54 (2.80-5.98)* 5.44 (3.59-7.18) 
MDRT (secs) 17.2 (12.3-20.7) 20.5 (14.0-24.0)* 18.1 (13.5-21.0) 
MC (%) 3.24 (1.66-4.57) 3.14(1.58-4.59) 2.78 (1.51-3.57) 
MCRT (secs) 19.7 (17.3-23.3) 20.3 (17.2-23.2) 21.2 (19.0-24.7) 
DA (%) 8.78 (6.78-10.18) 7.68 (5.24-9.00) 8.15 (5.39-10.18) 
bFR (%) 3.07 (1.02-4.83) 2.12 (0.43-4.05)* 2.91 (0.85-4.77) 
    
VEIN    
AD (AU) 156.73 (139.18-173.78) 156.00 (142.47-166.35) 151.92 (137.24-167.56) 
BDF (AU) 4.13 (2.56-5.12) 4.29 (2.68-5.31) 4.31 (1.56-5.25) 
MD (%) 5.59 (4.44-6.54) 5.64 (3.87-6.71) 6.94 (5.18-7.67) 
MDRT (secs) 20.1 (17.3-22.7) 19.9 (17.0-23.2) 19.8 (17.0-22.7) 
MC (%) 1.44 (0.33-4.84) 1.75 (0.63-2.16) 1.07 (0.22-1.79) 
MCRT (secs) 21.8 (19.7-25.3) 21.1 (18.6-23.7) 22.2 (19.5-26.0) 
DA (%) 7.27 (5.33-9.00) 7.39 (4.83-9.31) 7.99 (6.04-10.12) 
bFR (%) 3.12 (1.74-4.40) 3.16 (1.13-4.91) 3.73 (2.06-5.09) 
 
Table 6.7. Retinal arterial and venous measures for all groups. Values quoted in mean (IQR).    *Significant values in 
bold (p<0.05). AD: absolute diameter; BDF: baseline diameter fluctuation; MD: maximum dilation; MDRT: 
reaction time to reach maximum diameter to flicker stimulation; MC: maximum constriction; MCRT: 
reaction time to maximum constriction post flicker; DA: dilation amplitude; bFR: baseline-corrected 
flicker response. 
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          Figure 6.2. Retinal arterial MD differences between all groups. 
Lean                    Overweight                   Obese 
p= 0.812 
p= 0.039 p= 0.142 
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Figure 6.3. Brachial artery MD and obesity correlate analyses in the overweight sample. Left-hand 
side: spearmans correlation between MD and fat free mass (r= 0.620, p<0.001). Right-
hand side: Spearmans correlation between MD and PBF (r=-0.589, p<0.001). 
 
 
The overweight group also showed a moderate correlation (Figure 6.4) between brachial 
artery MD and retinal artery MD (spearmans r=0.31, p=0.021) that was not evident in lean 
(r=0.11, p=0.412) or obese (r=0.29, p=0.140) individuals. 
 
 
 
Figure 6.4. Brachial artery MD and retinal artery MD correlation in the overweight sample. Spearmans 
correlation (r=0.31, p=0.021). 
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6.6. Discussion 
This study examined the effects of obesity and overweight on vascular function at the micro- 
and macrovascular level. Additionally, the study aimed to further current human 
microcirculation data by investigating other markers of atherosclerosis and endothelial 
damage alongside Framingham risk scores and body composition analyses. 
 
The risk of obesity has been shown to be associated with retinal arteriolar attenuation and 
venous dilation as well as heightened CVD risk and mortality rates.[428-430] Moreover, there 
is extremely limited data on retinal vascular function by means of retinal vessel reactivity in 
obesity.[298, 304] The results presented in this paper shows work for the first time 
investigating early markers of endothelial dysfunction (brachial artery FMD), morphological 
arterial changes (c-IMT) and biochemical markers of inflammation (vWF) together with retinal 
vessel reactivity and CVD risk scores in obese and overweight individuals. 
 
By doing this, the results show that those that are obese, as well as those that are 
overweight present with patterns of dyslipidaemia, irregular systemic BP and abnormal body 
composition.  More importantly, the results in this thesis show for the first time that 
overweight individuals may present with greater CVD risk, future endothelial cell damage and 
impaired vascular function as found by increased c-IMT and vWF levels as well as 
attenuated brachial artery FMD (blunted MD) and retinal arterial dilation responses (reduced 
MD and bFR and prolonged MDRT). 
 
Many clinical trials have also found a variety of vascular alterations in overweight and obese 
subjects demonstrating not only an increased c-IMT, elevated BP values, higher TG, 
cholesterol and fasting blood glucose values, but also increased CRP and fasting insulin 
concentrations compared with normal weight subjects.[431] Furthermore, there is data to 
suggest that these alterations affect the structural and functional properties of macro- and 
microvasculature. Therefore, the data provided by this study supports previous clear 
evidence that being overweight or obese, are associated with dyslipidaemia, atherosclerosis, 
and alterations of major and minor blood vessels factors that are determinants of increased 
risk for cardiovascular diseases.  
 
Obesity has also been suggested to impair brachial artery FMD but no obvious associations 
have been found with BMI in overweight and obese individuals.  Although visceral obesity 
more strongly predicts endothelial function than BMI, obesity might not be a strong predictor 
of endothelial function in all populations. This is also confirmed by our own analyses showing 
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a non-significant correlation between BMI and FMD (r=0.041 and p=0.771 respectively). The 
present data however, does suggest that impairment in endothelial function by means of 
reduced brachial artery MD may represent a pathophysiological mechanism linking being 
overweight to CVD risk.[432] This is supported by correlations (Figure 6.3.) between brachial 
artery MD and fat free mass (spearmans r=0.620, p<0.001) and PBF (spearmans r=-0.589, 
p<0.001), but it is important to note that only a weak, but significant, correlation was found 
between brachial MD and vWF (spearmans r=0.283, p=0.049).  
 
Associations between increased BMI with pro-thrombotic factors, such as vWF, have also 
been reported previously, suggesting that obesity is indeed a risk factor whose effect is 
mediated partly by a pro-thrombotic state.[433] Despite significant differences in blood vWF 
levels in the current overweight group, no other correlations were found with anthropometric 
features to suggest similar vascular aetiology.  
 
Obesity may also extend to profound retinal effects, causing changes in retinal vasculature. 
For instance, an association between retinal arteriolar narrowing with obesity has been 
reported in different populations suggesting a possible role in microvascular structural 
change with the pathogenesis of weight gain.[428] The results of this paper show that using 
the newly-developed SDRA, as reported previously, allows for a valid means of screening in 
at risk groups, in particular overweight individuals.[216, 221] Although no differences were 
found in retinal vessel reactivity for obesity. Interestingly, overweight individuals showed 
early signs of impaired retinal vascular function by means of reduced arterial MD, bFR and 
delayed MDRT. As suggested previously, SDRA could be a useful measure in asymptomatic 
individuals and the reduced arterial MD and bFR may represent the possibility of reduced NO 
bio-availability to peripheral tissues in overweight individuals. Atherosclerotic vessel wall 
changes or increased arterial stiffness may also play an influence in impaired retinal 
reactivity.[415, 417] Indeed, an increased MDRT could also characterise a combination of 
one or both factors.[216] This would be supported by the data of the current work showing 
increased c-IMT thickness and reduced FMD values in the overweight sample when 
compared to their age- and sex-matched lean counterparts. Despite a weak-moderate 
correlation between retinal and brachial artery MD (Figure 6.4.), there were no further 
correlations with body composition, atherosclerosis measures or biochemical markers of 
endothelial function.  
 
Despite the newly reported applications of SDRA and validated markers of endothelial cell 
function and CVD risk in an overweight sample the relatively small sample size in this study 
only allows for generalised assumptions relating specifically to this sample to be made. 
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Larger studies would need to be conducted to investigate the vascular differences between 
overweight and obese individuals more closely. Furthermore, the use of SDRA in “at-risk” 
individuals including obesity and overweight needs further longitudinal and cross-sectional 
work. Additionally, adiposity has been found to be associated with insulin resistance (IR) and 
dyslipidemia, and as we did not identify insulin sensitivity in our groups, the results cannot be 
judged to be due to IR in the current overweight cohort.[432] 
 
The preliminary findings of this study suggest that the adverse effect of obesity on the long 
term risk of CVD may begin in those that are overweight. This is evident in apparent 
differences in cardiovascular markers (dyslipidaemia and c-IMT), biochemical analysis (vWF) 
and ocular (MD, bFR and MDRT) and systemic (brachial MD) vascular function. Whether 
these differences lead to a greater propensity for future CVD and vascular disease risk 
remains to be seen. Future work would, therefore, need to investigate the pathophysiological 
mechanisms behind obesity/overweight and vascular function. 
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7. Summary of Findings on Vascular Function in those at Risk of 
T2DM and CVD 
_________________________________________________________________________ 
 
7.1. Aims 
The effect of atherosclerosis, vascular inflammation and endothelial dysfunction on the 
pathophysiology of T2DM and CVD has been extensively reported. The impact of endothelial 
dysfunction as a precursor to vascular atherogenesis in known individuals at risk of T2DM 
however, has been scarcely investigated. Furthermore, the presence of haemodynamic 
relationships between macro- and micro-vasculature, if any, has also not been fully explored.  
The studies outlined in this thesis aimed to explore the use of surrogate markers for 
endothelial/vascular function and CVD risk by means of retinal vessel reactivity and SDRA 
against already available and validated measures (FMD, c-IMT, Framingham, vWF and ET-
1). Thus, any outcomes showing the relevance of retinal vascular function against these 
measures could impact new avenues in screening, diagnostic and therapeutic for T2DM and 
CVD. 
The aims of this thesis, therefore, were to investigate vascular function; by means of 
systemic, ocular and circulating plasma markers for endothelial function in relation to the risk 
of T2DM and CVD. The findings, including any established differences and associations 
between ocular and systemic function, are summarised below. 
 
7.2. Vascular Function in Normoglycaemic Individuals with and without a 
FH of T2DM  
Many studies have reported metabolic and vascular abnormalities in normoglycaemic 
individuals with a FH of T2DM. Vascular dysfunction has been investigated by brachial artery 
and skin microcirculation reactivity. Furthermore, elevated markers in plasma levels of 
vasoconstrictors, coagulators and inflammation have been found alongside increased c-IMT 
and decreased aortic distensibility in FH groups.[37, 234, 238, 340-343] However, the results 
of this thesis do not follow that reported previously. This furthers the argument about whether 
multiple vascular abnormalities are related to the presence of IR and/or are genetically 
determined. Therefore, further investigations would deserve evaluations of insulin 
sensitivity/resistance by means of a euglycaemic clamp.  
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7.3. Vascular Function in Normoglycaemic South Asians vs. White 
Europeans 
SAs originating from the Indian sub-continent represent an increasing population worldwide 
since 2001. This ethnic minority are at increased risk of developing vascular disorders; 
namely T2DM, CVD and stroke when compared to WEs.[21, 361] Therefore, this increased 
vascular predisposition towards the development of T2DM and CVD necessitates early 
identification of risk factors for the purposes of primary prevention.   
The increased levels of dyslipidaemia and blunted FMD response with disparities in retinal 
vessel reactivity components, found in this study, illustrate the need for tailored screening 
programmes in different ethnic minorities. The additional differences in SA men and women 
also illustrate the complexity in nature of the differences in vascular risk. Therefore, despite 
the lack of relevant data in screening and retinal haemodynamics, there is a definite need for 
more trials in SAs.[434] 
 
7.4. Vascular Function in Individuals Newly-diagnosed with IGT as 
compared to Healthy Controls 
Those with IGT have been identified to have increased levels of C-reactive protein, 
fibrinogen and plasminogen activators. Furthermore, impaired endothelium-dependent 
vasodilation in the brachial artery has been reported with elevated levels of ET-1 and 
adhesion molecules.[435] Therefore, it has been suggested that acute hyperglycaemia can 
contribute to vascular dysfunction by means of an oxidative stress mechanism in IGT 
individuals.[436]  
Alongside reduced plasma glutathione levels, IGT individuals showed greater levels of vWF 
and impaired brachial and retinal artery reactivity that suggests early risk for prolonged 
oxidative stress and endothelial cell dysfunction/damage that is implicated by certain cardio-
metabolic factors thus increasing the future risk for vascular disease. 
 
7.5. Vascular Function in Normal, Overweight and Obese Individuals 
As previously suggested the prevalence of vascular diseases such as T2DM, CVD and 
stroke and existing co-morbidity and mortality rates have been put down to the increasing 
levels of obesity and overweight worldwide. Therefore, the need to investigate the influence 
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of obesity and overweight on vascular function and preceding future vascular risk is indeed 
valid. 
This additional study aimed to further the understanding of vascular function in known risk 
factors and demonstrated the validity of the differently used techniques in other at-risk 
individuals. More importantly, this chapter shows that overweight individuals may carry risk 
for vascular disease as shown by impaired FMD, retinal artery MD, MDRT and bFR that 
existed alongside well-known markers for atherosclerosis (increased c-IMT and 
dyslipidaemia) and endothelial damage (higher plasma vWF levels).  
 
7.6. Future Directions 
The preliminary results reported in the major chapters of this thesis illustrate the use of 
SDRA as a surrogate marker for vascular function alongside clinically proven and validated 
markers for endothelial dysfunction. The limitations demonstrated from the studies also help 
to show future directions that can be adopted to further our understanding behind the 
biochemical, vascular and metabolic pathophysiological causes of vascular disease. 
 
7.6.1. Population Studies 
The sample sizes used in the studies of this thesis provide preliminary pilot study data. 
Therefore, to determine the role of vascular function screening and novel surrogate markers 
in ethnic minorities, larger cohort studies of SAs (essentially second-generation migrants) 
need to be established. This should involve adequate follow-up intervals including the 
development of efficient media to self-report dietary and exercise behaviours. This could also 
incorporate qualitative studies to investigate cultural attitudes and beliefs as well as literacy 
and language issues to govern the design of screening programmes where traditional 
methods have been deemed inappropriate.  
Further work should also investigate vascular and endothelial function in individuals with 
T2DM and DR. This would help determine the relationship of well-established vascular risk 
factors in T2DM and DR within the SA community and further investigate the difference, if 
any, in the pathogenesis and severity of the condition and its complications within this 
minority. This could also extend into those of SA origin with stroke or CVD. 
   
 
 
137 
 
7.6.2. Genetics Studies 
Genetic factors, albeit varied, are known to play a significant role into the pathogenesis of 
T2DM. This can involve monogenic (single gene defects) or polygenic (several gene 
polymorphisms) forms of T2DM. To this date, there is very limited genetic data on SA 
communities and at-risk individuals, and so to better understand the pathophysiology of 
T2DM further gene characterisation and genome-wide association studies are needed. This 
can also expand to genes associated with obesity, IR and dyslipidaemia in SAs. 
 
7.6.3. Biomedical Studies 
The logistical and financial issues of the studies encountered in this thesis limited the degree 
and extent of analysis undertaken for plasma markers of endothelial function and vascular 
inflammation. Namely, the investigation of fasted insulin levels and glycosylated haemoglobin 
are known to be of clinical use in T2DM screening and diagnosis programmes. Furthermore, 
the study of renal function, by means of creatinine and albuminuria levels would provide 
insight into vascular risk for microvascular disease in T2DM. 
Furthermore, the constraints of finances limited the resources to achieve available data on 
ET-1 levels in at-risk individuals. Additional work will need to investigate endothelial cell 
damage and vascular function. 
 
7.6.4. Intervention Studies 
The classic lipid profile of SAs, namely higher plasma TG and lower HDL-C levels is widely 
acknowledged and also documented in the studies of this thesis. Therefore, future ethnicity 
studies may focus on lipid-lowering therapies in this minority, researching the relative efficacy 
and thresholds for intervention of statins in SAs as compared to WEs. Furthermore, the 
emergence of new HDL-C raising agents into the pharmaceutical arena will be advantageous 
to SA individuals and therefore would require longitudinal clinical trials. 
This can further extend to evaluating therapeutic agents in those with IGT, in particular the 
investigation into the efficacy of IR agents with angiotensin-converting enzyme (ACE) 
inhibitors and angiotensin-receptor blockers (ARBs) in improving glucose regulation.  
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7.6.5. Data Analytical Studies 
Further work is necessary in compiling a normative database of values for a range of age 
and ethnicity categories across multiple sites to assess the application of SDRA and slope 
analysis. This can then help to further extend the development of complex algorithms and 
data-mining applications for larger samples in screening programmes for a range of ocular 
and vascular diseases.  
Current FMD analysis is restricted, and its use as a correlate with retinal vascular parameters 
is extremely limited as it is yet to be fully investigated. Future FMD analysis should 
incorporate more complex analyses, for example including BDF as a factor for FMD%, or 
slope calculations, and involve cluster-analysis with larger samples. 
 
7.6.6. Psychosocial Studies 
The effects of confounding factors other than vascular risk factors in at-risk individuals, for 
example, in SAs and obese individuals, include diet; lifestyle and other social issues have not 
been extensively researched.[21] Furthermore, the religious and hostility barriers evident in 
certain groups are known to impact the risk for future vascular burden.[261] Future work 
investigating the implications of these factors, namely sedentary lifestyles (restricted exercise 
and poor diet) on vascular health would thus be extremely useful in gearing treatment plans 
for those with, and at risk of vascular diseases like T2DM, CVD and stroke. 
 
7.7. Clinical Implications 
The findings of this thesis present preliminary work on the clinical applications of surrogate 
markers, namely the DRVA and its SDRA, alongside well known markers for atherosclerosis, 
metabolic function and systemic endothelial function in groups known to be at risk of future 
vascular disease. Therefore, the use of SDRA is valid and quite possibly clinically necessary 
with more research. The results of this thesis show that SDRA could be used in a number 
other applications, such as; mass population screening for vascular disease, therapeutic 
efficacy in overt disease, therapeutic (i.e. nutritional, exercise) prevention of vascular 
disease, assessment of vascular function in other vascular/ocular disorders (glaucoma, 
hypertensive retinopathy, age-related macular degeneration), vascular function in other at-
risk individuals (Afro-Caribbean origin) and demonstrating the use of the DRVA (retinal 
vessel reactivity, oximetry, static analysis and fundus photography) in patient diagnostic 
plans. 
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Experimental Protocol 
Suitable participant identified and approached. Information pack given to outline study and 
procedures. Menstrual cycle questionnaire given to female participants to determine phase of 
menstrual cycle. 
1. Letter sent to GP to notify of participation. 
2. Procedures and risks explained (Information sheet); consent form to be read, 
understood, completed and signed. 
3. Preliminary measurements to be taken: BCVA, spectacle prescription and IOP (of 
selected eye), height; body composition measurements, and baseline BP 
measurements. 
4. OGTT ADMINISTERED A WEEK BEFORE THE MAIN STUDY 
5. Collection of blood sample by venepuncture. 
6. Temperature of the room should be noted. 
7. BP measurements taken. 
8. Participant fitted with 24-hour blood pressure monitor. 
9. Flow-mediated dilation measurements to be taken. 
10. BP measurements taken. 
11. Retinal vessel analyser measurements to be taken. 
12. Drug side effects leaflet given. 
13. Clean all areas and equipment. 
14. Participant to return monitor 24 hours later. 
 
 
PROTOCOL FOR THE COLLECTION OF BLOOD SAMPLES BY VENEPUNCTURE 
1. Position the patient either sitting/supine and support the preferred arm. 
2. Assemble equipment. 
3. Check that the seal on the needle is intact and the expiry date has not been 
exceeded and attach to the holder. 
4. Apply the tourniquet 3-4 inches above the recommended site (antecubital fossa), for 
a maximum of 1 minute only, tight enough to slow the blood flow in the veins but not 
too tightly to prevent the blood flow of the arteries.  
5. Select a vein by palpation and trace its path. 
6. Swab the area thoroughly with 70% alcohol using increasing concentric movements 
starting at the puncture site. Allow the area to air dry for 30 seconds/wipe dry. 
7. Holding the vacutainer barrel in the correct manner, uncap the needle. Position with 
bevel side up and holding the patient‟s skin down to anchor the vein, insert the needle 
smoothly through the skin at an angle of 15°-30° along the direction of the selected 
vein. 
8. Using the flanges at the base of the barrel, fill the bottle in the correct order of draw, 
gently inverting the bottle (as often as indicated) as it is removed from the barrel. 
9. Release the tourniquet. 
10. Apply a clean swab over the puncture site, withdraw the needle and press firmly over 
the site for a minimum of 1 minute. 
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11. Dispose of needle and holder intact into a sharps box. 
12. Complete bottle inversions. 
13. Label tubes clearly by hand in the presence of the patient documenting any pre-
analytical variables. Check the venepuncture site and dress the wound. 
14. Remove gloves and dispose of all contaminated material. 
15. Wash hands/use antiseptic gel. 
16. Sample to be centrifuged (for plasma analysis) and stored (frozen). 
 
 
 
PROTOCOL FOR ORAL GLUCOSE TOLERANCE TEST 
 
1.  A baseline fasted capillary blood sample is drawn. 
2.  The participant is then given a glucose solution to drink. The WHO protocol for OGTT 
is a 75g glucose solution. It should be drunk within 5 minutes. 
3. Capillary blood sample drawn at 2 hour post glucose solution consumption. 
 
 
PROTOCOL FOR FLOW-MEDIATED DILATION  
1. BP measured. 
2. Procedure and risks explained. 
3. System, software and pre-decided settings set-up for artery examination.  
4. Patient to lie supine with arm on support/side table comfortably. 
5. 2 minute baseline measurements to be taken (CDI with vascular software). 
6. Wrist compression (50mmHg above systolic) with cuff/wrist sphygmomanometer. 
7. Measurements to be taken for 5 minutes. 
8. Cease wrist compression. 
9. 2 minute post cuff-release measurements to be taken. 
10. Patient to rest (supine) for 10 minutes. 
11. Another 2 minute baseline measurement to be taken. 
12. Administer glyceryl trinitrate 0.3mg sublingual tablet and begin wrist compression 
(50mmHg above systolic) simultaneously. 
13. Take further measurements for 5 minutes. 
14. Cease wrist compression. 
15. 2 minute post cuff-release measurements to be taken. 
16. Patient to rest (supine) once all measurements taken. 
17. Drug side effects leaflet to be given. 
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PROTOCOL FOR RETINAL VESSEL ANALYSER 
1. BP measured. 
2. Procedure explained. 
3. IOPs of the selected eye(randomised) to be taken 
4. Tropicamide 1% instilled (post explanation) to the selected eye. 
5. Wait 15-20 minutes for drugs to begin acting. 
6. Start program and fill in patient data, examination type, and location. 
7. Sit patient comfortably at the retinal camera.  
8. Ask patient to look at inner fixation target. 
9. Adjust focus of camera. 
10. Allow 1 minute for pupil adaptation to retinal camera illumination.  
11. Optimise illumination and arrange illumination to enter directly through pupil. 
12. Select retinal location (two chosen segments of the major temporal inferior branch of 
the arteriole and venule). 
13. Set eye tracking template. 
14. Mark the major artery and vein. 
15. Start automatic measurements: baseline measurement of 50 seconds and three 
flicker period measurements (20 seconds each), interrupted with 80 seconds of still 
illumination. 
16. Take IOPs (post-dilation) of the selected eye. 
17. Drug side effects leaflet to be given. 
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Ocular and Systemic Endothelial Function in the Normoglycaemic Offspring of 
Type II Diabetics: A Pilot Study 
Sunni Patel1*, Doina Gherghel1, Rebekka Heitmar1, Alexandra Benavente-Perez1, 2, Lu Qin1, 
George Balanos3, David McIntyre3, Jonathon Gibson1 
1Vascular Research and Imaging Laboratory, Ophthalmic Research Group, Aston University, 
Birmingham, UK 
2SUNY State College of Optometry, Biological Sciences, New York, USA 
3School of Sport and Exercise Sciences, University of Birmingham, UK 
Keywords: Diabetes Mellitus (T2DM), risk factors, screening, flow-mediated dilation (FMD), 
retinal vessel reactivity/analyser (RVR/RVA) 
 
Purpose 
 
To investigate ocular and systemic correlates of endothelial function in the 
normoglycaemic offspring of Type 2 Diabetics (T2DM). 
Methods 
 
Healthy participants aged between 25-65 years with (n=30) and without 
(n=39) a family history of Type II diabetes (T2DM) were recruited. Retinal 
vessel reactivity was assessed by using the Dynamic Retinal Vessel 
Analyser (DRVA, Imedos GmBH, Jena). In addition, systemic endothelial 
function was assessed by using the flow mediated dilation (FMD) technique.  
Results 
 
Statistical analysis showed no significant differences in anthropometric, 
blood assay or ocular and systemic function between both groups (p>0.05). 
The average maximum dilation (MD) in the measured retinal artery 
correlated significantly with the maximum dilation of the measured brachial 
artery (p=0.002 R=0.55) in healthy controls; however, this was not true for 
subjects with family history of T2DM. 
Conclusions 
 
Subjects with family history of T2DM show possibly early signs of endothelial 
dysfunction that, in certain conditions, could contribute to the higher risk of 
this group of developing similar pathology to their parents. Additionally this 
preliminary risk could be determined at an ocular level. 
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Abnormal Retinal Vascular Function and Lipid Levels in a Sample of Healthy 
UK South-Asians  
S R Patel (BSc)1, S Bellary (MD MRCP)1,3, L Qin (MD)1, PS Gill (DM FRCGP)2, S Taheri 
(PhD MRCP)3, R. Heitmar (PhD)1 J Gibson (MD FRCOphth)1, D Gherghel (MD PhD)1* 
1Vascular Research Laboratory, Ophthalmic Research Group, School of Life and Health 
Sciences, Aston University, Birmingham, UK 
2Primary Care Clinical Sciences, University of Birmingham, UK 
 
3 MIDRU, Heart of England NHS Trust and University of Birmingham, Birmingham,   UK 
 
Keywords – South Asians, Retinal Vessel Analysis, Cardiovascular Risk, Diabetes Risk 
 
Background/Aims: To investigate ethnic differences in retinal vascular function and their 
relationship to traditional risk indicators for cardiovascular disease (CVD). 
Methods: A total of 90 normoglycaemic subjects (45 South-Asian (SA) and 45 age- and 
gender- matched White Europeans (WE) were recruited for the present study. Retinal vessel 
reactivity to flickering light was assessed by means of the Dynamic Retinal Vessel Analyser 
(DRVA) according to a modified protocol. Fasting plasma glucose, triglycerides (TG), total, 
LDL and HDL cholesterol were also measured in all individuals. 
Results: SA individuals showed higher fasting triglyceride (p=0.001) and lower HDL levels 
(p=0.007), leading to a higher TG:HDL-C ratio (p=0.001) than age-matched WE subjects. 
Additionally, in SAs, the retinal arterial reaction time in response to flicker stimulation was 
significantly longer in the last flicker cycle than in the WEs (p=0.039), and this change 
correlated positively with measured plasma TG levels (r=0.60; p=0.01). No such relationship 
was observed in the WEs (p>0.05). 
Conclusion: Even in absence of overt vascular disease, in otherwise healthy SAs there are 
potential signs of retinal vascular function impairment that correlates with established plasma 
markers for CVD risk.  
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